US20030113733A1 - Gene regulator - Google Patents
Gene regulator Download PDFInfo
- Publication number
- US20030113733A1 US20030113733A1 US10/028,075 US2807501A US2003113733A1 US 20030113733 A1 US20030113733 A1 US 20030113733A1 US 2807501 A US2807501 A US 2807501A US 2003113733 A1 US2003113733 A1 US 2003113733A1
- Authority
- US
- United States
- Prior art keywords
- cell
- nmpf
- gene
- peptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 200
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 172
- 230000011664 signaling Effects 0.000 claims abstract description 122
- 230000014509 gene expression Effects 0.000 claims abstract description 105
- 230000000694 effects Effects 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 94
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 46
- 230000005937 nuclear translocation Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 248
- 241000282414 Homo sapiens Species 0.000 claims description 130
- 102000003945 NF-kappa B Human genes 0.000 claims description 111
- 108010057466 NF-kappa B Proteins 0.000 claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 84
- 108010038807 Oligopeptides Proteins 0.000 claims description 70
- 102000015636 Oligopeptides Human genes 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 102000040945 Transcription factor Human genes 0.000 claims description 33
- 230000004913 activation Effects 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 238000009739 binding Methods 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 24
- DXRXYJYFADHAPA-AUTRQRHGSA-N (2s)-2-[[2-[[(2s)-5-amino-2-[[(2s)-2-aminopropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N DXRXYJYFADHAPA-AUTRQRHGSA-N 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 230000003828 downregulation Effects 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 230000003827 upregulation Effects 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 230000001456 gonadotroph Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 62
- 201000010099 disease Diseases 0.000 abstract description 39
- 108020004999 messenger RNA Proteins 0.000 description 114
- 239000002158 endotoxin Substances 0.000 description 105
- 229920006008 lipopolysaccharide Polymers 0.000 description 103
- 238000002474 experimental method Methods 0.000 description 78
- 241000699670 Mus sp. Species 0.000 description 58
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 54
- 239000002953 phosphate buffered saline Substances 0.000 description 45
- 241000588724 Escherichia coli Species 0.000 description 42
- 241001465754 Metazoa Species 0.000 description 42
- 210000001185 bone marrow Anatomy 0.000 description 42
- 238000001802 infusion Methods 0.000 description 41
- 241000282693 Cercopithecidae Species 0.000 description 39
- 210000004443 dendritic cell Anatomy 0.000 description 37
- 230000037361 pathway Effects 0.000 description 34
- 230000001105 regulatory effect Effects 0.000 description 30
- 241000193738 Bacillus anthracis Species 0.000 description 28
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 27
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 27
- 210000002540 macrophage Anatomy 0.000 description 26
- 239000000284 extract Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 208000035475 disorder Diseases 0.000 description 23
- 230000004054 inflammatory process Effects 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 206010040070 Septic Shock Diseases 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 22
- 206010061218 Inflammation Diseases 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 230000035939 shock Effects 0.000 description 21
- 206010040047 Sepsis Diseases 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 230000033115 angiogenesis Effects 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 230000015556 catabolic process Effects 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 102000002689 Toll-like receptor Human genes 0.000 description 17
- 108020000411 Toll-like receptor Proteins 0.000 description 17
- -1 cyclopentenone prostaglandins Chemical class 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 244000052769 pathogen Species 0.000 description 17
- 239000002243 precursor Substances 0.000 description 17
- 230000036303 septic shock Effects 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 16
- 206010025482 malaise Diseases 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 206010011086 Coronary artery occlusion Diseases 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 108010025628 Apolipoproteins E Proteins 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 231100000518 lethal Toxicity 0.000 description 14
- 230000001665 lethal effect Effects 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000003053 toxin Substances 0.000 description 14
- 231100000765 toxin Toxicity 0.000 description 14
- 108700012359 toxins Proteins 0.000 description 14
- 238000011725 BALB/c mouse Methods 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
- 230000028709 inflammatory response Effects 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 102000013918 Apolipoproteins E Human genes 0.000 description 12
- 201000001320 Atherosclerosis Diseases 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 12
- 101710194807 Protective antigen Proteins 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 230000000770 proinflammatory effect Effects 0.000 description 11
- 230000005945 translocation Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 102100023132 Transcription factor Jun Human genes 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 102100022297 Integrin alpha-X Human genes 0.000 description 9
- 108010016731 PPAR gamma Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 9
- 101150037123 APOE gene Proteins 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 102100026679 Carboxypeptidase Q Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 101000910846 Homo sapiens Carboxypeptidase Q Proteins 0.000 description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 8
- 101710123496 Spindolin Proteins 0.000 description 8
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 210000002798 bone marrow cell Anatomy 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000004968 inflammatory condition Effects 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 102000006240 membrane receptors Human genes 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 7
- 108010001857 Cell Surface Receptors Proteins 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- 241000282560 Macaca mulatta Species 0.000 description 7
- 108090000315 Protein Kinase C Proteins 0.000 description 7
- 102000003923 Protein Kinase C Human genes 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 229940105596 baytril Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000015788 innate immune response Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 102000000853 LDL receptors Human genes 0.000 description 6
- 108010001831 LDL receptors Proteins 0.000 description 6
- 102000007999 Nuclear Proteins Human genes 0.000 description 6
- 108010089610 Nuclear Proteins Proteins 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000000703 anti-shock Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000002222 downregulating effect Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000010195 expression analysis Methods 0.000 description 6
- 208000026278 immune system disease Diseases 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000003094 microcapsule Substances 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 102000007863 pattern recognition receptors Human genes 0.000 description 6
- 108010089193 pattern recognition receptors Proteins 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 5
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 5
- 241000588722 Escherichia Species 0.000 description 5
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000000897 modulatory effect Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 229940064298 pregnyl Drugs 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 230000004862 vasculogenesis Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 108010051542 Early Growth Response Protein 1 Proteins 0.000 description 4
- 102100023226 Early growth response protein 1 Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101001133656 Homo sapiens Plasminogen activator inhibitor 1 RNA-binding protein Proteins 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 108060006678 I-kappa-B kinase Proteins 0.000 description 4
- 102000001284 I-kappa-B kinase Human genes 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- 108010028924 PPAR alpha Proteins 0.000 description 4
- 102000000536 PPAR gamma Human genes 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102100034055 Plasminogen activator inhibitor 1 RNA-binding protein Human genes 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000004721 adaptive immunity Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940121538 choriogonadotropin beta Drugs 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000037041 intracellular level Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
- 230000014493 regulation of gene expression Effects 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000003270 steroid hormone Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 3
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 3
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 3
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 3
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical group 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 3
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000828886 Homo sapiens GTP-binding protein 4 Proteins 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- 101001026573 Homo sapiens cAMP-dependent protein kinase type I-alpha regulatory subunit Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108010064052 Interferon-Stimulated Gene Factor 3 Proteins 0.000 description 3
- 102000014746 Interferon-Stimulated Gene Factor 3 Human genes 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 101150023417 PPARG gene Proteins 0.000 description 3
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 3
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 3
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 3
- 101000897961 Rattus norvegicus Endothelial cell-specific molecule 1 Proteins 0.000 description 3
- 102100025419 Serine protease inhibitor Kazal-type 2 Human genes 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 102000018594 Tumour necrosis factor Human genes 0.000 description 3
- 108050007852 Tumour necrosis factor Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 208000010399 Wasting Syndrome Diseases 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 229940065181 bacillus anthracis Drugs 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 102100037490 cAMP-dependent protein kinase type I-alpha regulatory subunit Human genes 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 201000004836 cutaneous anthrax Diseases 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 210000003278 egg shell Anatomy 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000008604 lipoprotein metabolism Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 230000004647 pro-inflammatory pathway Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 108010086158 rusticyanin Proteins 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- ISEIOOAKVBPQFO-AOHZBQACSA-N (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-pyren-1-ylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccc4ccc5cccc6ccc3c4c56)C(=O)N2[C@H]1C(O)=O ISEIOOAKVBPQFO-AOHZBQACSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- 206010004053 Bacterial toxaemia Diseases 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 2
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100030886 Complement receptor type 1 Human genes 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 102000006311 Cyclin D1 Human genes 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100030011 Endoribonuclease Human genes 0.000 description 2
- 101710199605 Endoribonuclease Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100023903 Glycerol kinase Human genes 0.000 description 2
- 108700016170 Glycerol kinases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102100022130 High mobility group protein B3 Human genes 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 2
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 101001006375 Homo sapiens High mobility group nucleosome-binding domain-containing protein 4 Proteins 0.000 description 2
- 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 2
- 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 2
- 101001120091 Homo sapiens Putative P2Y purinoceptor 10 Proteins 0.000 description 2
- 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 description 2
- 101001077727 Homo sapiens Serine protease inhibitor Kazal-type 2 Proteins 0.000 description 2
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 101000772913 Homo sapiens Ubiquitin-conjugating enzyme E2 D3 Proteins 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 2
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101710185515 Major outer membrane lipoprotein Lpp Proteins 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 2
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108700005084 Multigene Family Proteins 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 2
- 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 description 2
- 101710204094 NF-kappa-B inhibitor beta Proteins 0.000 description 2
- 102100033104 NF-kappa-B inhibitor epsilon Human genes 0.000 description 2
- 101710093997 NF-kappa-B inhibitor epsilon Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 101710107897 Nucleosome assembly protein Proteins 0.000 description 2
- 101710195703 Oxygen-dependent coproporphyrinogen-III oxidase Proteins 0.000 description 2
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 2
- 101710200437 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100036031 Podocalyxin Human genes 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100025198 Protein DBF4 homolog A Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 2
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 2
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 2
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 2
- 108010005509 RNA 3'-terminal phosphate cyclase Proteins 0.000 description 2
- 102000056032 RNA 3'-terminal phosphate cyclases Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000028589 Rab4 Human genes 0.000 description 2
- 102100025003 Ras-related protein R-Ras2 Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 102000018779 Replication Protein C Human genes 0.000 description 2
- 108010027647 Replication Protein C Proteins 0.000 description 2
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- 102100029665 Serine/arginine-rich splicing factor 3 Human genes 0.000 description 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 2
- 101001081186 Tetrahymena pyriformis High mobility group protein Proteins 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 208000013222 Toxemia Diseases 0.000 description 2
- 102100026143 Transferrin receptor protein 2 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102100030425 Ubiquitin-conjugating enzyme E2 D3 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010048215 Xanthomatosis Diseases 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003392 amylase inhibitor Substances 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108050002883 beta-defensin Proteins 0.000 description 2
- 102000012265 beta-defensin Human genes 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 208000002296 eclampsia Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000035780 glucosuria Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000052620 human IL10 Human genes 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000009449 inhalation anthrax Diseases 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000013190 lipid storage Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 101150071637 mre11 gene Proteins 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000011809 primate model Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 108010044923 rab4 GTP-Binding Proteins Proteins 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004865 vascular response Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 1
- ZSZXYWFCIKKZBT-IVYVYLGESA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-IVYVYLGESA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- HNICUWMFWZBIFP-BSZOFBHHSA-N 13-HODE Chemical compound CCCCCC(O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-BSZOFBHHSA-N 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-H 1D-myo-inositol 1,4,5-trisphosphate(6-) Chemical compound O[C@@H]1[C@H](O)[C@@H](OP([O-])([O-])=O)[C@H](OP([O-])([O-])=O)[C@@H](O)[C@@H]1OP([O-])([O-])=O MMWCIQZXVOZEGG-XJTPDSDZSA-H 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- PENWAFASUFITRC-UHFFFAOYSA-N 2-(4-chlorophenyl)imidazo[2,1-a]isoquinoline Chemical compound C1=CC(Cl)=CC=C1C1=CN(C=CC=2C3=CC=CC=2)C3=N1 PENWAFASUFITRC-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical class NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- SNLFYGIUTYKKOE-UHFFFAOYSA-N 4-n,4-n-bis(4-aminophenyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1N(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 SNLFYGIUTYKKOE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102100023777 60S ribosomal protein L31 Human genes 0.000 description 1
- 101710187890 60S ribosomal protein L31 Proteins 0.000 description 1
- 108010042833 7,8-diaminopelargonic acid aminotransferase Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100021407 ATP-dependent RNA helicase DDX18 Human genes 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 1
- 102100026661 Activity-dependent neuroprotector homeobox protein 2 Human genes 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 108010049831 Alkylglycerone-phosphate synthase Proteins 0.000 description 1
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 1
- 102100035740 BH3-interacting domain death agonist Human genes 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102100027058 Bleomycin hydrolase Human genes 0.000 description 1
- 108010025544 Bleomycin hydrolase Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102000038625 CMGCs Human genes 0.000 description 1
- 108091007913 CMGCs Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102100038712 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000000425 Chagas Cardiomyopathy Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102100030556 Coagulation factor XII Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010063075 Cryptogenic cirrhosis Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100028992 Cytochrome c oxidase subunit 6A1, mitochondrial Human genes 0.000 description 1
- 101710091570 Cytochrome c oxidase subunit 6A1, mitochondrial Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102100021389 DNA replication licensing factor MCM4 Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 101710146519 Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102000008013 Electron Transport Complex I Human genes 0.000 description 1
- 108010089760 Electron Transport Complex I Proteins 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101000633600 Equus caballus Thyrotropin subunit beta Proteins 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010015549 Euthyroid sick syndrome Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010003163 GDP dissociation inhibitor 1 Proteins 0.000 description 1
- 102000013740 GRB2, N-terminal SH3 domains Human genes 0.000 description 1
- 108050003580 GRB2, N-terminal SH3 domains Proteins 0.000 description 1
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 1
- 101710084647 GTP-binding nuclear protein Ran Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 108091009389 Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 108010047214 HLA-DRB1*03:01 antigen Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101800000791 Hemagglutinin-esterase-fusion glycoprotein chain 1 Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 101710103773 Histone H2B Proteins 0.000 description 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
- 102100021640 Histone H2B type 1-L Human genes 0.000 description 1
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 1
- 101000775844 Homo sapiens AMP deaminase 1 Proteins 0.000 description 1
- 101001041703 Homo sapiens ATP-dependent RNA helicase DDX18 Proteins 0.000 description 1
- 101000690901 Homo sapiens Activity-dependent neuroprotector homeobox protein 2 Proteins 0.000 description 1
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
- 101000802809 Homo sapiens BH3-interacting domain death agonist Proteins 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000737554 Homo sapiens Complement factor D Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 description 1
- 101000940871 Homo sapiens Endonuclease Proteins 0.000 description 1
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 description 1
- 101001010787 Homo sapiens Endoribonuclease Proteins 0.000 description 1
- 101000905392 Homo sapiens Glycerol kinase Proteins 0.000 description 1
- 101000578329 Homo sapiens Glycylpeptide N-tetradecanoyltransferase 1 Proteins 0.000 description 1
- 101000979544 Homo sapiens Glycylpeptide N-tetradecanoyltransferase 2 Proteins 0.000 description 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101000898901 Homo sapiens Histone H2B type 1-L Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101001047746 Homo sapiens Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101001047731 Homo sapiens Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- 101000965689 Homo sapiens Lutropin subunit beta Proteins 0.000 description 1
- 101000962483 Homo sapiens Max dimerization protein 1 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101500028620 Homo sapiens Motilin-associated peptide Proteins 0.000 description 1
- 101000655246 Homo sapiens Neutral amino acid transporter A Proteins 0.000 description 1
- 101000589482 Homo sapiens Nuclear cap-binding protein subunit 2 Proteins 0.000 description 1
- 101001098523 Homo sapiens PAX-interacting protein 1 Proteins 0.000 description 1
- 101000734572 Homo sapiens Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Proteins 0.000 description 1
- 101000582929 Homo sapiens Plasmolipin Proteins 0.000 description 1
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 description 1
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 description 1
- 101000599464 Homo sapiens Protein phosphatase inhibitor 2 Proteins 0.000 description 1
- 101100034367 Homo sapiens RILPL2 gene Proteins 0.000 description 1
- 101001048702 Homo sapiens RNA polymerase II elongation factor ELL2 Proteins 0.000 description 1
- 101001061518 Homo sapiens RNA-binding protein FUS Proteins 0.000 description 1
- 101000700734 Homo sapiens Serine/arginine-rich splicing factor 9 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 101000617964 Homo sapiens Sorcin Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000685001 Homo sapiens Stromal cell-derived factor 2-like protein 1 Proteins 0.000 description 1
- 101000633601 Homo sapiens Thyrotropin subunit beta Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000652707 Homo sapiens Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 1
- 101000835086 Homo sapiens Transferrin receptor protein 2 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000844521 Homo sapiens Transient receptor potential cation channel subfamily M member 5 Proteins 0.000 description 1
- 101000800463 Homo sapiens Transketolase Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000809046 Homo sapiens Ubiquitin conjugation factor E4 B Proteins 0.000 description 1
- 101000805450 Homo sapiens Voltage-dependent anion-selective channel protein 1 Proteins 0.000 description 1
- 101000760182 Homo sapiens Zinc finger protein 45 Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150057269 IKBKB gene Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 1
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000046961 MRE11 Homologue Human genes 0.000 description 1
- 108700019589 MRE11 Homologue Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010007784 Methionine adenosyltransferase Proteins 0.000 description 1
- 108010042046 Mitochondrial processing peptidase Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 101100043050 Mus musculus Sox4 gene Proteins 0.000 description 1
- 102100034711 Myb-related protein A Human genes 0.000 description 1
- 101710115158 Myb-related protein A Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 1
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 1
- 101710083073 NF-kappa-B inhibitor alpha Proteins 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102100032884 Neutral amino acid transporter A Human genes 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 101000606406 Nicotiana tabacum Pistil-specific extensin-like protein Proteins 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100032342 Nuclear cap-binding protein subunit 2 Human genes 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100037141 PAX-interacting protein 1 Human genes 0.000 description 1
- 101150039326 PCK1 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100027006 Paraplegin Human genes 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100034796 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102100030265 Plasmolipin Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010041472 Poly(A)-Binding Protein II Proteins 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108700006317 Purine-nucleoside phosphorylases Proteins 0.000 description 1
- 102100026173 Putative P2Y purinoceptor 10 Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100033758 RILP-like protein 2 Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 102100028191 Ras-related protein Rab-1A Human genes 0.000 description 1
- 102100030705 Ras-related protein Rap-1b Human genes 0.000 description 1
- 101710116844 Ras-related protein Rap-1b Proteins 0.000 description 1
- 101001077668 Rattus norvegicus Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000009445 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 1
- 108010048858 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 102000011260 Retinoblastoma Binding Proteins Human genes 0.000 description 1
- 108010023377 Retinoblastoma Binding Proteins Proteins 0.000 description 1
- 102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 1
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 1
- 108091008770 Rev-ErbAß Proteins 0.000 description 1
- 102100025622 Rho GDP-dissociation inhibitor 2 Human genes 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 1
- 101150044829 SRSF3 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 description 1
- 101710099809 Serine hydroxymethyltransferase, cytosolic Proteins 0.000 description 1
- 101710147214 Serine protease inhibitor Kazal-type 2 Proteins 0.000 description 1
- 102100035701 Serine/arginine-rich splicing factor 10 Human genes 0.000 description 1
- 101710117510 Serine/arginine-rich splicing factor 10 Proteins 0.000 description 1
- 101710123508 Serine/arginine-rich splicing factor 3 Proteins 0.000 description 1
- 102100029710 Serine/arginine-rich splicing factor 6 Human genes 0.000 description 1
- 101710123515 Serine/arginine-rich splicing factor 6 Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 101710154408 Serine/threonine-protein kinase sax-1 Proteins 0.000 description 1
- 101710130108 Serine/threonine-protein kinase tricornered Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 101100174184 Serratia marcescens fosA gene Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 108010042291 Serum Response Factor Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 101150102611 Smad2 gene Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100023183 Stromal cell-derived factor 2-like protein 1 Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101000760986 Sus scrofa 5'-AMP-activated protein kinase subunit gamma-1 Proteins 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 101150104012 TOP2 gene Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 101150050472 Tfr2 gene Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102100029530 Thyrotropin subunit beta Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 1
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 1
- 102100030833 Transcription initiation factor TFIID subunit 4 Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- 235000001468 Triticum dicoccon Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100038487 Ubiquitin conjugation factor E4 B Human genes 0.000 description 1
- 101710132695 Ubiquitin-conjugating enzyme E2 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 102100026522 Zinc finger protein 267 Human genes 0.000 description 1
- 102100024670 Zinc finger protein 45 Human genes 0.000 description 1
- 101710160545 Zinc finger protein 45 Proteins 0.000 description 1
- 101710204001 Zinc metalloprotease Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- NPDSHTNEKLQQIJ-ZJHFMPGASA-N alpha-dimorphecolic acid Chemical compound CCCCC\C=C/C=C/C(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-ZJHFMPGASA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 239000003525 auxine Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 101150023452 bioD gene Proteins 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000004736 colon carcinogenesis Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 108020003468 cytochrome b558 Proteins 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 108010050073 dethiobiotin synthetase Proteins 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108010050651 factor XIII activation peptide Proteins 0.000 description 1
- 208000003816 familial cirrhosis Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 101150078861 fos gene Proteins 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017931 gastrointestinal anthrax Diseases 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 102000045507 human CFD Human genes 0.000 description 1
- 102000051556 human ELL2 Human genes 0.000 description 1
- 102000052301 human GNAZ Human genes 0.000 description 1
- 102000044980 human MTOR Human genes 0.000 description 1
- 102000044255 human PCNA Human genes 0.000 description 1
- 102000046104 human TMPO Human genes 0.000 description 1
- 102000057493 human ZNF45 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000023372 inhalational anthrax Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000019697 interleukin-15 production Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000003644 lens cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000032820 leukocyte apoptotic process Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108091006026 monomeric small GTPases Proteins 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108010009127 mu transposase Proteins 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- JBPWDTQELHPIPV-UHFFFAOYSA-N n-(3,6-dihydro-2h-pyridin-1-yl)pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NN1CCC=CC1 JBPWDTQELHPIPV-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000020395 negative regulation of osteoclast differentiation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000006776 neuronal homeostasis Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 108010036962 polypeptide 3 90kDa ribosomal protein S6 kinase Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000031339 positive regulation of inflammatory response Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 108020004098 protein phosphatase inhibitor-2 Proteins 0.000 description 1
- 102000006241 protein phosphatase inhibitor-2 Human genes 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 108010054067 rab1 GTP-Binding Proteins Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008597 receptor serine/threonine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000025501 regulation of leukocyte apoptotic process Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108010065332 rho Guanine Nucleotide Dissociation Inhibitor beta Proteins 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 101150086583 rlp2 gene Proteins 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000998 shell membrane Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 108010014657 sortilin Proteins 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 229950009638 tepoxalin Drugs 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Gene control is generally thought to occur at four levels: 1) transcription (either initiation or termination), 2) processing of primary transcripts, 3) stabilization or destabilization of mRNAs, and 4) mRNA translation.
- the primary function of gene control in cells is to adjust the enzymatic machinery of the cell to its nutritional, chemical and physical environment.
- the membrane-impermeable signal molecules include acetylcholine, growth factors, extracellular matrix components, thrombin, lysophosphatidic acid, the yeast mating factors and, for the social amoeba Dictyostellium discoideum , folic acid and cyclic AMP. They are recognized by receptors, which are localized on the plasma membrane of the cell. The receptors are specific for one particular signal molecule or a family of closely related signal molecules. Upon binding of their ligands, these receptors transduce the signals by several mechanisms.
- cyclopentenone prostaglandins may be endogenous anti-inflammatory mediators and promote the resolution of inflammation in vivo. Others have shown a temporal shift to the production of anti-inflammatory lipoxins during the resolution of inflammation. In recent years, apoptosis has been identified as an important mechanism for the resolution of inflammation in vivo. It has been postulated that defects in leukocyte apoptosis are important in the pathogenesis of inflammatory disease. In addition, the selective induction of apoptosis in leukocytes may offer a new therapeutic approach to inflammatory disease.
- NF-kappaB is thought by many to be a primary effector of disease (A. S. Baldwin, J. Clin. Invest., 2001, 107:3-6), numerous efforts are underway to develop safe inhibitors of NF-kappaB to be used in treatment of both chronic and acute disease situations. Specific inhibitors of NF-kappaB should reduce side effects associated with drugs such as NSAIDS and glucocorticoids and would offer significant potential for the treatment of a variety of human and animal diseases.
- peptides or analogues can be circularised (for example by providing them with (terminal) cysteines, dimerised or multimerised, for example by linkage to lysine or cystein or other compounds with side-chains that allow linkage or multimerisation, brought in tandem- or repeat-configuration, conjugated or otherwise linked to carriers known in the art, if only by a labile link that allows dissociation.
- the invention also provides a signalling molecule for modulating expression of a gene in a cell comprising a small peptide or functional analogue or derivative thereof.
- a small peptide acts as a signalling molecule that can modulatesignal transduction pathways and gene expression.
- a functional analogue or derivative of a small peptide that acts as such a signalling molecule for modulating expression of one or more genes in a cell can be identified or obtained by at least one of various methods for finding such a signalling molecule as provided herein.
- the I ⁇ B family is characterized by the presence of multiple copies of ankyrin repeats, which are protein-protein interaction motifs that interact with NF- ⁇ B via the RHD.
- I ⁇ B phosphorylated by I ⁇ B kinases (IKKs), polyubiquitinated by a ubiquitin ligase complex, and degraded by the 26S proteosome. Consequently, NF- ⁇ B is released and translocates into the nucleus to initiate gene expression.
- IKKs I ⁇ B kinases
- NF- ⁇ B related transcription factors regulate the expression of a wide variety of genes that play critical roles in innate immune responses.
- NF- ⁇ B target genes include those encoding cytokines (e.g., IL-1, IL-2, IL-6, IL-12, TNF- ⁇ , LT ⁇ , LT ⁇ , and GM-CSF), adhesion molecules (e.g., ICAM, VCAM, endothelial leukocyte adhesion molecule [ELAM]), acute phase proteins (e.g., SAA), and inducible enzymes (e.g., iNOS and COX-2).
- cytokines e.g., IL-1, IL-2, IL-6, IL-12, TNF- ⁇ , LT ⁇ , LT ⁇ , and GM-CSF
- adhesion molecules e.g., ICAM, VCAM, endothelial leukocyte adhesion molecule [ELAM]
- SAA endothelial leukocyte adhesion molecule
- NF-kappaB is rapidly activated upon microbial and viral invasion, and this activation usually correlates with resistance of the host to infection.
- persistent activation of NF-kappaB may lead to the production of excessive amounts of pro-inflammatory mediators such as IL-12 and TNF-alpha, resulting in tissue damage, as in insulin dependent diabetes mellitus, atherosclerosis, Crohn's disease, organ failure, and even death of the host, as in bacterial infection-induced septic shock.
- the invention surprisingly provides a signalling molecule capable of modulating expression of a gene in a cell, the molecule being a short peptide, preferably of at most 30 amino acids long or a functional analogue or derivative thereof.
- the peptide is an oligopeptide of from about 3 to at about 15 amino acids long, preferably 4 to 12, more preferably 4 to 9, most preferably 4 to 6 amino acids long, or a functional analogue or derivative thereof.
- signalling molecule can be longer, for example by extending it (N- and/or C-terminally, with more amino acids or other side groups, which can for example be (enzymatically) cleaved off when the molecule enters the place of final destination. Such extension may even be preferable to prevent the signalling molecule from becoming active in an untimely fashion, however, the core or active fragment of the molecule comprises the aforementioned oligopeptide or analogue or derivative thereof.
- the invention provides a modulator of NF-kappaB/Rel protein activation comprising a signalling molecule according to the invention.
- modulators are widely searched after these days.
- the invention provides use of a signalling molecule according to the invention for the production of a pharmaceutical composition for the modulation of gene expression.
- the treatment comprises administering to the subject a pharmaceutical composition comprising an oligopeptide or functional analogue thereof also capable of reducing production of NO by a ceel, for example wherein the composition comprises at least two oligopeptides or functional analogues thereof each capable of reducing production of NO and/or TNF-alpha by a cell, in particular wherein the at least two oligopeptides are selected from the group LQGV, AQGV and VLPALP.
- a signal molecule is administered in an effective concentration to an animal or human systemically, e.g. by intravenous, intra-muscular or intraperitoneal administration.
- Another way of administration comprises perfusion of organs or tissue, be it in vivo or ex vivo, with a perfusion fluid comprising a signal molecule according to the invention.
- Topical administration e.g. in ointments or sprays, may also apply, e.g. in inflammations of the skin or mucosal surfaces of for example mouth, nose and/or genitals.
- Suitable approach for single dose delivery of an active molecule in accordance with the present invention involves the use of viscous installates.
- high molecular weight carriers are used in admixture with the active molecule, giving rise to a structure which produces a solution with high viscosity.
- Suitable high molecular weight carriers include, but are not limited to, the following: dextrans and cyclodextrans; hydrogels; (cross-linked) viscous materials, including (cross-linked) viscoelastics; carboxymethylcellulose; hyaluronic acid; and chondroitin sulfate.
- dextrans and cyclodextrans include, but are not limited to, the following: dextrans and cyclodextrans; hydrogels; (cross-linked) viscous materials, including (cross-linked) viscoelastics; carboxymethylcellulose; hyaluronic acid; and chondroitin sulfate.
- the preparation and use of drug-loaded viscous instillates is well
- NF-kappaB/Rel proteins are a group of structurally related and evolutionarily conserved proteins (Rel). Well known are c-Rel, RelA (p65), RelB, NF-kappaB 1 (p50 and its precursor p105), and NF-kappaB2 (p52 and its precursor p100). Most NF-kappaB dimers are activators of transcription, p50/p50 and p52/p52 homodimers repress the transcription of their target genes. All NF-kappaB/Rel proteins share a highly conserved NH2-terminal Rel homology domain (RHD). RHD is responsible for DNA binding, dimerization, association with inhibitory proteins known as IkappaBs.
- RHD NH2-terminal Rel homology domain
- IkappaB Upon appropriate stimulation, IkappaB is phosphorylated by IkappaB Kinase (IKKs), polyubiquitinated by ubiquitin ligase complex, and degraded by the 26S proteosome. NF-kappaB is released and translocates into nucleus to initiate gene expression.
- IKKs IkappaB Kinase
- NF-kappaB NF-kappaB is released and translocates into nucleus to initiate gene expression.
- the invention also provides a method to mitigate or treat neonatal lung disease, also called chronic lung disease of prematurity, a condition often seen with premature children who develop a prolonged pulmonary inflammation or bronchopulmonary dysplasia. Treating such premature children with an NF-kappaB inhibitor, such as oligopeptide LQGV, or functional analogue or derivative thereof, as provided herein allows such lung conditions to be prevented or ameliorated as well.
- neonatal lung disease also called chronic lung disease of prematurity
- an NF-kappaB inhibitor such as oligopeptide LQGV, or functional analogue or derivative thereof, as provided herein allows such lung conditions to be prevented or ameliorated as well.
- the invention thus also provides a method of treatment of a bone disease, such as osteoporosis (which is often, but not exclusively seen with post-meno-pausal women) Furthermore, NO and TNF-alpha modulators as provided herein inhibit the inflammatory response and bone loss in periodontitis. Furthermore, considering that there is a correlation between TNF-alpha activity, and severity of clinical manifestations in ankylosing spondylitis, the invention provides the treatment of spondylitis by use of a signalling molecule as provided herein.
- PAMPS Pathogen associated molecular patterns
- LPS lipopolysaccharides
- BLP lipoproteins
- PPN peptidoglycans
- LAM lipoarabinomannan
- LTA lipoteichoic acid
- a signalling molecule according to the invention is found in the prevention or mitigation of ischemia-related tissue damage seen after infarcts, seen for example in vivo in brain or heart, or ex vivo in organs or tissue that is being prepared or stored in preparation of further use as a transplant. Ischemia related tissue damage can now be mitigated by perfusing the (pre)ischemic area with a signalling molecule according to the invention that inhibits NF-kappaB activation.
- the invention provides a method for perfusing a transplant with a perfusing fluid comprising at least one signalling molecule according to the invention; ischemic or pre-implantation damage due to activation of NF-kappaB in the transplant can than greatly be diminished, allowing a wider use of the transplants.
- the invention provides a method and a signalling molecule for the treatment of conditions that are associated with dysfunctional LDL receptors such as ApoE and other members of the apolipoprotein family.
- a signalling molecule comprising GVLPALPQ and/or VLPALP or a functional analogue or derivative thereof is preferred.
- the invention provides the use of a signalling molecule according to the invention for the preparation of a pharmaceutical composition or medicament for modulating angiogenesis or vascularisation, in particular during embryonal development, or after transplantation to stimulate vascularisation into the transplanted organ or inhibit it in a later phase.
- Signalling molecules that effect angiogenesis are disclosed herein in the detailed description.
- FIGS. 20 - 32 In vivo treatment of fertilised chicken eggs with NMPF and the effect of NMPF on angiogenesis. Fertile chicken eggs (day 0) were treated with either PBS, NMPF, VEGF or VEGF in combination with NMPF. Ten eggs were injected for every condition. On day 8 of incubation, the embryos were removed from the eggs and were placed in a 100-mm Petri dish. The embryo and the blood vessels were photographed in vivo with the use of a microscope. Of each egg one overview picture was taken and 4 detail pictures of the blood vessels were taken. Quantification of angiogenesis (vessels branches) was accomplished by counting the number of blood vessels branches. Quantification of this vasculogenesis was accomplished by measuring the blood vessel thickness.
- FIG. 50 show the NO production of LPS (10 ⁇ g/ml) stimulated RAW 264.7 macrophages co-stimulated with different NMPF peptides (1 pg/ml).
- FIG. 51 These figures show the NO production of LPS (10 ⁇ g/ml) stimulated RAW 264.7 macrophages co-stimulated with different NMPF peptides with three different concentrations.
- NF-kappaB which can be activated within minutes by a variety of stimuli, including membrane receptors (for example pattern recognition receptors like Toll-like receptor binding to pathogen-associated molecular patterns), inflammatory cytokines such as TNF- ⁇ , IL-1, T-cell activation signals, growth factors and stress inducers.
- Apolipoprotein E (apo E) deficiency is associated with a series of pathological conditions including dyslipidemia, atherosclerosis, Alzheimer's disease, increase body weight and shorter life span. Inheritance of different alleles of the POLYMORPHIC apoE gene is responsible for 10% of the variation in plasma cholesterol in most populations. Individuals HOMOZYGOUS for one variant. apoE2, can develop type III dysbetalipoproteinaemia if an additional genetic or environmental factor is present. Some much rarer alleles of apoE produce dominant expression of this disorder in heterozygous individuals.
- ApoE is a ligand for the LDL receptor and its effects on plasma cholesterol are mediated by differences in the affinity of the LDL receptor for lipoproteins carrying variant apoE proteins.
- the factors that regulate apoE gene transcription have been investigated extensively by the expression of gene constructs in transgenic mice and involve complex interactions between factors that bind elements in the 5′ promoter region, in the first intron and in 3′ regions many kilobases distant from the structural gene.
- Deletion of the apo E gene is associated with changes in lipoprotein metabolism [plasma total cholesterol), HDL cholesterol, HDL/TC, and HDL/LDL ratios, esterification rate in apo B-depleted plasma, plasma triglyceride, hepatic HMG-CoA reductase activity, hepatic cholesterol content, decreased plasma homocyst(e)ine and glucose levels, and severe atherosclerosis and cutaneous xanthomatosis.
- peptides that show the modulation of translocation of NF-kB are: (NMPF-1)VLPALPQVVC, (NMPF-2)LQGVLPALPQ, (NMPF-3)LQG, (NMPF-4)LQGV, (NMPF-5)GVLPALPQ, (NMPF-6)VLPALP, (NMPF-7)VLPALPQ, (NMPF-8)GVLPALP, (NMPF-9)VVC, (NMPF-11)MTRV, (NMPF-12)MTR.
- FIG. 34 shows HPLC chromatograph (wave length 206) in which data profile obtained from the nuclear protein extracts of LPS and LPS in combination with NMPF-4 (LQGV) stimulated RAW264.7 cells are overlayed. This figure also show the presence or absence of number of molecule signals in the nuclear extracts of oligopeptide+LPS treated cells as compared to nuclear extracts of LPS treated cells. Since HPLC profile of LQGV showed that the peptide elutes at around 12 minutes (data not shown), fraction corresponding to region 10-15 minutes was collected and analysed for the presence of this peptide in MS.
- FIG. 35 shows some other molecular weights. This is to be explained by the high concentration of the peptide which induces the formation of dimers and sodium-adducts (m/z 416-[M+H]+, 438-[M+Na]+, 831-[2M+H]+, 853-[2M+Na]+, 1245-[3M+H]+, 1257-[3M+Na]+).
- FIG. 36 shows the MS results of 10-15 min. fraction of nuclear extract obtained from LPS stimulated cells. These results show the absence of 416 dalton mass, while FIG. 37 shows the presence of 416 dalton mass of which the MSn data (FIG. 37) and MS-sequence confirm the presence of LQGV peptide in the nuclear protein extract obtained from LQGV+LPS stimulated RAW264.7 cells.
- mice were injected i.p. either with 10 mg/kg or with 11 mg/kg LPS ( E. coli 026:B6; Difco Lab., Detroit, Mich., USA). Subsequently mice were treated after 2 hours and 24 hours of LPS treatment with NMPF peptides.
- LPS E. coli 026:B6; Difco Lab., Detroit, Mich., USA.
- FIGS. 4 - 7 there is a significant decrease in cell yield in LPS treated BM cells as compared to PBS.
- NMPF have immunoregulatory effects in chronic inflammatory as well as acute inflammatory mice models. Since certain cytokines like TGF-beta1, TNF-alpha, IL-1 and ROS (reactive oxygen species) have been implicated in irreversible myocardial damage produced by prolonged episodes of coronary artery occlusion and reperfusion in vivo that leads to ischaemia and myocardial infarct, we tested the cardio-protective properties of peptides in ad libitum fed male Wistar rats (300 g).
- the coronary artery was re-occluded and was perfused with 10 ml Trypan Blue (0.4%, Sigma Chemical Co.) to stain the normally perfused myocardium dark blue and delineate the nonstained area at risk (AR).
- the heart was then quickly excised and cut into slices of 1 mm from apex to base. From each slice, the right ventricle was removed and the left ventricle was divided into the AR and the remaining left ventricle, using micro-surgical scissors. The AR was then incubated for 10 min in 37° C. Nitro-Blue-Tetrazolium (Sigma Chemical Co.; 1 mg per 1 ml Sorensen buffer, pH 7.4), which stains vital tissue purple but leaves infarcted tissue unstained. After the infarcted area (IA) was isolated from the noninfarcted area, the different areas of the LV were dried and weighed separately. Infarct size was expressed as percentage of the AR. Control rats were treated with PBS.
- FIGS. 20 - 30 show that NMPF 3, 4, 9 and 11 promoted angiogenesis (p ⁇ 0.05), while NMPF VEGF, 7, 43, 44, 45, 46, 51 and 56 inhibited angiogenesis (p ⁇ 0.05).
- NMPF 6, 7, 12, 45, 46 and 66 were able to inhibit angiogenesis induced by VEGF.
- NMPF 6 itself did not show any effect on angiogensis, but it inhibited (p ⁇ 0.05) NMPF 3 induced angiogenesis.
- the RAW 264.7 murine macrophage cell line obtained from American Type Culture Collection (Manassas, Va., USA), were cultured at 37° C. in 5% CO 2 using DMEM containing 10% fetal calf serum (FCS), 50 U/ml penicillin, 50 ⁇ g/ml streptomycin, 0.2 M Na-pyruvate, 2 mM glutamine and 50 ⁇ M 2-mercaptoethanol (Bio Whittaker, Europe). The medium was changed every 2 days.
- FCS fetal calf serum
- penicillin 50 ⁇ g/ml streptomycin
- 0.2 M Na-pyruvate 2 mM glutamine
- 2-mercaptoethanol Bio Whittaker, Europe
- the invention provides a method and a signalling molecule for the treatment of conditions that are associated with dysfunctional LDL receptors such as ApoE and other members of the apolipoprotein family.
- a signalling molecule comprising GVLPALPQ (NMPF-5) and/or VLPALP (NMPF-6) or a functional analogue or derivative thereof is preferred.
- AI188872 11.3 366 327 18 382 [ Homo sapiens ]qd27c01.x1 Soares_placenta — 8 to 9weeks — 2NbHP8 to 9W
- AI126906 19.8 418 343 1 418 [ Homo sapiens ]qb95f01.x1 Soares_fetal_heart_NbHH19W
- AI221581 29.1 456 341 23 510 [ Homo sapiens ]qg20a03.x1 Soares_placenta — 8 to 9 weeks 2 NbHP8 to 9W Homo sapiens cDNA clone IMAGE:1760044 3′ similar to gb:J00117 CHORIOGONADOTROPIN BETA CHAIN PRECURSOR (HUMAN);, mRNA sequence.; minus strand; translated
- VLQAILPSAPQ LQA, LQAIL, PSAP, LPS
- VLQAILPSAPQ LQA, LQAIL, PSAP, PSAPQ
- Hs.303116.2 PROTSIM pir; T33097 stromal cell-derived factor 2-like1; translated
- MMRVLQAVLPPLPQVVC MMR, MMRV, LQA, LQAV, VLPPLP, PPLP, QVVC, VVC, VLPPLPQ, AVLPPLP, AVLPPLPQ
- MMRVLQAVLPPVPQVVC MMR, MMRV, LQA, LQAG, VLPPVP, VLPPVPQ, QVVC, VVC, AVLPPVP, AVLPPVPQ
- NMPF a mixture 1:1:1 of LQGV, AQGV and VLPALP
- NMPF a mixture 1:1:1 of LQGV, AQGV and VLPALP
- Overwhelming inflammatory and immune responses are essential features of septic shock and play a central part in the pathogenesis of tissue damage, multiple organ failure, and death induced by sepsis.
- Cytokines especially tumour necrosis factor (TNF)- ⁇ interleukin (IL)-1 ⁇ , and macrophage migration inhibitory factor (MIF) have been shown to be critical mediators of septic shock. Yet, traditional anti-TNF and anti-IL-1 therapies have not demonstrated much benefit for patients with severe sepsis.
- the monkeys were kept anaesthetized throughout the observation period and sacrificed 7 hours after the start of the bacterium infusion for pathological examination.
- the animals underwent a gross necropsy in which the abdominal and throrac cavities were opened and internal organs examined in situ.
- the Escherichia coli strain was purchased from ATCC ( E - coli; 086a: K61 serotype, ATCC 33985). In a control experiment the strain proved equally susceptible to bactericidal factors in human and rhesus monkey serum.
- E.coli dose was used to calculate the E.coli dose and E.coli stock was suspended in isotonic saline (N.P.B.I., Emmer-Compascuum, The Netherlands) at the concentration needed for infusion (total dose volume for infusion approximately 10 ml/kg.
- the E.coli suspension was kept on ice until infusion.
- the femoral or the cephalic vein was cannulated and used for infusing isotonic saline, live E.coli and antibiotic administration. Insensible fluid loss was compensated for by infusing isotonic saline containing 2.5% glucose (Fresenius, 's Hertogenbosch, The Netherlands) at a rate of 3.3 ml/kg/hr.
- Baytril was administered intravenously immediately after completion of the 2 h. E.coli infusion (i.v.; dose 9 mg/kg).
- NMPF NMPF oligopeptide
- LQGV LQGV
- AQGV AQGV
- VLPALP VLPALP
- Tissues of all organs were preserved in neutral aqueous phosphate buffered 4% solution of formaldehyde. Lymphoid organs were be cryopreserved. All tissues will be processed for histopathological examination.
- the gene chip expression analysis revealed that due to LQGV treatment of PM1 (T-cell line) cells for 4 hours in the presence of PHA/IL-2 down-regulated at least 120 genes more than 2 fold as compared to control PM1 cells (stimulated with PHA/IL-2) only. Moreover, at least 6 genes were up-regulated more than 2 fold in peptide treated cells as compared to control cells.
- HEF1 Homo sapiens enhancer of filamentation
- H.sapiens NAP nucleosome assembly protein
- complete cds /cds (75,1250)
- Some diseases associated with dysregulation of NF-kB and related transcription factors are: Atherosclerosis, asthma, arthritis, anthrax, cachexia, cancer, diabetes, euthyroid sick syndrome, AIDS, inflammatory bowel disease, stroke, (sepsis) septic shock, inflammation, neuropathological diseases, autoimmunity, thrombosis, cardiovascular disease, psychological disease, post surgical depression, wound healing, burn-wounds healing and neurodegenerative disorders.
- PKC plays an essential role in T cell activation via stimulation of for example AP-1 and NF-kB that selectively translocate to the T cell synapse via Vav/Rac pathway.
- PKC is involved in a variety of immunological and non-immunological diseases as is clear from standard text books of internal medicine (examples are metabolic diseases, cancer, angiogenesis, immune mediated disorders, diabetes etc.)
- LPS and ceramide induce differential multimeric receptor complexes, including CD14, CD11b, Fc-gRIII, CD36, TAPA, DAF and TLR4. This signal transduction pathway explains the altered function of monocytes in hypercholesterolemia and lipid disorders.
- Oxidized low-density lipoproteins contribute to stages of the atherogenic process and certain concentrations of oxidized low-density lipoproteins induce apoptosis in macrophages through signal transduction pathways. These pathways are involved in various vascular diseases such as atherosclerosis, thrombosis etc.
- TLR9 Toll like receptor 9
- MyD88 Toll like receptor 9
- TLR9 Toll like receptor 9
- MyD88 Toll like receptor 9
- Recognition of dsRNA during viral infection seems to be dependent on intracellular recognition by the dsRNA dependent protein kinase PKR.
- TLRs play an essential role in the immune system and they are important in bridging and balancing innate immunity and adaptive immunity. Modulation of these receptors or their down-stream signalling pathways are important for the treatment of various immunological conditions such as infections, cancer, immune-mediated diseases, autoimmunity, certain metabolic diseases with immunological component, vascular diseases, inflammatory diseases etc.
- PDGF-AA Effect of growth factor PDGF-AA on NF-kB and proinflammatory cytokine expression in rheumatoid synoviocytes; PDGF-AA augmented NF-kB activity and mRNA expression of IL-1b, IL-8 and MIP-1a. Therefore, PDGF-AA may play an important role in progression of inflammation as well as proliferation of synoviocytes in RA.
- DC activation is a critical event for the induction of immune responses.
- DC activation induced by LPS can be separated into two distinct processes: first, maturation, leading to upregulation of MHC and costimulatory molecules, and second, rescue from immediate apoptosis after withdrawal of growth factors (survival).
- LPS induces NF-kB transcription factor. Inhibition of NF-kB activation blocked maturation of DCs in terms of upregulation of MHC and costimulatory molecules.
- LPS activates the extracellular signal-regulated kinases (ERK), and specific inhibition of MEK1, the kinase which activates ERK, abrogate the ability of LPS to prevent apoptosis but do not inhibit DC maturation or NF-kB nuclear translocation.
- ERK and NF-kB regulate different aspects of LPS induced DC activation.
- Our DC data and NF-kB data also show the various effects of NMPF peptide on DC maturation and proliferation in the presence or absence of LPS.
- NMPF peptides modulate these pathways and are novel tools for the regulation of DC function and immunoregulation. This opens new ways for the treatment of immune diseases, particularly those in which the immune system is in disbalance (DC1-DC2, Th1-Th2, regulatory cell etc.)
- DC cells and other antigen presenting cells like macrophages, B-cells
- DC cells and other antigen presenting cells play an essential role in the immune system and they are also important in bridging and balancing innate immunity and adaptive immunity. Modulation of these cells or their down-stream signalling pathways are important for the treatment of various immunological conditions such as infections, cancer, immune-mediated diseases, autoimmunity, certain metabolic diseases with immunological component, vascular diseases, inflammatory diseases etc.
- mast cells play important roles in exerting the innate immunity by releasing inflammatory cytokines and recruitment of neutrophils after recognition of infectious agents through TLRs on mast cells.
- STAT1 In murine macrophages infected with Mycobacterium tuberculosis through JAK pathway activate STAT1 and activation of STAT1 may be the main transcription factor involved in IFN-g-induced MHC class II inhibition.
- MBL mannose-binding lectin
- NFkappaB Nuclear factor-kappaB
- PPARs Peroxisome proliferator-activated receptors
- PPAR alpha is highly expressed in liver, muscle, kidney and heart, where it stimulates the beta-oxidative degradation of fatty acids.
- PPAR gamma is predominantly expressed in intestine and adipose tissue, where it triggers adipocyte differentiation and promotes lipid storage. Recently, the expression of PPAR alpha and PPAR gamma was also reported in cells of the vascular wall, such as monocyte/macrophages, endothelial and smooth muscle cells.
- hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPAR alpha and PPAR gamma, respectively.
- fatty acid-derivatives and eicosanoids are natural PPAR ligands: PPAR alpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPAR gamma ligand, as well as of some components of oxidized LDL, such as 9- and 13-HODE.
- PPAR activators were shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNF alpha and metalloproteases) by negatively interfering with the NF-kappa B, STAT and AP-1 signalling pathways in cells of the vascular wall.
- inflammatory response genes such as IL-2, IL-6, IL-8, TNF alpha and metalloproteases
- PPARs may also control lipid metabolism in the cells of the atherosclerotic plaque.
- PPARs are also involved in a variety of immunological and non-immunological diseases as is clear from standard text books of internal medicine (examples are metabolic diseases, cancer, angiogenesis, immune mediated disorders, diabetes etc.)
- Proliferative diabetic retinopathy is one of the major causes of acquired blindness.
- the hallmark of PDR is neovascularisation (NV), abnormal angiogenesis that may ultimately cause severe vitreous cavity bleeding and/or retinal detachment.
- NV neovascularisation
- NMPF peptides have angiogenesis stimulatory as well as inhibitory effects and have the ability to modulate intracellular signaling involved in growth factors (like insulin)
- pharmacologic therapy with certain NMPF peptides can improve metabolic control (like glucose) or blunt the biochemical consequences of hyperglycaemia (through mechanisms such as in which aldose reductase, protein kinase C (PKC), PPARs are involved).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing said cell with a signalling molecule comprising a peptide or functional analogue thereof. Furthermore, the invention provides a method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing said cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor.
Description
- Gene control is generally thought to occur at four levels: 1) transcription (either initiation or termination), 2) processing of primary transcripts, 3) stabilization or destabilization of mRNAs, and 4) mRNA translation. The primary function of gene control in cells is to adjust the enzymatic machinery of the cell to its nutritional, chemical and physical environment.
- It is generally thought that gene expression is regulated at both the level of transcription and translation. Modulation or regulation of gene expression requires factors called transcriptional factors. The term gene control or regulation also refers to the formation and use of mRNA. Although control can be exerted at a number of different molecular steps, differential transcription probably most frequently underlies the differential rate of protein synthesis in prokayotes as well as eukaryotes. It is generally thought that activator proteins (also called transcription factors or transcriptional activators) bind to DNA and recruit the transcriptional machinery in a cell to a promotor, thereby stimulating gene expression. Further, differential processing of RNA transcripts in the cell nucleus, differential stabilization of mRNA in the cytoplasm, and differential translation of mRNA into protein are also important in eukaryotic gene control. These steps define the regulatory decisions in a transcriptional circuit and misregulation at any stage can result in a variety of diseases.
- Where in unicellular organisms, be it of prokaryotic or eukaryotic origin, a cell's response to its environment is influenced by many stimuli from the outside world, reflecting the often widely variable environment of the single cell, most cells in multicellular organisms experience a fairly constant environment. Perhaps for this reason, genes that are devoted to responses to environmental changes constitute a much smaller fraction of the total number of genes in multicellular organisms than in single-cell organisms.
- As said above, cells react to environmental changes, which they perceive through extracellular signals. These signals can be either physical (e.g. light, temperature, pressure and electricity) or chemical (e.g. food, hormones and neurotransmitters). Cells can both sense and produce signals. This makes it possible that they communicate with each other. In order to achieve this, there are complex signal-sensing and -producing mechanisms in uni- and multi-cellular organisms.
- Two groups of chemical signals can be distinguished: membrane permeable and membrane-impermeable signals. The membrane-permeable signal molecules comprise the large family of steroid hormones, such as estrogens, progesterone and androgens. Steroids pass the plasma membrane and bind to specific receptors, which are localized in the cytoplasm or nucleus of the cell. After binding of the hormone, the receptor undergoes a conformational change. The receptor is then able to bind to DNA itself or to proteins which can in turn interact with DNA. In general, steroid hormones can directly regulate gene expression by means of this process. The membrane-impermeable signal molecules include acetylcholine, growth factors, extracellular matrix components, thrombin, lysophosphatidic acid, the yeast mating factors and, for the social amoebaDictyostellium discoideum, folic acid and cyclic AMP. They are recognized by receptors, which are localized on the plasma membrane of the cell. The receptors are specific for one particular signal molecule or a family of closely related signal molecules. Upon binding of their ligands, these receptors transduce the signals by several mechanisms.
- The most characteristic and exacting requirement of gene control on multicellular organisms is the execution of precise developmental decisions so that the right gene is activated in the right cell at the right time. These developmental decisions include not only those related to the development of an organism perse, as for example can be seen during embryogenesis and organogenesis, or in response to disease but also relate to the differentiation or proliferation or apoptosis of those cells that merely carry out their genetic program essentially without leaving progeny behind.
- Such cells, such as skin cells, precursors of red blood cells, lens cells of the eye, antibody-producing cells, are also often regulated by patterns of gene control that serve the need of the whole organism and not the survival of an individual cell.
- It is generally reasoned that there are at least three components of gene control: molecular signals, levels and mechanisms. Firstly, it is reasoned that specific signalling molecules exist to which a specific gene can respond. Secondly, control is exerted on one or more levels (i.e. the step or steps) in the chain of events leading from the transcription of DNA to the use of mRNA in protein synthesis. Thirdly, at each of those levels, specific molecular mechanisms are employed to finally exert the control over the gene to be expressed.
- Many genes are regulated not by a signalling molecule that enters the cells but by molecules that bind to specific receptors on the surface of cells. Interaction between cell-surface receptors and their ligands can be followed by a cascade of intracellular events including variations in the intracellular levels of so-called second messengers (diacylglycerol, Ca2+, cyclic nucleotides). The second messengers in turn lead to changes in protein phosphorylation through the action of cyclic AMP, cyclic GMP, calcium-activated protein kinases, or protein kinase C, which is activated by diaglycerol.
- Many of the responses to binding of ligands to cell-surface receptors are cytoplasmatic and do not involve immediate gene activation in the nucleus. Some receptor-ligand interactions, however, are known to cause prompt nuclear transcriptional activation of a specific and limited set of genes. For example, one proto-oncogene, c-fos, is known to be activated in some cell types by elevation of almost every one of the known second messengers and also by at least two growth factors, platelet-derived growth factor and epidermal growth factor. However, progress has been slow in determining exactly how such activation is achieved. In a few cases, the transcriptional proteins that respond to cell-surface signals have been characterized.
- One of the clearest examples of activation of a pre-existing inactive transcription factor following a cell-surface interaction is the nuclear factor (NF)-kappaB, which was originally detected because it stimulates the transcription of genes encoding immunoglobulins of the kappa class in B-lymphocytes. The binding site for NK-kappaB in the kappa gene is well defined (see for example P. A. Baeuerle and D. Baltimore, 1988, Science 242:540), providing an assay for the presence of the active factor. This factor exists in the cytoplasm of lymphocytes complexed with an inhibitor. Treatment of the isolated complex in vitro with mild denaturing conditions dissociates the complex, thus freeing NK-kappaB to bind to its DNA site. Release of active NF-kappaB in cells is now known to occur after a variety of stimuli including treating cells with bacterial lipopolysaccharide (LPS) and extracellular polypeptides as well as chemical molecules (e.g. phobol esters) that stimulate intracellular phosphokinases. Thus a phosphorylation event triggered by many possible stimuli may account for NF-kappaB conversion to the active state. The active factor is then translocated to the cell nucleus to stimulate transcription only of genes with a binding site for active NF-kappaB.
- The inflammatory response involves the sequential release of mediators and the recruitment of circulating leukocytes, which become activated at the inflammatory site and release further mediators (Nat. Med. 7:1294;2001). This response is self-limiting and resolves through the release of endogenous anti-inflammatory mediators and the clearance of inflammatory cells. The persistent accumulation and activation of leukocytes is a hallmark of chronic inflammation. Current approaches to the treatment of inflammation rely on the inhibition of pro-inflammatory mediator production and of mechanisms that initiate the inflammatory response. However, the mechanisms by which the inflammatory response resolves might provide new targets in the treatment of chronic inflammation. Studies in different experimental models of resolving inflammation have identified several putative mechanisms and mediators of inflammatory resolution. We have shown that cyclopentenone prostaglandins (cyPGs) may be endogenous anti-inflammatory mediators and promote the resolution of inflammation in vivo. Others have shown a temporal shift to the production of anti-inflammatory lipoxins during the resolution of inflammation. In recent years, apoptosis has been identified as an important mechanism for the resolution of inflammation in vivo. It has been postulated that defects in leukocyte apoptosis are important in the pathogenesis of inflammatory disease. In addition, the selective induction of apoptosis in leukocytes may offer a new therapeutic approach to inflammatory disease.
- Considering that NF-kappaB is thought by many to be a primary effector of disease (A. S. Baldwin, J. Clin. Invest., 2001, 107:3-6), numerous efforts are underway to develop safe inhibitors of NF-kappaB to be used in treatment of both chronic and acute disease situations. Specific inhibitors of NF-kappaB should reduce side effects associated with drugs such as NSAIDS and glucocorticoids and would offer significant potential for the treatment of a variety of human and animal diseases. Specific diseases or syndromes where patients would benefit from NF-kappaB inhibition vary widely, and range from rheumatoid artrhritis, athereosclerosis, multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuritis, asthma, inflammatory bowel disease, toHelicobacter pylori-associated gastritis and other inflammatory responses, and a variety of drugs that have effects on NF-kappaB activity, such as corticosteroids, sulfasalazine, 5-aminosalicylic acid, aspirin, tepoxalin, leflunomide, curcumin, antioxidants and proteasome inhibitors. These drugs are considered to be non-specific and often only applicable in high concentrations that may end up toxic for the individual treated.
- Inactive cytoplasmatic forms of transcription factors can thus be activated by removal of an inhibitor, as is the case with NF-kapppaB, or alternatively, by association of two (or more) proteins neither of which is active by itself as in the case of interferon-alpha-stimulated factor (D. E. Levy et al., 1989, Genes and Development 3:1362). After interferon-alpha attaches to its cell-surface receptor, one of the proteins is changed within a minute or less, and the two can combine. The active (combined) factor is then translocated to the cell nucleus to stimulate transcription only of genes with a binding site for the protein. Considering that interferon-alpha is a mediator of responses of the body directed at pathogens and self-antigens, modulating regulation of genes that are under influence of the interferon-alpha-stimulated factor would contribute to the treatment of a variety of human and animal diseases.
- Other typical examples of signalling molecules that affect gene expression via cell-surface receptor interaction are polypeptide hormones such as insulin, glucagon, various growth factors such as EGF, VEGF, and so on.
- The steroid hormones and their receptors represent one of the best understood cases that affect transcription. Because steroid hormones are soluble in lipid membranes, they can diffuse into cells. They affect transcription by binding to specific intracellular receptors that are site specific DNA-binding molecules. Other examples of signalling molecules that enter the cell and act intra-cellularly are thyroid hormone (T3), vitamin D and retinoic acid, other small lipid-soluble signalling molecules that enter cells and modulate gene expression. The characteristic DNA-binding sites for the receptors for these signalling molecules are also known as response elements.
- Another example of a small molecule that is involved in regulation of gene expression is ethylene, a gas that for example induces the expression of genes involved in fruit ripening. Also, small plant hormones, known as auxines and cytokinins regulate plant growth and differentiation directly by regulating gene expression.
- Given the critical role of regulatory factors in gene regulation, the development of artificial or synthetic counterparts that could be used in methods to rectify errors in gene expression has been a long standing goal at the interface of chemistry and biology.
- The invention also relates to the treatment of anthrax. Anthrax, the disease caused by the spore-formingBacillus anthracis (B. anthracis), continues to be a worldwide problem, among domesticated and wild herbivores in Asia and Africa and poses a worldwide threat when being used as biological weapons for biological warfare or bioterrorism. Human infections occur after contact with infected animals or contaminated animal products. Outbreaks or epidemics are a constant threat for endemic regions because spores can persist in the soil for long periods of time. Importation controls on certain animal products are necessary to prevent the establishment of anthrax where the disease is not endemic. Human anthrax is usually classified by the portal of entry into the host. Cutaneous anthrax, which accounts for the vast majority of human anthrax cases, is a localized infection with generally mild systemic symptoms and characterized by a painless papule that is surrounded by edema which can be quite extensive. The papule ulcerates by
day - The invention relates to the modulation of gene expression in a cell, also called gene control, in relation to the treatment of a variety of diseases such as anthrax. As said, anthrax is a disease of animals and humans, poses a significant threat as an agent of biological warfare and terrorism. Inhalational anthrax, inwhich spores ofB. anthracis are inhaled, is almost always fatal, as diagnosis is rarely possible before the disease has progressed to a point where antibiotic treatment is ineffective. The major virulence factors of B. anthracis are a poly-D-glutamic acid capsule and anthrax toxin. Anthrax toxin consists of three distinct proteins that act in concert: two enzymes, lethal factor (LF) and edema factor (EF; an adenylate cyclase); and protective antigen (PA). The PA is a four-domain protein that binds a host cell-surface receptor by its carboxy-terminal domain; cleavage of its N-terminal domain by a furin-like protease allows PA to form heptamers that bind the toxic enzymes with high affinity through homologous N-terminal domains. The complex is endocytosed; acidification of the endosome leads to membrane insertion of the PA heptamer by forming a 14-stranded beta-barrel, followed by translocation of the toxic enzymes into the cytosol by an unknown mechanism. The binary combination of PA and LF is sufficient to induce rapid death in animals when given intravenously, and certain metalloprotease inhibitors block the effects of the toxin in vitro. Thus, LF is a potential target for therapeutic agents that would inhibit its catalytic activity or block its association with PA. LF is a protein (relative molecular mass 90,000) that is critical in the pathogenesis of anthrax. It comprises four domains: domain I binds the membrane-translocating component of anthrax toxin, the PA; domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of mitogen-activated protein kinase kinase-2 (MAPKK-2) before cleavage. Domain II resembles the ADP-ribosylating toxin from Bacillus cereus, but the active site has been mutated and recruited to augment substrate recognition. Domain III is inserted into domain II, and seems to have arisen from a repeated duplication of a structural element of domain II. Domain IV is distantly related to the zinc metalloprotease family, and contains the catalytic centre; it also resembles domain I. The structure thus reveals a protein that has evolved through a process of gene duplication, mutation and fusion, into an enzyme with high and unusual specificity.
- The MAPKK family of proteins are the only known cellular substrates of LF. Cleavage by LF near to their N termini removes the docking sequence for the downstream cognate MAP kinase. The effect of lethal toxin on tumour cells, for example, is to inhibit tumour growth and angiogenesis, most probably by inhibiting the MAPKK-1 and MAPKK-2 pathways. However, the primary cell type affected in anthrax pathogenesis is the macrophage. LF has been shown to cleave short N-terminal fragments from mitogen or extracellular signal-regulated MAPKK-1, MAPKK-2, MAPKK-3, and MAPPKK-6, the upstream activators of extracellular signal-regulated kinase 1 (ERK1), ERK2, and p38. Recent data show that this results in inhibiting release, but not production, of the pro-inflammatory mediators, NO and tumor necrosis factor-alpha (TNF-alpha). In addition, high levels of lethal toxin lead to lysis of macrophages within a few hours, by an unknown mechanism. Recent data suggests that this happens due to inhibition of growth-factor pathways leading to macrophage death. These observations suggest that at an early stage in infection, lethal toxin may reduce (or delay) the immune response, whereas at a late stage in infection, high titres of the bacterium in the bloodstream trigger macrophage lysis and the sudden release of high levels of NO and TNF-alpha. This may explain the symptoms before death which are characterized by the hyperstimulation of host macrophage inflammatory pathways, leading to dramatic hypotension and shock. These symptoms resemble those of LPS induced septic shock, whereby it is of note LPS-nonresponder mice such as C3H/HeJ are also quite resistant against anthrax toxine.
- The recognition sites for LF require the presence of the proline (P) residue followed by a hydrophobic residue or a glycine (G) residue, between which LF cleaves. The recognition sites further require an uncharged amino acid following the hydrophobic residue, and at least one positively charged amino acid (and no negatively charged amino acid, such as Asp and Glu) within the 5 amino acids to the N-terminal side of the proline residue. Other residues in the sequence provide appropriate spacing between the critical residues or between the donor and acceptor, and thus their composition is not critical, and can include any natural or unnatural amino acid.
- The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signalling molecule comprising an oligopeptide or functional analogue or derivative thereof. Such a molecule is herein also called NMPF and referenced by number. Since peptides, and functional analogues and derivatives of relatively short amino acid sequences, are easily synthesised these days, the invention provides a method to modulate gene expression with easily obtainable synthetic compounds such as synthetic peptides or functional analogues or derivatives thereof.
- The invention also provides a method for the treatment of an inflammatory condition comprising administering to a subject in need of such treatment a molecule comprising an oligopeptide peptide or functional analogue or derivative thereof the molecule capable of reducing production of NO by a cell, in particular wherein the molecule additionally is capable of modulating translocation and/or activity of a gene transcription factor present in a cell, especially wherein the gene transcription factor comprises a NF-kappaB/Rel protein. Advantageously, the invention provides a method wherein the modulating translocation and/or activity of a gene transcription factor allows modulation of TNF-alpha production by the cell, in particular wherein the TNF-alpha production is reduced. Considering that TNF-alpha production is central to almost all, if not all, inflammatory conditions, reducing TNF-alpha production can greatly alleviate, or mitigate, a great host of inflammatory conditions that are described herein. In particular, the invention provides a method wherein the inflammatory condition comprises an acute inflammatory condition, and it is especially useful to treat anthrax related disease, especially when considering that with anthrax, both NO and TNF-alpha reduction will greatly mitigate the course of disease. Table 6 lists oligopeptides according to the invention that have such modulatory effect. In particular, the invention provides a method of treatment wherein the treatment comprises administering to the subject a pharmaceutical composition comprising an oligopeptide or functional analogue or derivative thereof capable of reducing production of NO by a cell, preferably wherein the composition comprises at least two oligopeptides or functional analogues or derivatives thereof capable of reducing production of NO by a cell, example of such combinations can be selected under guidance of table 6, whereby it suffices to select two, or more, with a desired effect, such as wherein the at least two oligopeptides are selected from the group LQGV, AQGV and VLPALP.
- The invention also provides an isolated, preferably synthetic, oligopeptide or functional analogue or derivative thereof or mixture of such oligopeptides or analogues or derivatives capable of reducing production of NO by a cell. Such cell is preferably of a macrophage or DC lineage, considering the central role these cells play in the inflammatory process. The invention also provides a pharmaceutical composition comprising an oligopeptide or functional analogue or derivative according to the invention or comprising at least two oligopeptides or functional analogues or derivatives thereof capable of reducing production of NO by a cell. Furthermore, the invention provides the use of an oligopeptide or functional analogue or derivative thereof capable of reducing production of NO by a cell for the production of a pharmaceutical composition for the treatment of an inflammatory condition by the reduction of NO production by macrophages or DC in the subject to be treated.
- A functional analogue or derivative of a peptide is defined as an amino acid sequence, or other sequence monomers, which has been altered such that the functional properties of the sequence are essentially the same in kind, not necessarily in amount. An analogue or derivative can be provided in many ways, for instance through conservative amino acid substitution. Also peptidomimetic compounds can be designed that functionally or structurally resemble the original peptide taken as starting point but that are for example composed of non-naturally occurring amino acids or polyamides. With conservative amino acid substitution, one amino acid residue is substituted with another residue with generally similar properties (size, hydrophobicity, etc), such that the overall functioning is likely not to be seriously affected. However, it is often much more desirable to improve a specific function. A derivative can also be provided by systematically improving at least one desired property of an amino acid sequence. This can for instance be done by an Ala-scan and/or replacement net mapping method. With these methods, many different peptides are generated, based on an original amino acid sequence but each containing a substitution of at least one amino acid residue. The amino acid residue may either be replaced by alanine (Ala-scan) or by any other amino acid residue (replacement net mapping). This way, many positional variants of the original amino acid sequence are synthesized. Every positional variant is screened for a specific activity. The generated data are used to design improved peptide derivatives of a certain amino acid sequence.
- A derivative or analogue can also for instance be generated by substitution of an L-amino acid residue with a D-amino acid residue. This substitution, leading to a peptide which does not naturally occur in nature, can improve a property of an amino acid sequence. It is for example useful to provide a peptide sequence of known activity of all D-amino acids in retro inversion format, thereby allowing for retained activity and increase half-life values. By generating many positional variants of an original amino acid sequence and screening for a specific activity, improved peptide derivatives comprising such D-amino acids can be designed with further improved characteristics.
- A person skilled in the art is well able to generate analogous compounds of an amino acid sequence. This can for instance be done through screening of a peptide library. Such an analogue has essentially the same functional properties of the sequence in kind, not necessarily in amount. Also, peptides or analogues can be circularised (for example by providing them with (terminal) cysteines, dimerised or multimerised, for example by linkage to lysine or cystein or other compounds with side-chains that allow linkage or multimerisation, brought in tandem- or repeat-configuration, conjugated or otherwise linked to carriers known in the art, if only by a labile link that allows dissociation.
- The invention also provides a signalling molecule for modulating expression of a gene in a cell comprising a small peptide or functional analogue or derivative thereof. Surprisingly, the inventors found that a small peptide acts as a signalling molecule that can modulatesignal transduction pathways and gene expression. A functional analogue or derivative of a small peptide that acts as such a signalling molecule for modulating expression of one or more genes in a cell can be identified or obtained by at least one of various methods for finding such a signalling molecule as provided herein.
- For example, one method as provided herein for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprises providing the cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of one or more gene transcription factors. Such activity can be determined in various ways using means and/or methods honed to the specific transcription factor(s) under study. In the detailed description, it is provided to study NF-kappaB/Rel protein translocation and/or activity, but it is of course also easily possible to study translocation and/or activity of any other transcription factor for which such tools are available or can be designed. One such other transcription factor is for example the interferon-alpha-stimulated factor as discussed above. Other useful transcription factors to study in this context comprise c-Jun, ATF-2, Fos, and their complexes, ELK-1, EGR-1, IRF-1, IRF-3/7, AP-1, NF-AT, C/EBPs, Sp1, CREB, PPARgamma, STAT proteins to name a few. Considering that many proteins are subject to proteolytic breakdown whereby oligopeptide fragments are generated, many already before the full protein even has exerted a function, it is hereby established that oligopeptide fragments of such proteins (of which a non-extensive list is given in the detailed description, but one can for example think of MAPKK-2 that can give rise to a peptide MLARRKPVLPALTINP, and subsequently to a peptide comprising MLARRKP or MLAR or VLPALT or VLPAL, but also of nitric oxide synthase that can give rise to peptides FPGC or PGCP, GVLPAVP, LPA, VLPAVP, or PAVP after proper proteolysis) are involved in feedback mechanisms regulating gene expression, likely by the effect of transcription factors on gene expression. In addition, oligopeptide fragments of proteins (of which a non-extensive list is given in the detailed description) can also modulate the activity of extracellular components such as factor XIII (example of oligopeptide fragments obtained from factor XIII are LQGV, LQGVVPRGV, GVVP, VPRGV, PRG, PRGV) or activated protein C (APC) and thereby eventually leading to the modulation of intracellular signal transduction pathways and gene(s) expression.
- As said, the invention provides active oligopeptides acting as a signalling molecule. To allow for improved bio-availability of such a signalling molecule (which is useful as a pharmacon, especially when produced artificially) the invention also provides a method for determining whether a small peptide or derivative or analogue thereof can act as a functional signalling molecule according to the invention, the method further comprising determining whether the signalling molecule is membrane-permeable.
- The invention for example provides a method a process or method for obtaining information about the capacity or tendency of an oligopeptide, or a modification or derivative thereof, to regulate expression of a gene comprising the steps of:
- a) contacting the oligopeptide, or a modification or derivative thereof, with at least one cell;
- b) determining the presence of at least one gene product in or derived from the cell. It is preferred that the oligopeptide comprises an amino acid sequence corresponding to a fragment of a naturally occurring polypeptide, such as hCG, or MAPKK, or another kinase, be it of plant or animal cell, or of eukaryotic or prokaryotic origin, or a synthase of a regulatory protein in a cell, such as wherein the regulatory protein is a (pro-) inflammatory mediator, such as a cytokine. Several candidate proteins and peptide fragments are listed in the detailed description which are a first choice for such an analysis from the inventors perspective, but the person skilled in the art, and working in a specific field of interest in biotechnology shall immediately understand which protein to select for such analyses for his or her own purposes related to his or her field.
- In particular it is provided to perform a process according to the invention further comprising a step c) comprising determining the presence of the gene product in or derived from a cell which has not been contacted with the oligopeptide, or a modification or derivative thereof, and determining the ratio of gene product found in step b to gene product found in step c, as can easily been done with the present day genechip technology (see for example the detailed description herein) and related methods of expression profiling known in the art.
- Another method provided herein for identifying or obtaining information on a signalling molecule, (or for that matter the signalling molecule itself, considering that the next step of synthesising the molecule, generally being a short peptide, is whole within the art) comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprises providing the cell with a peptide or derivative or analogue thereof and determining relative up-regulation and/or down-regulation of at least one gene expressed in the cell. The up-regulation can classically be studied by determining via for example Northern or Western blotting or nucleic acid detection by PCR or immunological detection of proteins whether a cell or cells make more (in the case of up-regulation) or less (in the case of down-regulation) of a gene expression product such as mRNA or protein after the cell or cells have been provided with the peptide or derivative or analogue thereof. Of course, various methods of the invention can be combined to better analyse the functional analogue of the peptide or derivative or analogue under study. Furthermore, relative up-regulation and/or down-regulation of a multitude or clusters of genes expressed in the cell can be easily studied as well, using libraries of positionally or spatially addressable predetermined or known relevant nucleic acid sequences or unique fragments thereof bound to an array or brought in an array format, using for example a nucleic acid library or so-called gene chip expression analysis systems. Lysates of cells or preparations of cytoplasma and/or nuclei of cells that have been provided with the peptide or derivative or analogue under study are than contacted with the library and relative binding of for example mRNA to individual nucleic acids of the library is than determined, as further described herein in the detailed description.
- A functional analogue or derivative of a small peptide that can act as a signalling molecule for modulating expression of a gene in a cell can also be identified or obtained by method for identifying or obtaining a signalling molecule comprising an oligopeptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing a peptide or derivative or analogue thereof and determining binding of the peptide or derivative or analogue thereof to a factor related to gene control. Such a factor related to gene control can be any factor related to transcription (either initiation or termination), processing of primary transcripts, stabilization or destabilization of mRNAs, and mRNA translation.
- Binding of a peptide or derivative or analogue thereof to such a factor can be determined by various methods known in the art. Classically, peptides or derivatives or analogues can be (radioactively) labelled and binding to the factor can be determined by detection of a labelled peptide-factor complex, such as by electrophoresis, or other separation methods known in the art. However, for determining binding to such factors, array techniques, such as used with peptide libraries, can also be employed, comprising providing a multitude of peptides or derivatives or analogues thereof and determining binding of at least one of the peptides or derivatives or analogues thereof to a factor related to gene control.
- In a preferred embodiment, the factor related to gene control comprises a transcription factor, such as a NF-kappaB-Rel protein or another transcription factor desired to be studied. When binding of a functional analogue according to the invention to such factor has been established, it is of course possible to further analyse the analogue by providing a cell with the peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor in the cell, and/or by providing a cell with the peptide or derivative or analogue thereof and determining relative up-regulation and/or down-regulation of at least one gene expressed in the cell.
- The invention thus provides a signalling molecule useful in modulating expression of a gene in a cell and/or useful for reducing NO production by a cell and identifiable or obtainable by employing a method according to the invention. Useful examples of such a signalling molecule can be selected from the group of oligopeptides LQG, AQG, LQGV, AQGV, LQGA, VLPALPQVVC, VLPALP, ALPALP, VAPALP, ALPALPQ, VLPAAPQ, VLPALAQ, LAGV, VLAALP, VLAALP, VLPALA, VLPALPQ, VLAALPQ, VLPALPA, GVLPALP, GVLPALPQ, LQGVLPALPQVVC, VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCAL, RPRCRPINATLAVEK, EGCPVCITVNTTICAGYCPT, SKAPPPSLPSPSRLPGPS, SIRLPGCPRGVNPVVS, LPGCPRGVNPVVS, LPGC, MTRV, MTR, VVC, QVVC and functional analogues or derivatives thereof.
- A preferred size of a signalling molecule according to the invention is at most 30-40 amino acids, although much smaller molecules, in particular of oligopeptide size, have been shown to be particularly effective. Surprisingly, the invention provides here the insight that gene expression can be modulated or regulated by small peptides, that are most likely breakdown products of larger polypeptides such as chorionic gonadotrophin (CG) and growth hormones or growth factors such as fibroblast growth factor, EGF, VEGF,
RNA 3′terminal phosphate cyclase and CAP18. In principle such regulating peptide sequences can be derived from a part of any protein of polypeptide molecule produced by prokaryotic and/or eukaryotic cells, and the invention provides the insight that breakdown products of polypeptides, preferably oligopeptides at about the sizes as provided herein, are naturally involved as signalling molecule in modulation of gene expression. In particular, as signalling molecule a (synthetic) peptide is provided obtainable or derivable from beta-human chorionic gonadotrophin (beta-HCG), preferably from nicked beta-HCG. It was thought before that breakdown products of nicked-beta hCG were involved in immuno-modulation (PCT International Patent Application WO99/59671) or in the treatment of wasting syndrome (PCT International Patent Application WO97/49721) but a relationship with modulation of gene expression was not forwarded in these publications. Of course, such an oligopeptide, or functional equivalent or derivative thereof is likely obtainable or derivable from other proteins that are subject to breakdown or proteolysis and that are close to a gene regulatory cascade. Preferably, the peptide signalling molecule is obtained from a peptide having at least 10 amino acids such as a peptide having an amino acid sequence MTRVLQGVLPALPQVVC, SIRLPGCPRGVNPVVS, VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCAL, RPRCRPINATLAVEKEGCPVCITVNTTICAGYCPT, CALCRRSTTDCGGPKDHPLTC, SKAPPPSLPSPSRLPGPS, CRRSTTDCGGPKDHPLTC, TCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ or functional fragment (e.g. a breakdown product) or functional analogue thereof. Functional analogue herein relates to the signalling molecular effect or activity as for example can be measured by measuring nuclear translocation of a relevant transcription factor, such as NF-kappaB in an NF-kappaB assay, or AP-1 in an AP-1 assay, or by another method as provided herein. Fragments can be somewhat (i.e. 1 or 2 amino acids) smaller or larger on one or both sides, while still providing functional activity. - Not wishing to be bound by theory, it is postulated herein that an unexpected mode of gene regulation has been uncovered. Polypeptides, such as endogenous CG, EGF etc, but also polypeptides of pathogens such as viral, bacterial or protozoal polypeptides, are subject to breakdown into distinct oligopeptides, for example by intracellular proteolysis. Distinct proteolytic enzymes are widely available in the cell, for example in eukaryotes in the lysosomal or proteasomal system. Some of the resulting breakdown products are oligopeptides of 3 to 15, preferably 4 to 9, most preferably 4 to 6 amino acids long that are surprisingly not without any function or effect to the cell, but as demonstrated herein may be involved, possibly via a feedback mechanism in the case of breakdown of endogenous polypeptides, as signalling molecules in the regulation of gene expression, as demonstrated herein by the regulation of the activity or translocation of a gene transcription factor such as NF-kappaB by for example peptide LQGV, VLPALPQVVC, LQGVLPALPQ, LQG, GVLPALPQ, VLPALP, VLPALPQ, GVLPALP, VVC, MTRV, MTR. Synthetic versions of these oligopeptides as described above, and functional analogues or derivatives of these breakdown products are herein provided to modulate gene expression in a cell and be used in methods to rectify errors in gene expression or the treatment of disease. Oligopeptides such as LQG, AQG, LQGV, AQGV, LQGA, VLPALP, ALPALP, VAPALP, ALPALPQ, VLPAAPQ, VLPALAQ, LAGV, VLAALP, VLAALP, VLPALA, VLPALPQ, VLAALPQ, VLPALPA, GVLPALP, GVLPALPQ, LQGVLPALPQVVC, SIRLPGCPRGVNPVVS, SKAPPPSLPSPSRLPGPS, LPGCPRGVNPVVS, LPGC, MTRV, MTR, VVC, or functional analogues or derivatives (including break down products) of the longer sequences thereof, are particularly effective.
- By using the insight as expressed herein, in a preferred embodiment, the invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signalling molecule comprising an oligopeptide or functional analogue or derivative thereof wherein the signalling molecule is membrane-permeable in that it enters the cell. Most small peptides as described herein have already an inherent propensity to become intracellularly involved, but signalling molecules as provided herein can also be provided with additional peptide sequences, such as arginine or lysine rich stretches of amino acids, that allow for improved internalisation across a lipid bilayer membrane, and may possibly be cleaved off later by internal proteolytic activity.
- In a preferred embodiment, the invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signalling molecule comprising a small peptide (amino acid sequence) or functional analogue or derivative thereof, wherein the signalling molecule modulates NF-kappaB/Rel protein conversion or translocation. As said, NF-κB was originally identified as a gene transcription factor that bound to an enhancer element in the gene for the Igκ light chain and was believed to be B cell-specific. However, subsequent studies revealed that NF-kappaB/Rel proteins are ubiquitously expressed and play a central role as transcription factor in regulating the expression of many genes, particularly those involved in immune, inflammatory, developmental and apoptotic processes. NF-κB related gene transcription factors can be activated by different stimuli such as microbial products, proinflammatory cytokines, T- and B-cell mitogens, and physical and chemical stresses. NF-κB in turn regulates the inducible expression of many cytokines, chemokines, adhesion molecules, acute phase proteins, and antimicrobial peptides.
- NF-κB represents a group of structurally related and evolutionarily conserved gene transcription factors. So far, five mammalian NF-κB proteins named Rel (c-Rel), RelA (p65), RelB, NF-κB (p50 and its precursor p105), and NF-κB (p52 and it precursor p100) have been described. NF-κB proteins can exist as homo- or heterodimers, and although most NF-κB dimers are activators of transcription, the p50/p50 and p52/p52 homodimers often repress the transcription of their target genes. In Drosophila, three NF-κB homologs named Dorsal, Dif, and Relish have been identified and characterized. Structurally, all NF-κB/Rel proteins share a highly conserved NH2-terminal Rel homology domain (RHD) that is responsible for DNA binding, dimerization, and association with inhibitory proteins known as IκBS. In resting cells, NF-κB/Rel dimers are bound to IκBs and retained in an inactive form in the cytoplasm. Like NF-κB, IkBs are also members of a multigene family containing seven known mammalian members including IκBα, IκBβ, Iκbγ, IκBε, Bcl-3, the precursor Rel-proteins, p100, and p105, and one Drosophila IκB named Cactus. The IκB family is characterized by the presence of multiple copies of ankyrin repeats, which are protein-protein interaction motifs that interact with NF-κB via the RHD. Upon appropriate stimulation, IκB is phosphorylated by IκB kinases (IKKs), polyubiquitinated by a ubiquitin ligase complex, and degraded by the 26S proteosome. Consequently, NF-κB is released and translocates into the nucleus to initiate gene expression.
- NF-κB related transcription factors regulate the expression of a wide variety of genes that play critical roles in innate immune responses. Such NF-κB target genes include those encoding cytokines (e.g., IL-1, IL-2, IL-6, IL-12, TNF-α, LTα, LTβ, and GM-CSF), adhesion molecules (e.g., ICAM, VCAM, endothelial leukocyte adhesion molecule [ELAM]), acute phase proteins (e.g., SAA), and inducible enzymes (e.g., iNOS and COX-2). In addition, it has been demonstrated recently that several evolutionary conserved antimicrobial peptides, e.g., β-defensins, are also regulated by NF-κB, a situation similar to Drosophila. Besides regulating the expression of molecules involved in innate immunity, NF-κB also plays a role in the expression of molecules important for adaptive immunity, such as MHC proteins, and the expression of critical cytokines such as IL-2, IL-12 and IFN-γ. Finally NF-κB plays an important role in the overall immune response by affecting the expression of genes that are critical for regulating the apoptotic process, such as c-IAP-1 and c-IAP-2, Fas ligand, c-myc, p53, and cyclin D1.
- Under normal conditions, NF-kappaB is rapidly activated upon microbial and viral invasion, and this activation usually correlates with resistance of the host to infection. However, persistent activation of NF-kappaB may lead to the production of excessive amounts of pro-inflammatory mediators such as IL-12 and TNF-alpha, resulting in tissue damage, as in insulin dependent diabetes mellitus, atherosclerosis, Crohn's disease, organ failure, and even death of the host, as in bacterial infection-induced septic shock. It is interesting to note that in order to survive in the host, certain pathogens, such as Bordetella, Yersinia,Toxoplasma gondii and African Swine Fever Virus have evolved mechanisms to counteract or escape the host system by inhibiting NF-kappaB activation. On the other hand, some viruses, including HIV-1, CMV and SV-40 take advantage of NF-kappaB as a host factor that is activated at sites of infection.
- Furthermore, the invention provides a method to explore alterations in gene expression in antigen presenting cells such as dendritic cells in response to microbial exposure by analysing a gene-expression profile of dendritic cells in response to micro organisms such as for example bacteria such asEscherichia coli or other pathogenic bacteria, fungi or yeasts such as Candida albicans, viruses such as influenza virus and the effect of (simultameous) treatment of these diseases with a signalling molecule according to the invention. For example, human monocyte-derived dendritic cells are cultured with one or more pathogens for 1-36 hours, and gene expression is analysed using an oligonucleotide array representing a (be it large or small) set of genes. When the pathogens regulate the expression of a core set of a distinct number genes, these genes may be classified according to their kinetics of expression and function. Generally, within 4 hours of pathogen exposure, genes associated with pathogen recognition and phagocytosis will be downregulated, whereas genes for antigen processing and presentation are upregulated-8 hours post-exposure. Treatment of such dendritic cells with a signalling molecule according to the invention (be it simultaneous or before or after the treatment of the cells with the pathogen) allows studying the effect of a signalling molecule according to the invention has on the effect a pathogen has on an antigen presenting cell.
- In short, the invention surprisingly provides a signalling molecule capable of modulating expression of a gene in a cell, the molecule being a short peptide, preferably of at most 30 amino acids long or a functional analogue or derivative thereof. In a much preferred embodiment, the peptide is an oligopeptide of from about 3 to at about 15 amino acids long, preferably 4 to 12, more preferably 4 to 9, most preferably 4 to 6 amino acids long, or a functional analogue or derivative thereof. Of course, such signalling molecule can be longer, for example by extending it (N- and/or C-terminally, with more amino acids or other side groups, which can for example be (enzymatically) cleaved off when the molecule enters the place of final destination. Such extension may even be preferable to prevent the signalling molecule from becoming active in an untimely fashion, however, the core or active fragment of the molecule comprises the aforementioned oligopeptide or analogue or derivative thereof.
- In particular, the invention provides a modulator of NF-kappaB/Rel protein activation comprising a signalling molecule according to the invention. Such modulators are widely searched after these days. Furthermore, the invention provides use of a signalling molecule according to the invention for the production of a pharmaceutical composition for the modulation of gene expression.
- Also, the invention provides a method for the treatment of bone disease such as osteoporosis comprising administering to a subject in need of such treatment a molecule comprising an oligopeptide peptide or functional analogue thereof the molecule capable of modulating production of NO and/or TNF-alpha by a cell. Such a method of treatment is particularly useful in post-menopausal women that do not longer experience the benefits of being provided with a natural source of several of the signalling molecules as provided herein, hCG and its breakdown products. Furthermore, the invention provides method for the treatment of an inflammatory condition associated with TNF-alpha activity of fibroblasts, such as seen with chronic arthritis or synovitis comprising administering to a subject in need of such treatment a molecule comprising an oligopeptide peptide or functional analogue thereof wherein the molecule is capable of modulating translocation and/or activity of a gene transcription factor present in a cell, in particular of the NF-kappaB factor. Such a treatment can be achieved by systemic administration of a signalling molecule according to the invention, but local administration in joints, bursae or tendon sheaths is provided as well. The molecule can be selected from table 6 or identified in a method according to the invention. It is preferred when the treatment comprises administering to the subject a pharmaceutical composition comprising an oligopeptide or functional analogue thereof also capable of reducing production of NO by a ceel, for example wherein the composition comprises at least two oligopeptides or functional analogues thereof each capable of reducing production of NO and/or TNF-alpha by a cell, in particular wherein the at least two oligopeptides are selected from the group LQGV, AQGV and VLPALP.
- Furthermore, the invention provides use of an oligopeptide or functional analogue thereof capable of reducing production of NO and/or TNF-alpha by a cell for the production of a pharmaceutical composition for the treatment of an inflammatory condition or a post-meno-pausal condition, or a bone disease such as osteoporosis, or for the induction of weight loss. The term pharmaceutical composition as used herein is intended to cover both the active signalling molecule alone or a composition containing the signalling molecule together with a pharmaceutically acceptable carrier, diluent or excipient. Acceptable diluents of an oligopeptide as described herein in the detailed description are for example physiological salt solutions or phosphate buffered salt solutions. In one embodiment of the present invention, a signal molecule is administered in an effective concentration to an animal or human systemically, e.g. by intravenous, intra-muscular or intraperitoneal administration. Another way of administration comprises perfusion of organs or tissue, be it in vivo or ex vivo, with a perfusion fluid comprising a signal molecule according to the invention. Topical administration, e.g. in ointments or sprays, may also apply, e.g. in inflammations of the skin or mucosal surfaces of for example mouth, nose and/or genitals. Local administration can occur in joints, bursae, tendon sheaths, in or around the spinal cord at locations where nerve bundles branch off, at the location of hernias, in or around infarcted areas in brain or heart, etc. The administration may be done as a single dose, as a discontinuous sequence of various doses, or continuously for a period of time sufficient to permit substantial modulation of gene expression In the case of a continuous administration, the duration of the administration may vary depending upon a number of factors which would readily be appreciated by those skilled in the art.
- The administration dose of the active molecule may be varied over a fairly broad range. The concentrations of an active molecule which can be administered would be limited by efficacy at the lower end and the solubility of the compound at the upper end. The optimal dose or doses for a particular patient should and can be determined by the physician or medical specialist involved, taking into consideration well known relevant factors such as the condition, weight and age of the patient, etc.
- The active molecule may be administered directly in a suitable vehicle, such as e.g. phosphate-buffered saline (PBS) or as solutions in alcohol or DMSO. Pursuant to preferred embodiments of the present invention, however, the active molecule is administered through a single dose delivery using a drug-delivery system, such as a sustained-release delivery system, which enables the maintenance of the required concentrations of the active molecule for a period of time sufficient for adequate modulation of gene expression. A suitable drug-delivery system would be pharmacologically inactive or at least tolerable. It should preferably not be immunogenic nor cause inflammatory reactions, and should permit release of the active molecule so as to maintain effective levels thereof over the desired time period. A large variety of alternatives are known in the art as suitable for purposes of sustained release and are contemplated as within the scope of the present invention. Suitable delivery vehicles include, but are not limited to, the following: microcapsules or microspheres; liposomes and other lipid-based release systems; viscous instillates; absorbable and/or biodegradable mechanical barriers and implants; and polymeric delivery materials, such as polyethylene oxide/polypropylene oxide block copolymers, polyesters, cross-linked polyvinylalcohols, polyanhydrides, polymethacrylate and polymethacrylamide hydrogels, anionic carbohydrate polymers, etc. Useful delivery systems are well known in the art.
- A highly suitable formulation to achieve the active molecule release comprises injectable microcapsules or microspheres made from a biodegradable polymer, such as poly(dl-lactide), poly(dl-lactide-co-glycolide), polycaprolactone, polyglycolide, polylactic acid-co-glycolide, poly(hydroxybutyric acid), polyesters or polyacetals. Injectable systems comprising microcapsules or microspheres having a diameter of about 50 to about 500 micrometers offer advantages over other delivery systems. For example, they generally use less active molecule and may be administered by paramedical personnel. Moreover, such systems are inherently flexible in the design of the duration and rate of separate drug release by selection of microcapsule or microsphere size, drug loading and dosage administered. Further, they can be successfully sterilised by gamma irradiation.
- The design, preparation and use of microcapsules and microspheres are well within the reach of persons skilled in the art and detailed information concerning these points is available in the literature. Biodegradable polymers (such as lactide, glycolide and caprolactone polymers) may also be used in formulations other than microcapsules and microspheres; e.g. pre-made films and spray-on films of these polymers containing the active molecule would be suitable for use in accordance with the present invention. Fibres or filaments comprising the active molecule are also contemplated as within the scope of the present invention.
- Another highly suitable formulation for a single-dose delivery of the active molecule in accordance with the present invention involves liposomes. The encapsulation of an active molecule in liposomes or multilamellar vesicles is a well known technique for targeted drug delivery and prolonged drug residence. The preparation and use of drug-loaded liposomes is well within the reach of persons skilled in the art and well documented in the literature.
- Yet another suitable approach for single dose delivery of an active molecule in accordance with the present invention involves the use of viscous installates. In this technique, high molecular weight carriers are used in admixture with the active molecule, giving rise to a structure which produces a solution with high viscosity. Suitable high molecular weight carriers include, but are not limited to, the following: dextrans and cyclodextrans; hydrogels; (cross-linked) viscous materials, including (cross-linked) viscoelastics; carboxymethylcellulose; hyaluronic acid; and chondroitin sulfate. The preparation and use of drug-loaded viscous instillates is well known to persons skilled in the art.
- Pursuant to yet another approach, the active molecule may be administered in combination with absorbable mechanical barriers such oxidised regenerated cellulose. The active molecule may be covalent or non-covalently (e.g. ionically) bound to such a barrier, or it may simply be dispersed therein. A pharmaceutical composition as provided herein is particularly useful for the modulation of gene expression by inhibiting NF-kappaB/Rel protein activation.
- NF-kappaB/Rel proteins are a group of structurally related and evolutionarily conserved proteins (Rel). Well known are c-Rel, RelA (p65), RelB, NF-kappaB 1 (p50 and its precursor p105), and NF-kappaB2 (p52 and its precursor p100). Most NF-kappaB dimers are activators of transcription, p50/p50 and p52/p52 homodimers repress the transcription of their target genes. All NF-kappaB/Rel proteins share a highly conserved NH2-terminal Rel homology domain (RHD). RHD is responsible for DNA binding, dimerization, association with inhibitory proteins known as IkappaBs. In resting cells, NF-kappaB/Rel dimers are bound to IkappaBs and retained in an inactive form in the cytoplasm. IkappaBs are members of a multigene family (IkappaBalpha, IkappaBbeta, IkappaBgamma, IkappaBepsilon, Bcl-3, the precursor Rel-proteins, p100 and p105. Presence of multiple copies of ankyrin repeats to interact with NF-kappaB via the RHD (protein-protein interaction. Upon appropriate stimulation, IkappaB is phosphorylated by IkappaB Kinase (IKKs), polyubiquitinated by ubiquitin ligase complex, and degraded by the 26S proteosome. NF-kappaB is released and translocates into nucleus to initiate gene expression.
- NF-kappaB regulation of gene expression includes innate immune responses: such as regulated by cytokines IL-1, IL-2, IL-6, IL-12, TNF-alpha, LT-alpha, LT-beta, GM-CSF; expression of adhesion molecules (ICAM, VCAM, endothelial leukocyte adhesion molecule [ELAM]), acute phase proteins (SAA), inducible enzymes (iNOS and COX-2) and antimicrobial peptides (beta-defensins). For adaptive immunity MHC proteins, IL-2, IL-12 and IFN-alpha are regulated by NF-kappaB. Regulation of overall immune response includes the regulation of genes critical for regulation of apoptosis (c-IAP-1 and c-IAP-2, Fas Ligand, c-myc, p53 and cyclin D1.
- Considering that NF-kappaB and related transcription factors are cardinal pro-inflammatory transcription factors, and considering that the invention provides a signalling molecule, such as an oligopeptide and functional analogues or derivatives thereof that are capable of inhibiting NF-kappaB and likely also other pro-inflammatory transcription factors, herein also called NF-kappaB inhibitors, the invention provides a method for modulating NF-kappaB activated gene expression, in particular for inhibiting the expression and thus inhibiting a central pro-inflammatory pathway.
- The consequence of this potency to inhibit this pro-inflammatory pathway is wide and far reaching. The invention for example provides a method to mitigate or treat inflammatory airway disease such as asthma. Generally, asthma patients show persistent activation of NF-kappaB of cells lining the respiratory tract. Providing these patients, for example by aerosol application, with a signalling molecule according to the invention, such as LQGV or AQGV or MTRV or functional analogue or derivative thereof, will alleviate the inflammatory airway response of these individuals, by inhibiting NF-kappaB activation of the cells. Such compositions can advantageously be made with signalling molecules that are taken up in liposomes.
- As said, inflammation involves the sequential activation of signalling pathways leading to the production of both pro- and anti-inflammatory mediators. Considering that much attention has focused on pro-inflammatory pathways that initiate inflammation, relatively little is known about the mechanisms that switch off inflammation and resolve the inflammatory response. The transcription factor NF-kB is thought to have a central role in the induction of pro-inflammatory gene expression and has attracted interest as a new target for the treatment of inflammatory disease. However NF-kB activation of leukocytes recruited during the onset of inflammation is also associated with pro-inflammatory gene expression, whereas such activation during the resolution of inflammation is associated with the expression of anti-inflammatory genes and the induction of apoptosis. Inhibition of NF-kB during the resolution of inflammation protracts the inflammatory response and prevents apoptosis. This shows that NF-kB has an anti-inflammatory role in vivo involving the regulation of inflammatory resolution. The invention provides a tool to modulate the inflammation at the end phase, a signalling molecule or modulator as provided herein allows the modulation of the NF-kappaB pathway at different stages of the inflammatory response in vivo, in a particular embodiment, the invention provides a modulator of NF-kappaB for use in the resolution of inflammation, for example through the regulation of leukocyte apoptosis. Useful oligopeptides can be found among those that accelerate shock.
- The invention also provides a method to mitigate or treat neonatal lung disease, also called chronic lung disease of prematurity, a condition often seen with premature children who develop a prolonged pulmonary inflammation or bronchopulmonary dysplasia. Treating such premature children with an NF-kappaB inhibitor, such as oligopeptide LQGV, or functional analogue or derivative thereof, as provided herein allows such lung conditions to be prevented or ameliorated as well.
- Recent advances in bone biology provide insight into the pathogenesis of bone diseases. The invention also provides a method of treatment of a post-menopausal condition such as osteoporosis comprising modulation and inhibition of osteoclast differentiation and inhibiting TNF-alpha induced apoptosis of osteoblasts, thereby limiting the dissolve of bone structures, otherwise so prominent in post-menopausal women that have no longer a natural source of hCG and thus lack the modulatory effect of the signal molecules that are derived of hCG as shown herein. The invention thus also provides a method of treatment of a bone disease, such as osteoporosis (which is often, but not exclusively seen with post-meno-pausal women) Furthermore, NO and TNF-alpha modulators as provided herein inhibit the inflammatory response and bone loss in periodontitis. Furthermore, considering that there is a correlation between TNF-alpha activity, and severity of clinical manifestations in ankylosing spondylitis, the invention provides the treatment of spondylitis by use of a signalling molecule as provided herein.
- Furthermore, considering that an important pathogenic component in the development of insulin-dependent diabetes mellitus (type 1) comprises over-activation of the NF-kappaB pathway as seen in dendritic cells, treatment with an NF-kappaB inhibitor according to the invention will lead to reduced symptoms of diabetes, or at least to a prolonged time to onset of the disease. Particularly effective oligopeptide signalling molecules according to the invention in this context are GVLPALPQ, LQGV MTRV, VLPALPQVVC, VLPALP, VLPALPQ, LPGCPRGVNPVVS, LPGC, VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCAL, CPRGVNPVVS which were shown herein to postpone onset of diabetes in an Non-obese Diabetic Mouse (NOD). Another approach to treatment of diabetes, in particular insulin-independent diabetes (type 2) comprises inhibition of the PPARgamma cascade with an oligopeptide signalling molecule or functional analogue or derivative thereof.
- Other use that is provided relates to a method for combating or treating auto-immune disease. A non-limiting list of an immune diseases includes:
- Hashimoto's thyroiditis, primary myxoedema thyrotoxicosis, pernicious anaemia, autoimmune atrophic gastritis, Addison's disease, premature menopause, insulin-dependent diabetes mellitus, stiff-man syndrome, Goodpasture's syndrome, myasthenia gravis, male infertility, pemphigus vulgaris, pemphigoid, sympathetic ophthalmia, phacogenic uveitis, multiple sclerosis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjögren's syndrome, rheumatoid arthritis, dermatomyositis, polymyositis, scleroderma, mixed connective tissue disease, discoid lupus erythematosus, and systemic lupus erythematosus.
- Other use that is provided relates to a method for combating or treating infections caused by micro-organisms, in particular those infections that are caused by micro-organisms that activate the NF-kappaB pathway during infections.
- Such micro-organisms are manifold, including bacteria, viruses, fungi, protozoa, but other pathogens (e.g. worms) can have the same effect. Activation of the NFkappaB pathway by a microbial infection in general occurs via activation of the Toll-like receptor pathway. The invention provides a method to modulate and in particular to inhibit parts of gene expression that are related to the inflammatory responses of an organism that are generally activated through one of the Toll-like receptor pathways.
- Toll-like receptor-mediated NF-kappa-B activation is central in recognition of pathogens by a host. Such recognition of pathogens generally occurs through germline-encoded molecules, the so-called pattern recognition receptors (PRRs). These PRRs recognize widespread pathogen associated molecular patterns (PAMPs). The pattern recognition receptors are expressed as either membrane-bound or soluble proteins. They include CD14, beta2-integrins (CD11/CD18), C-type lectins, macrophage scavenger receptors, complement receptors (CR1/CD35, CR2/CD21) and Toll-like receptors (TLRs). TLRs are distinguished from other PRRs by their ability to recognise and discriminate between different classes of pathogens. TLRs represent a family of transmembrane proteins that have an extracellular domain comprising multiple copies of leucine rich repeats (LRRs) and a cytoplasmic: Toll/IL-IR (TIR) motif that has significant homology to the intracellular signaling domain of the type I IL-1 receptor (IL-1 RI). Therefore, TLRs are thought to belong to the IL-IR superfamily.
- Pathogen associated molecular patterns (PAMPS) are not expressed by hosts but are components of the pathogenic micro-organism. Such PAMPS comprise bacterial cell wall components such as lipopolysaccharides (LPS), lipoproteins (BLP), peptidoglycans (PGN), lipoarabinomannan (LAM), lipoteichoic acid (LTA), DNA containing unmethylated CpG motifs, yeast and fungal cell walls mannans and beta-glucans, double stranded RNA, several unique glycosylated proteins and lipids of protozoa, and so on.
- Recognition of these PAMPS foremost provides for differential recognition of pathogens by TLRs. For example, TLR2 is generally activated in response to BLPs, PGNs of gram-positive bacteria, LAM of mycobacteria, and mannans of yeasts, whereas TLR4 is often activated by LPS of gram-negative bacteria and LTA of gram-negative bacteria; also a secreted small molecule MD-2 can account for TLR4 signalling.
- Several oligopeptides capable of modulating gene expression according to the invention have earlier been tested, both ex vivo as in vivo, and in small animals but a relationship with modulation of gene expression was not brought forward. A beneficial effect of these oligopeptides on LPS induced sepsis in mice, namely the inhibition of the effect of the sepsis, was observed. Immunomodulatory effects with these oligopeptides have been observed in vitro and in ex vivo such as in T-cell assays showing the inhibition of pathological Th1 immune responses, suppression of inflammatory cytokines (MIF), increase in production of anti-inflammatory cytokines (IL-10, TGF-beta) and immunomodulatory effects on antigen presenting cells (APC) like dendritic cells, monocytes and macrophages.
- Now that the insight has been provided that distinct synthetic oligopeptides or functional analogues or derivatives thereof, for example those that resemble breakdown products which can be derived by proteolysis from endogenous proteins such as hCG, can be used to modulate gene expression, for example by NF-kappaB inhibition, such oligopeptides find much wider application. Release of active NF-kappaB in cells is now known to occur after a variety of stimuli including treating cells with bacterial lipopolysaccharide (LPS) and the interaction with a Toll-like receptor (see for example Guha and Mackman, Cell. Sign. 2001, 13:85-94). In particular LPS stimulation of dendritic cells, monocytes and macrophages induces many genes that are under the influence of activation by transcription factors such as NF-kappaB, p50, EGR-1, IRF-1 and others that can be modulated by a signalling molecule according to the invention. Considering that LPS induction of EGR-1 is required for maximal induction of TNF-alpha, it is foreseen that inhibition of EGR-1 considerably reduces the effects of sepsis seen after LPS activation. Now knowing the gene modulatory effect of the signalling molecules such as oligopeptides as provided herein allows for rational design of signal molecule mixtures that better alleviate the symptoms seen with sepsis. One such mixture, a 1:1:1 mixture of LQGV, AQGV and VLPALP was administered to primates in a gram-negative induced rhesus monkey sepsis model for prevention of septic shock and found to be effective in this primate model. Accordingly, the invention provides a pharmaceutical composition for the treatment of sepsis in a primate, and a method for the treatment of sepsis in a primate comprising subjecting the primate to a signalling molecule according to the invention, preferably to a mixture of such signalling molecules. Administration of such a signalling molecule or mixture preferably occurs systematically, e.g. by intravenous or intraperitoneal administration. In a further embodiment, such treatment also comprises the use of for example an antibiotic, however, only when such use is not contra-indicated because of the risk of generating further toxin loads because of lysis of the bacteria subject to the action of those antibiotics in an individual thus treated.
- Other use that is contemplated relates to a method for combating or treating viral infections, in particular those infections that are caused by viruses that activate the NF-kappaB pathway during infections. Such virus infections are manifold, classical examples are hepatitis B virus induced cell transformation by persistent activation of NF-kappaB. Use of a signalling molecule according to the invention is herein provided to counter or prevent this cell transformation.
- Other disease where persistent NF-kappaB activation is advantageously inhibited by a signalling molecule according to the invention is a transplantation-related disease such as transplantation-related immune responses, graft-versus-host-disease, in particular with bone-marrow transplants, acute or chronic xeno-transplant rejection, and post-transfusion thrombocytopenia.
- Other case where persistent NF-kappaB activation is advantageously inhibited by a signalling molecule according to the invention is found in the prevention or mitigation of ischemia-related tissue damage seen after infarcts, seen for example in vivo in brain or heart, or ex vivo in organs or tissue that is being prepared or stored in preparation of further use as a transplant. Ischemia related tissue damage can now be mitigated by perfusing the (pre)ischemic area with a signalling molecule according to the invention that inhibits NF-kappaB activation. Example of conditions where ischemia (also called underperfusion) plays a role are for example eclampsia which can be ascribed to focal cerebral ischemia resulting from vasoconstriction, consistent with the evidence of changes detected by new cerebral imaging techniques. The liver dysfunction intrinsic to the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome could also be attributed to the effects of acute underperfusion. Other conditions of ischemia are seen after coronary occlusion leading to irreversible myocardial damage produced by prolonged episodes of coronary artery occlusion and reperfusion in vivo, which has already been discussed in PCT/NL01/00259 as well.
- Now that the insight has been provided that distinct synthetic oligopeptides, for example those that resemble breakdown products which can be derived by proteolysis from endogenous proteins such as hCG, can be used to modulate gene expression, for example by NF-kappaB inhibition, the oligopeptides find much wider application. For example, the invention provides a method for perfusing a transplant with a perfusing fluid comprising at least one signalling molecule according to the invention; ischemic or pre-implantation damage due to activation of NF-kappaB in the transplant can than greatly be diminished, allowing a wider use of the transplants.
- The invention provides a signalling molecule useful in modulating expression of a gene in a cell. Several examples of the use of such a signalling molecule for the production of a pharmaceutical composition for the treatment of medical or veterinary conditions are herewith given. In one embodiment, the invention provides such use in the treatment of an immune-mediated-disorder, in particular of those cases whereby a central role of NF-kappaB/Rel proteins in the immune response is found. However as said, modulating gene expression via modulating activity of other transcription factors, such as AP-1 or PPARgamma, and others is also provided, now that the gene modulating role of signalling molecules such as the oligopetides or analogues or derivatives thereof is understood. As also said, now knowing that oligopeptides, likely breakdown products, play such a central role in modulation of gene expression, the invention provides straightforward ways for identifying further gene expression modulating oligopeptides, and provides synthetic versions of these, and analogues and derivatives thereof for use in a wide variety of disorders and for use in the preparation of a wide variety of pharmaceutical compositions. Examples of such treatment and useful pharmaceutical compositions are for example found in relation to conditions wherein the immune-mediated disorder comprises chronic inflammation, such as diabetes, multiple sclerosis or acute or chronic transplant rejection, in particular in those cases whereby antigen presenting cells (APC's) or dendritic cells (DCs) are enhanced by (overactive) and persistent NF-kappaB expression or wherein the immune-mediated disorder comprises acute inflammation, such as septic or anaphylactic shock or acute transplant rejection. Other immune-mediated disorders that can be treated with a pharmaceutical composition comprising a signalling molecule according to the invention comprise auto-immune disease, such as systemic lupus erythematosus or rheumatoid arthritis (in particular by inhibiting IL-8 and/or IL-15 production by inhibiting NF-kappaB activity on the expression of these genes), allergy, such as asthma or parasitic disease, overly strong immune responses directed against an infectious agent, such as a virus or bacterium (in particular responses that include rapid haemorrhagic disease caused by infection with organisms such asYersinia pestis, Ebola-virus, Staphylococcus aureus (e.g. in cases of tampon-disease), bacterial (such as meningococcal) or viral meningitis and/or encephalitis, and other life-threatening conditions). Such overly strong responses are seen with for example pre-eclampsia, recurrent spontaneous abortions (RSA) or preterm parturition or other pregnancy related disorders. Especially with forms of eclampsia/pre-eclampsia that are associated with genetically programmed increased production of tumour-growth factor beta-1, treatment according to the invention is recommended. Also, in situations where RSA is likely attributable to increased IL-10 levels during pregnancy, or to increased TNF-alpha activity, for example due to the presence of an unfavourable allele, in particular of a G to A polymorphism in the promotor of the gene encoding TNF-alpha, treatment with a pharmaceutical composition as provided herein is recommended. Treatment directed at such pregnancy-related immune disorders is herein also provided by inhibiting NF-kappaB activity directed at activating natural killer (NK) cell activity. Also, LPS induced reduced fertility, or abortions, seen in pregnant sows, can be reduced by applying a signalling molecule or method as provided herein.
- Such use in treatment of an immune-mediated disorder preferably comprises regulating relative ratios and/or cytokine activity of lymphocyte, dendritic or antigen presenting cell subset-populations in a treated individual, in particular wherein the subset populations comprise Th1 or Th2, or DC1 or DC2 cells. Other embodiments of the invention comprise use of a signalling molecule according to the invention for the manufacture of a medicament for modulating a cardiovascular or circulatory disorder, such as coronary arterial occlusion and also in a pregnancy related cardiovascular or circulatory disorder.
- Furthermore, the invention provides a pharmaceutical composition for modulating a cardiovascular or circulatory disorder, in particular a pregnancy related cardiovascular or circulatory disorder, comprising a signalling molecule according to the invention or mixtures thereof. Such a composition finds it use in a method for modulating a cardiovascular or circulatory disorder, in particular a pregnancy related cardiovascular or circulatory disorder, comprising subjecting an animal (in particular a mammal) to treatment with at least one signalling molecule according to the invention. Non-pregnancy related disorders, that are for example related to hypercholesterolaemia, are susceptible to treatment with a signalling molecule according to the invention as well. For example, apolipoprotein E (apo E) deficiency is associated with a series of pathological conditions including dyslipidemia, atherosclerosis, Alzheimer's disease, increase body weight and shorter life span. Inheritance of different alleles of the POLYMORPHIC apoE gene is responsible for 10% of the variation in plasma cholesterol in most populations. Individuals HOMOZYGOUS for one variant. apoE2, can develop type III dysbetalipoproteinaemia if an additional genetic or environmental factor is present. Some much rarer alleles of apoE produce dominant expression of this disorder in heterozygous individuals. ApoE, is a ligand for the LDL receptor and its effects on plasma cholesterol are mediated by differences in the affinity of the LDL receptor for lipoproteins carrying variant apoE proteins. The factors that regulate apoE gene transcription have been investigated extensively by the expression of gene constructs in transgenic mice and involve complex interactions between factors that bind elements in the 5′ promoter region, in the first intron and in 3′ regions many kilobases distant from the structural gene. Deletion of the apo E gene is associated with changes in lipoprotein metabolism [plasma total cholesterol), HDL cholesterol, HDL/TC, and HDL/LDL ratios, esterification rate in apo B-depleted plasma, plasma triglyceride, hepatic HMG-CoA reductase activity, hepatic cholesterol content, decreased plasma homocyst(e)ine and glucose levels, and severe atherosclerosis and cutaneous xanthomatosis. The invention provides a method and a signalling molecule for the treatment of conditions that are associated with dysfunctional LDL receptors such as ApoE and other members of the apolipoprotein family. In particular, use of a signalling molecule comprising GVLPALPQ and/or VLPALP or a functional analogue or derivative thereof is preferred.
- The invention also provides use of a signalling molecule for the preparation of a pharmaceutical composition or medicament and methods of treatment for various medical conditions that are other than use in the preparation of a pharmaceutical composition for the treatment of an immune-mediated-disorder or a method of treatment of an immune-mediated-disorder. For example, the invention provides topical application, for example in an ointment or spray comprising a signal molecule according to the invention, for the prevention or mitigation of skin afflictions, such as eczemas, psoriasis, but also of skin damage related to over-exposure to UV-light.
- Also, use is contemplated in palliative control, whereby a gene related to prostaglandin synthesis is modulated such that COX2 pathways are effected.
- Furthermore, the invention also provides use of a signalling molecule for the preparation of a pharmaceutical composition or medicament and methods of treatment for various medical conditions that are other than use in the preparation of a pharmaceutical composition for the treatment of wasting syndrome, such as the treatment of particular individuals that are suffering from infection with HIV or a method of treatment of wasting syndrome of such individuals.
- In one embodiment, the invention provides the use of a signalling molecule according to the invention for the preparation of a pharmaceutical composition or medicament for modulating angiogenesis or vascularisation, in particular during embryonal development, or after transplantation to stimulate vascularisation into the transplanted organ or inhibit it in a later phase. Signalling molecules that effect angiogenesis are disclosed herein in the detailed description.
- Use as provided herein also comprises regulating TNF-alpha receptor (e.g. CD27) expression on cells, thereby modulating the relative ratios and/or cytokine activity of lymphocyte, dendritic or antigen presenting cell subset-populations in a treated individual. As for example described in the detailed description, particular oligopeptide according to the invention is capable of down-regulating CD27 expression on cells of the T-cell lineage.
- Down-regulating TNF-alpha itself is also particularly useful in septic-shock-like conditions that not only display increased TNF-alpha activity but display further release of other inflammatory compounds, such as NO. NO production is a central mediator of the vascular and inflammatory response. Our results show that inflammatory cells like macrophages stimulated with an inflammatory active compound such as LPS produce large amounts of NO. However, these cells co-stimulated with most of the NMPF peptides (
NMPF peptide 1 to 14, 43 to 66 and 69), even in a very low dose (1 pg/ml), inhibited production of NO. Typical septic-shock-like conditions that can preferably be treated by down-regulating TNF-alpha and NO production comprise disease conditions such as those caused by Bacillus anthracis (anthrax) and Yersinia pestis toxins or infections with these micro-organisms likely involved in bio-terrorism. Anthrax toxin is produced by Bacillus anthracis, the causative agent of anthrax, and is responsible for the major symptoms of the disease. Clinical anthrax is rare, but there is growing concern over the potential use of B. anthracis in biological warfare and terrorism. Although a vaccine against anthrax exists, various factors make mass vaccination impractical. The bacteria can be eradicated from the host by treatment with antibiotics, but because of the continuing action of the toxin, such therapy is of little value once symptoms have become evident. Thus, a specific inhibitor of the toxin's action will prove a valuable adjunct to antibiotic therapy. The toxin consists of a single receptor-binding moiety, termed protective antigen (PA), and two enzymatic moieties, termed edema factor (EF) and lethal factor (LF). After release from the bacteria as nontoxic monomers, these three proteins diffuse to the surface of mammalian cells and assemble into toxic, cell-bound complexes. - Cleavage of PA into two fragments by a cell-surface protease enables the fragment that remains bound to the cell, PA63, to heptamerize and bind EF and LF with high affinity. After internalization by receptor-mediated endocytosis, the complexes are trafficked to the endosome. There, at low pH, the PA moiety inserts into the membrane and mediates translocation of EF and LF to the cytosol. EF is an adenylate cyclase that has an inhibitory effect on professional phagocytes, and LF is a protease that acts specifically on macrophages, causing their death and the death of the host.
- Down-regulating TNF-alpha itself, and/or a receptor for TNF-alpha, as is herein also provided, is also beneficial in individuals with Chagas cardiomyopathy.
- Also, use of a signalling molecule according to the invention for the preparation of a pharmaceutical composition for modulation of vascularisation or angiogenesis in wound repair, in particular of burns, is herein provided. Also, use of a pharmaceutical composition as provided herein is provided in cases of post-operative physiological stress, whereby not only vascularisation will benefit from treatment, but the general well-being of the patient is improved as well.
- Another use of a signalling molecule according to the invention comprises its use for the preparation of another pharmaceutical composition for the treatment of cancer. Such a pharmaceutical composition preferably acts viamodulating and up-regulating apoptotic responses that are classically down-regulated by NF-kappaB activity. Inhibiting the activity with a signalling molecule according to the invention allows for increased cell death of tumorous cells. Another anti-cancerous activity of a signalling molecule as provided herein comprises down-regulation of c-myb, in particular in the case of hematopoietic tumors in humans. In this context, down-regulation of 14.3.3 protein is also provided.
- A further use of a signalling molecule according to the invention comprises its use for the preparation of a further pharmaceutical composition for the treatment of cancer. Such a pharmaceutical composition preferably acts via modulating and down-regulating transferrine receptor availability, in particular on tumorous cells. Transferrine receptors are classically up-regulated by NF-kappaB activity. Inhibiting the activity with a signalling molecule according to the invention allows for reduced iron up-take and increased cell death of tumorous cells. In particular erythroid and thromboid cells are susceptible to the treatment.
- Yet a further use of a signalling molecule according to the invention comprises its use for the preparation of yet another pharmaceutical composition for the treatment of cancer, in particular of cancers that are caused by viruses, such as is the case with retroviral-induced malignancies and other viral-induuced malignancies. Such a pharmaceutical composition preferably acts via modulating and down-regulating cell-proliferative responses that are classically up-regulated by virus-induced transcriptional or NF-kappaB activity. Inhibiting the activity with a signalling molecule according to the invention allows for decreased proliferation and increased cell death of tumorous cells. Such a pharmaceutial composition may also act via modulating angiogenic responses induced by IL-8, whereby for example inhibition of IL-8 expression via inhibition of transcription factor AP-1 or NF-kappaB expression results in the inhibition of vascularisation dependent tumor growth.
- Furthermore, the invention provides the use of a signalling molecule for the preparation of a pharmaceutical composition for optimising human or animal fertility and embryo survival, and a method for optimising fertility and embryo survival. In particular, the invention provided for a method and composition allowing the down-regulation of TNF-alpha in the fertilized individual, optimally in combination with a composition and method for up-regulating IL-10 in the individual. Such a composition and method finds immediate use in both human and veterinary medicine.
- Also, the invention provides the use of a signalling molecule for the preparation of a pharmaceutical composition for modulating the body weight of an individual, in particular by modulating gene expression of a gene under influence of peroxisome proliferator-activated receptor gamma (PPARgamma) activation and lipid metabolism by applying a signalling molecule according to the invention, and a method for modulating bodyweight comprising providing an individual with a signalling molecule according to the invention.
- A further use of a signalling molecule as provided herein lies in the modulation of expression of a gene in a cultured cell. Such a method as provided herein comprises subjecting a signalling molecule according to the invention to the cultured cell. Proliferation and/or differentiation of cultured cells (cells having been or being under conditions of in vitro cell culture known in the art) can be modulated by subjecting the cultured cell to a signalling molecule according to the invention. It is contemplated that for example research into proliferation or differentiation of cells, such as stem-cell research will benefit greatly from understanding that a third major way of effecting gene modulation exists, and considering the ease of application of synthetic peptides, and analogues or derivatives thereof.
- Furthermore, it is contemplated that a signalling molecule as provided herein finds an advantageous use as a co-stimulatory substance in a vaccine, accompanying modern day adjuvants or replacing the classically used mycobacterial adjuvants, especially considering that certain mycobacteria express hCG-like proteins, of which it is now postulated that these bacteria have already made use of the this third pathway found in gene modulation as provided herein by providing the host with breakdown products mimicking the signalling molecules identified herein. Treatment and use of the compositions as provided herein is not restricted to animals only, plants and other organisms are also subject to this third pathway as provided herein. Furthermore, now that the existence of such a pathway has been demonstrated, it is herein provided to make it subject of diagnosis as well, for example to determine the gene modulatory state of a cell in a method comprising determining the presence or absence of a signalling molecule as provided herein or determining the presence or absence of a protease capable of generating such a signalling molecule from a (preferable endogenous) protein.
- FIGS.1-2. Bone marrow (BM) cell yield of treated BALB/c mice (n=6). BM cells were isolated from treated mice and cultured in vitro in the presence of rmGM-CSF for nine days. These figures show cell yield after nine days of culture of BM cells isolated from mice treated with PBS, LPS or LPS in combination with
NMPF peptides - FIG. 3. Effect of in vivo treatment on MHC-II expression on CD11c+ cells. Bone marrow (BM) cells were isolated from treated BALB/c mice (n=6) and cultured in vitro in the presence of rmGM-CSF for nine days. This figure shows MHC-II expression expressed in mean fluorescence intensity (MFI) after nine days of culturing of BM cells isolated from PBS, LPS or LPS in combination with NMPF. Each condition consists of 6 Petri dishes and results shown in these figures are representative of 6 dishes. Differences of ≧20% were considered significant and line bars represent significant data as compared to LPS control group. A representative experiment is shown. Findings involving all experimental conditions were entirely reproduced in 3 additional experiments.
- FIGS.4-7. Bone marrow (BM) cell yield of in vitro treated BM cultures. BM cells from BALB/c mice (n=3) were cultured in vitro and treated with either PBS, LPS (t=6),
NMPF - FIGS.8-11. Effect of in vitro treatment on MHC-II expression on CD11c+ cells. BM cells from BALB/c mice (n=3) were cultured in vitro and treated with either PBS, LPS (t=6),
NMPF - FIGS.12-15. Bone marrow (BM) cell yield of treated BALB/c mice (n=6). BM cells were isolated from treated mice and cultured in vitro in the presence of rmGM-CSF for nine days. These figures show cell yield after nine days of culture of BM cells in suspension (unattached) and attached to Petri dish (attached). BM cells were isolated from mice treated with PBS, LPS or LPS in combination with different NMPF peptides. In these figures cell yield is expressed in relative percentage of cells compared to PBS. Each condition consists of 6 Petri dishes and results shown here are representative of 6 dishes. Differences of ≧20% were considered significant and line bars represent significant data as compared to LPS control group. A representative experiment is shown. Findings involving all experimental conditions were entirely reproduced in 3 additional experiments.
- FIGS.16-17. Bone marrow (BM) cell yield of in vitro treated BM cultures from NOD mice. BM cells from 15 weeks old female NOD mice (n=3) were cultured in vitro and treated with either PBS or NMPF in the presence of rmGM-CSF for nine days. These figures show cell yield after nine days of culture of BM cells in suspension (unattached) and attached to Petri dishes (attached). In these figures cell yield is expressed in relative percentage of cells compared to PBS. Each condition consists of 6 Petri dishes and results shown here are representative of 6 dishes. Differences of ≧20% were considered significant and dotted bars represent significant data as compared to PBS control group. A representative experiment is shown. Findings involving all experimental conditions were entirely reproduced in 3 additional experiments.
- FIGS.20-32. In vivo treatment of fertilised chicken eggs with NMPF and the effect of NMPF on angiogenesis. Fertile chicken eggs (day 0) were treated with either PBS, NMPF, VEGF or VEGF in combination with NMPF. Ten eggs were injected for every condition. On
day 8 of incubation, the embryos were removed from the eggs and were placed in a 100-mm Petri dish. The embryo and the blood vessels were photographed in vivo with the use of a microscope. Of each egg one overview picture was taken and 4 detail pictures of the blood vessels were taken. Quantification of angiogenesis (vessels branches) was accomplished by counting the number of blood vessels branches. Quantification of this vasculogenesis was accomplished by measuring the blood vessel thickness. The number of blood vessel branches and vessel thichness was measured in the pictures and were correlated to a raster (in the pictures) of 10 mm2 for comparison. The mean number of branches and the mean blood vessel thickness of each condition (N=10) were calculated and compared to either the PBS or VEGF controls using a Student's T-test. Line bars represent significant (p<0.05) data as compared to PBS control group and dotted bars represent significant (p<0.05) data as compared to VEGF group. FIGS. 20-30 show the effect of NMPF on vessel branches. FIGS. 31-32 show the effect of NMPF on vessel thickness. - FIG. 33. Detection of NF-kB via EMSA. This figure shows the presence of NF-kB in the nuclear extracts of RAW264.7 cells treated with LPS or NMPF in combination with LPS for 4 hours. Numbers 1-13 correspond to nuclear extracts from cells treated with NMPF and LPS. CTL corresponds to nuclear extracts from cells treated with LPS only. Specificity of the radioactively labeled NF-kB probe is shown by competition with the unlabeld oligonucleotide (u1, u2, u3) in three different concentrations (1×, 10×, 100×) with nuclear extracts of CTL and olg corresponds to samples containing only labeled oligonucleotide (without nuclear extract). Description: (NMPF-1)VLPALPQVVC, (NMPF-2)LQGVLPALPQ, (NMPF-3)LQG, (NMPF-4)LQGV, (NMPF-5)GVLPALPQ, (NMPF-6)VLPALP, (NF-7)VLPALPQ, (NMPF-8)GVLPALP, (NMPF-9)VVC, (NMPF-1)MTRV, (NMPF-12)MTR
- FIG. 34. HPLC chromatograph (wave length 206) in which data profile obtained from the nuclear protein extracts of LPS and LPS in combination with NMPF stimulated RAW264.7 cells are overlayed.
- FIG. 35. MSn analysis of NMPF-4 peptide.
- FIG. 36. MSn analysis of fraction from nuclear extract of LPS stimulated RAW264.7 cells. Upper panel shows full spectrum of the fraction and lower panel shows the MS/MS spectrum of mass 413.13.
- FIG. 37. MSn analysis of fraction from nuclear extract of LPS in combination with NMPF-4 stimulated RAW264.7 cells. Upper panel shows full spectrum of the fraction and lower panel shows the MS/MS spectrum of mass 416.07.
- FIGS.38-49 Effect of NMPF on septic shock syndrome in Rhesus monkeys. On the
time point 70 minutes E.coli was infused and at the end of E.coli infusion (time point 190 minutes) the antibiotic Baytril was injected. The control monkey (monkey 429) was treated with 0.9% NaCl at the time point of 100 minutes, whereas the NMPF treated monkeys (monkey 459 and 427) received the NMPF treatment at the same time point as the control monkey. Heart rate (beats per minute), blood pressure (mmHg), difference between systolic and diastolic blood pressure and blood oxygen concentration (saturation in %) of the control monkey 429 (FIGS. 38-41), NMPF treated monkey 459 (FIGS. 42-45) and 427 (FIGS. 46-49) in the time (minutes) during the experiment are shown. - FIG. 50 These figures show the NO production of LPS (10 μg/ml) stimulated RAW 264.7 macrophages co-stimulated with different NMPF peptides (1 pg/ml).
- FIG. 51 These figures show the NO production of LPS (10 μg/ml) stimulated RAW 264.7 macrophages co-stimulated with different NMPF peptides with three different concentrations.
- FIG. 52 This figure shows the percentage of diabetic NOD mice treated for 2 weeks with the various NMPF peptides
- FIG. 53 This figure shows the performed glucose tolerance test (GTT) in NOD mice treated with NMPF peptides (A), and fasting blood glucose levels (B).
- Cells react to environmental and intrinsic changes, which they perceive through extracellular and inter- as well as intracellular signals. The nature of these signals can be either for example physical or chemical. Moreover, different classes of molecules present in blood react to each other and induce cascade of reaction that have direct effect on other molecules and/or eventually lead to cellular responses, for example complement system and blood coagulation proteins.
- Many genes are regulated not by a signalling molecule that enters the cells but by molecules that bind to specific receptors on the surface of cells for example receptors with enzymatic activity (receptor tyrosine kinases, receptor-like protein tyrosine phosphatases, receptor serine/threonine kinases, histidine kinases, guanylyl cyclases) and receptors without enzymatic activity (cytokine receptors, integrins, G-protein-coupled receptors). Interaction between cell-surface receptors and their ligands can be followed by a cascade of intracellular events that modulate one or more intracellular transducing proteins, including variations in the intracellular levels of so-called second messengers (diacylglycerol, Ca2+, cyclic nucleotides, inositol(1,4,5) trisphosphate, phosphatidylinositol(3,4,5) trisphosphate, phosphatidylinositol transfer protein (PITP)). This leads to the activation or inhibition of a so-called ‘effector protein’. The second messengers in turn lead to changes in protein for example protein phosphorylation through the action of cyclic AMP, cyclic GMP, calcium-activated protein kinases, or protein kinases (for example AGC group serine/threonine protein kinases, CAMK group serine/threonine protein kinases, CMGC group serine/threonine kinases, protein tyrosine kinase group, or others like MEK/Ste7p). Phosphorylation by protein kinases is one of the regulatory mechanisms in signal transmission that modulate different cellular pathways such as Ras/MAPK pathway, MAP kinase pathway, JAK-STAT pathway, wnt-pathway. In many instances this all results in altered gene expression (for example genes for the regulation of other genes, cell survival, growth, differentiation, maturation, functional activity).
- Many of the responses to binding of ligands to cell-surface receptors are cytoplasmatic and do not involve immediate gene activation in the nucleus. In some instances a pre-existing inactive transcription factor following a cell-surface interaction is activated that lead to immediate gene activation. For example the protein NF-kappaB, which can be activated within minutes by a variety of stimuli, including membrane receptors (for example pattern recognition receptors like Toll-like receptor binding to pathogen-associated molecular patterns), inflammatory cytokines such as TNF-α, IL-1, T-cell activation signals, growth factors and stress inducers.
- Our genomic experiment with NMPF peptide LQGV showed very immediate effects on signal transduction and gene regulation since the cells were treated with the peptide for only four hours. In this short period of time LQGV down-regulated at least 120 genes and up-regulatedat least 6 genes in the presence of a strong stimulator (PHA/IL-2 stimulated T-cell line (PM1)), demonstrating the profound effect on signalling molecule according to the invention and modulatory effect on gene expression. The genes affected by LQGV include onco-genes, genes for transcription factors, intracellular enzymes, membrane receptors, intracellular receptors, signal transducing proteins (for example kinases) and some genes for unkown molecules. This shows that LQGV as an example of the synthetic signalling molecule (oligopeptide or functional analogue or derivative thereof) as described here, has broad spectrum of effects at different extracellular and intracellular levels. In addition, our HPLC/MS data have shown the presence of LQGV in the nucleus of a macrophage cell line (RAW267.4) within half hour and also indicates the direct effects on DNA level as well as at intracellular level which is further supported by NF-kappaB experiments. The ultimate modulatory effect of LQGV is dependent on, for example, type of the cell, differentiation and maturation status of the cell, the functional status and the presence of other regulatory molecules. This was evident by shock experiment in which different NMPF peptides had similar or different effects on the disease. Same results were obtained with DC, fertilized chicken egg experiments, and CAO experiments; NMPF effects were dependent on type of co-stimulation (GM-CSF alone or in combination with LPS, or VEGF) and time of the treatment. Due to this NMPF have the ability to modulate cellular responses at different levels.
- The invention is further explained with the aid of the following illustrative examples.
- Material and Methods
- Peptide Synthesis
- The peptides as mentioned in this document such as LQG, AQG, LQGV, AQGV, LQGA, VLPALP, ALPALP, VAPALP, ALPALPQ, VLPAAPQ, VLPALAQ, LAGV, VLAALP, VLPALA, VLPALPQ, VLAALPQ, VLPALPA, GVLPALP, VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCAL, RPRCRPINATLAVEKEGCPVCITVNTTICAGYCPT, SKAPPPSLPSPSRLPGPS, LQGVLPALPQVVC, SIRLPGCPRGVNPVVS, LPGCPRGVNPVVS, LPGC, MTRV, MTR, VVC were prepared by solid-phase synthesis (Merrifield, 1963) using the fluorenylmethoxycarbonyl (Fmoc)/tert-butyl-based methodology (Atherton, 1985) with 2-chlorotrityl chloride resin (Barlos, 1991) as the solid support. The side-chain of glutamine was protected with a trityl function. The peptides were synthesised manually. Each coupling consisted of the following steps: (i) removal of the alpha-amino Fmoc-protection by piperidine in dimethylformamide (DMF) (ii) coupling of the Fmoc amino acid (3 eq) with diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt) in DMF/N-methylformamide (NMP) (iii) capping of the remaining amino functions with acetic anhydride/diisopropylethylamine (DIEA) in DMF/NMP. Upon completion of the synthesis, the peptide resin was treated with a mixture of trifluoroacetic acid (TFA)/H2O/triisopropylsilane (TIS) 95:2.5:2.5. After 30 minutes TIS was added until decouloration. The solution was evaporated in vacuo and the peptide precipitated with diethylether. The crude peptides were dissolved in water (50-100 mg/ml) and purified by reverse-phase high-performance liquid chromatography (RP-HPLC). HPLC conditions were: column: Vydac TP21810C18 (10×250 mm); elution system: gradient system of 0.1% TFA in water v/v (A) and 0.1% TFA in acetonitrile (ACN) v/v (B); flow
rate 6 ml/min; absorbance was detected from 190-370 nm. There were different gradient systems used. For example for peptides LQG and LQGV: 10minutes 100% A followed by linear gradient 0-10% B in 50 minutes. For example for peptides VLPALP and VLPALPQ: 5minutes 5% B followed bylinear gradient 1% B/minute. The collected fractions were concentrated to about 5 ml by rotation film evaporation under reduced pressure at 40° C. The remaining TFA was exchanged against acetate by eluting two times over a column with anion exchange resin (Merck II) in acetate form. The elute was concentrated and lyophilised in 28 hours. Peptides later were prepared for use by dissolving them in PBS. - Transcription Factor Experiment
- Macrophage cell line. The RAW 264.7 macrophages, obtained from American Type Culture Collection (Manassas, Va.), were cultured at 37° C. in 5% CO2 using DMEM containing 10% FBS and antibiotics (100 U/ml of penicillin, and 100 μg/ml streptomycin). Cells (1×106/ml) were incubated with peptide (10 μg/ml) in a volume of 2 ml. After 8 h of cultures cells were washed and prepared for nuclear extracts.
- Nuclear extracts. Nuclear extracts and EMSA were prepared according to Schreiber et al. Methods (Schriber et al. 1989, Nucleic Acids Research 17). Briefly, nuclear extracts from peptide stimulated or nonstimulated macrophages were prepared by cell lysis followed by nuclear lysis. Cells were then suspended in 400 μl of buffer (10 mM HEPES pH 7.9), 10 mM KCl, 0.1 mM KCL, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and protease inhibitors), vigorously vortexed for 15 s, left standing at 4° C. for 15 min, and centrifuged at 15,000 rpm for 2 min. The pelleted nuclei were resuspended in buffer (20 mM HEPES (pH 7.9), 10% glycerol, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and protease inhibitors) for 30 min on ice, then the lysates were centrifuged at 15,000 rpm for 2 min. The supernatants containing the solubilized nuclear proteins were stored at −70° C. until used for the Electrophoretic Mobility Shift Assays (EMSA).
- EMSA. Electrophoretic mobility shift assays were performed by incubating nuclear extracts prepared from control (RAW 264.7) and peptide treated RAW 264.7 cells with a 32P-labeled double-stranded probe (5′
AGCTCAGAGGGGGACTTTCCGAGAG 3′) synthesized to represent the NF-kappaB binding sequence. Shortly, the probe was end-labeled with T4 polynucleotide kinase according to manufacturer's instructions (Promega, Madison, Wis.). The annealed probe was incubated with nuclear extract as follows: in EMSA, binding reaction mixtures (20 μl) contained 0.25 μg of poly(dI-dC) (Amersham Pharmacia Biotech) and 20,000 rpm of 32P-labeled DNA probe in binding buffer consisting of 5 mM EDTA, 20% Ficoll, 5 mM DTT, 300 mM KCl and 50 mM HEPES. The binding reaction was started by the addition of cell extracts (10 μg) and was continued for 30 min at room temperature. The DNA-protein complex was resolved from free oligonucleotide by electrophoresis in a 6% polyacrylamide gel. The gels were dried and exposed to x-ray films. - Apo E Experiments
- Apolipoprotein E (apo E) deficiency is associated with a series of pathological conditions including dyslipidemia, atherosclerosis, Alzheimer's disease, increase body weight and shorter life span. Inheritance of different alleles of the POLYMORPHIC apoE gene is responsible for 10% of the variation in plasma cholesterol in most populations. Individuals HOMOZYGOUS for one variant. apoE2, can develop type III dysbetalipoproteinaemia if an additional genetic or environmental factor is present. Some much rarer alleles of apoE produce dominant expression of this disorder in heterozygous individuals. ApoE, is a ligand for the LDL receptor and its effects on plasma cholesterol are mediated by differences in the affinity of the LDL receptor for lipoproteins carrying variant apoE proteins. The factors that regulate apoE gene transcription have been investigated extensively by the expression of gene constructs in transgenic mice and involve complex interactions between factors that bind elements in the 5′ promoter region, in the first intron and in 3′ regions many kilobases distant from the structural gene. Deletion of the apo E gene is associated with changes in lipoprotein metabolism [plasma total cholesterol), HDL cholesterol, HDL/TC, and HDL/LDL ratios, esterification rate in apo B-depleted plasma, plasma triglyceride, hepatic HMG-CoA reductase activity, hepatic cholesterol content, decreased plasma homocyst(e)ine and glucose levels, and severe atherosclerosis and cutaneous xanthomatosis.
- Results
- NF-kB Experiments
- The transcription factor NF-kB participates in the transcriptional regulation of a variety of genes. Nuclear protein extracts were prepared from LPS and peptide treated RAW264.7 cells or from LPS treated RAW264.7 cells. In order to determine whether the peptide modulates the translocation of NF-kB into the nucleus, on these extracts EMSA was performed. FIG. 33 shows the amount of NF-kB present in the nuclear extracts of RAW264.7 cells treated with LPS or LPS in combination with peptide for 4 hours. Here we see that indeed some peptides are able to modulate the translocation of NF-kB since the amount of labeled oligonucleotide for NF-kB is reduced. In this experiment peptides that show the modulation of translocation of NF-kB are: (NMPF-1)VLPALPQVVC, (NMPF-2)LQGVLPALPQ, (NMPF-3)LQG, (NMPF-4)LQGV, (NMPF-5)GVLPALPQ, (NMPF-6)VLPALP, (NMPF-7)VLPALPQ, (NMPF-8)GVLPALP, (NMPF-9)VVC, (NMPF-11)MTRV, (NMPF-12)MTR.
- Nuclear Location of Peptide Experiment
- Reverse-phase high-performance liquid chromatography (RP-HPLC) method was used to prove the presence of synthetic oligo-peptide in the nuclear extracts. We used a Shimadzu HPLC system equipped with Vydac monomeric C18 column (column218MS54, LC/MS C18 reversed phase, 300A, 5 □m, 4.6 mm ID×250 mm L); elution system: gradient system of 0.01% TFA and 5% acetonitrile (CAN) in water v/v (A) and 0.01% TFA in 80% acetonitrile (ACN) v/v (B); flow rate 0.5 ml/min; absorbance was detected from 190-370 nm. The gradient time programe was as follows:
Time (min) Buffer B concentration 0.01 0 5.0 0 30.0 80 40.0 100 60.0 100 65.0 0 70.0 0 - The elution time of peptide LQGV was determined by injecting 2 □g of the peptide in a separate run. Mass spectrometry (MS) analysis of fraction which contained possible NMPF-4 (LQGV) (elution time was determined by injecting the peptide in the same or separate run) was performed on LCQ Deca XP (Thermo Finnigan).
- Results
- Nuclear Location of Peptide Experiment
- The nuclear protein extracts used in EMSA experiments were also checked for the presence of LQGV by means of HPLC and MS. FIG. 34 shows HPLC chromatograph (wave length 206) in which data profile obtained from the nuclear protein extracts of LPS and LPS in combination with NMPF-4 (LQGV) stimulated RAW264.7 cells are overlayed. This figure also show the presence or absence of number of molecule signals in the nuclear extracts of oligopeptide+LPS treated cells as compared to nuclear extracts of LPS treated cells. Since HPLC profile of LQGV showed that the peptide elutes at around 12 minutes (data not shown), fraction corresponding to region 10-15 minutes was collected and analysed for the presence of this peptide in MS.
- The peptide's molecular weight is around 416 Daltons. Besides 416 mass FIG. 35 shows some other molecular weights. This is to be explained by the high concentration of the peptide which induces the formation of dimers and sodium-adducts (m/z 416-[M+H]+, 438-[M+Na]+, 831-[2M+H]+, 853-[2M+Na]+, 1245-[3M+H]+, 1257-[3M+Na]+). FIG. 36 shows the MS results of 10-15 min. fraction of nuclear extract obtained from LPS stimulated cells. These results show the absence of 416 dalton mass, while FIG. 37 shows the presence of 416 dalton mass of which the MSn data (FIG. 37) and MS-sequence confirm the presence of LQGV peptide in the nuclear protein extract obtained from LQGV+LPS stimulated RAW264.7 cells.
- Endotoxin Shock Model (Sepsis)
- Sepsis. For the endotoxin model, BALB/c mice were injected i.p. with 8-9 mg/kg LPS (E. coli 026:B6; Difco Lab., Detroit, Mich., USA). Control groups (PBS) were treated with PBS i.p. only. To test the effect of NMPF from different sources (synthetic, commercial hCG preparation [c-hCG]), we treated BALB/c with a dose of 300-700 IU of different hCG preparations (PG23; Pregnyl batch no. 235863, PG25; Pregnyl batch no. 255957) and with synthetic peptides (5 mg/kg) after two hours of LPS injection. In other experiments BALB/c mice were injected i.p. either with 10 mg/kg or with 11 mg/kg LPS (E. coli 026:B6; Difco Lab., Detroit, Mich., USA). Subsequently mice were treated after 2 hours and 24 hours of LPS treatment with NMPF peptides.
- Semi-quantitative sickness measurements. Mice were scored for sickness severity using the following measurement scheme:
- 1 Percolated fur, but no detectable behaviour differences compared to normal mice.
- 2 Percolated fur, huddle reflex, responds to stimuli (such as tap on cage), just as active during handling as healthy mouse.
- 3 Slower response to tap on cage, passive or docile when handled, but still curious when alone in a new setting.
- 4 Lack of curiosity, little or no response to stimuli, quite immobile.
- 5 Laboured breathing, inability or slow to self-right after being rolled onto back (moribund)
- 6 Sacrificed
- Results
- Endotoxin Shock Model (Sepsis)
- Sepsis experiments. To determine the effect of synthetic peptides (NMPF) in high-dose LPS shock model, BALB/c mice were injected intraperitoneally with different doses of LPS and survival was assessed daily for 5 days. In this experiment (for the LPS endotoxin model) BALB/c mice were injected i.p. with 8-9 mg/kg LPS (E. coli 026:B6; Difco Lab., Detroit, Mich., USA). Control groups (PBS) were treated with PBS i.p. only. We treated BALB/c mice with a dose of 300-700 IU of different hCG preparations (PG23; Pregnyl batch no. 235863, PG25; Pregnyl batch no. 255957) or with peptides (5 mg/kg) after two hours of LPS injection.
- These experiments showed (table 1.) that
NMPF peptides peptides peptides - In Table 2 we see the effect of ALA-replacement (PEPSCAN) in peptide LQG, LQGV, VLPALP, VLPALPQ in septic shock experiments. We conclude, that the change in even one amino acid by a neutral amino acid can lead to different activity. So, genomic differences as well as polymorphism in these peptides can regulate the immune response very precise. Derivatives of these peptides, for example (but not limited to) by addition of classical and non-classical amino acids or derivatives that are differentially modified during or after synthesis, for example benzylation, amidation, glycosylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand etc. could also lead to a better effectiveness of the activity.
- To determine whether treatment of BALB/c mice with NMPF inhibit septic shock at different stages of disease, synthetic peptides (NMPF) were injected i.p. at 2 and 24 hours after the induction of septic shock with high dose LPS (10 mg/kg).
- As shown in Tables 3 and 4, control mice treated PBS after the shock induction, reached a sickness score of 5 at 14 and 24 hours, and remained so after the second injection with PBS. The survival rate in control group mice was 0% at 48 hours. In contrast to control mice, mice treated with
NMPF NMPF NMPF 3 reached sickness scores of 3-4 and the second NMPF injection did save these mice. These experiments show that NMPF peptides have anti-shock activity at different stages of the disease and NMPF have anti-shock activity even at disease stage when otherwise irreversible damage had been done. This indicates that NMPF have effects on different cellular levels and also have repairing and regenerating capacity. - Dendritic Cells Experiments
- Mice. The mouse strain used in this study was BALB/c (Harlan, Bicester, Oxon, GB). All mice used in experiments were females between 8 and 12 weeks of age.
- Mice were housed in a specific-pathogen-free facility. The Animal Use Committee at the Erasmus University Rotterdam, The Netherlands approved all studies.
- In vivo treatment. At least six mice per group were injected intraperitonally (i.p) with LPS (10 mg/kg; Sigma). After 2 and 24 hrs of LPS induction, mice were injected i.p. with either NMPF (5 mg/kg) or Phosphate Buffered Saline (PBS), in a volume of 100 μl. LPS induced shock in this model had more than 90% mortality at 48 hrs.
- Bone marrow cell culture. From treated mice, bone-marrow cells were isolated and cultured as follows. BALB/c mice were killed by suffocation with CO2. The femurs and tibiae were removed and freed of muscles and tendons under aseptic conditions. The bones were placed in R10 medium (RPMI 1640, supplemented with 50 U/ml penicillin, 50 μg/ml streptomycin, 0.2 M Na-pyruvate, 2 mM glutamine, 50 μM 2-mercaptoethanol and 10% fetal calf serum (Bio Whittaker, Europe)).
- The bones were then cleaned more thoroughly by using an aseptic tissue and were transferred to an ice cold mortier with 2 ml of R10 medium. The bones were crushed with a mortel to get the cells out of the bones. Cells were filtered through a sterile 100 μM filter (Beckton Dickinson Labware) and collected in a 50 ml tube (FALCON). This procedure was repeated until bone parts appeared translucent.
- The isolated cells were resuspended in 10 ml of R10 and 30 ml of Geys medium was added. The cell suspension was kept on ice for 30 minutes, to lyse the red blood cells. Thereafter, the cells were washed twice in R10 medium. Upon initiation of the culture, the cell concentration was adjusted to 2×1 cells per ml in R10 medium supplemented with 20 ng/ml recombinant mouse Granulocyte Monocyte-Colony Stimulating Factor (rmGM-CSF; BioSource International, Inc., USA) and seeded in 100 mm non-adherent bacteriological Petri dishes (Falcon). For each condition six Petri dishes were used and for further analysis, cells were pooled and analysed as described ahead. The cultures were placed in a 5% CO2-incubator at 37° C. Every three days after culture initiation, 10 ml fresh R10 medium supplemented with rmGM-CSF at 20 ng/ml was added to each dish.
- Nine days after culture initiation, non-adherent cells were collected and counted with a Coulter Counter (Coulter).
- Alternatively, BM cells from untreated mice were isolated and cultured as described above and were in vitro treated with the following conditions:
NMPF 4,NMPF 46,NMPF 7, NMPF 60 (20 μg/ml) were added to the culture either atday 0 orday 6 after culture initiation. Or LPS (1 μg/ml) was added to the culture atday 6 with or without the NMPF. - Immunofluorescence staining. Cells (2×105) were washed with FACS-buffer (PBS with 1% BSA and 0.02% sodium azide), and transferred to a round-bottomed 96-well plate (NUNC). The antibodies used for staining were against MHC-II (I-A/I-E) PE and CD11c/CD18 FITC (PharMingen/Becton Dickinson, Franklin Lakes, N.J., US).
- Cells were resuspended in 200 μl FACS-buffer containing both of the antibodies at a concentration of 2.5 ng/μl per antibody. Cells were then incubated for 30 min at 4° C. Thereafter, cells were washed 3 times and finally resuspended in 200 μl FACS-buffer for flow-cytometric analysis in a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, Germany). All FACS-data were analyzed with CellQuest software (Becton Dickinson, Heidelberg, Germany).
- Statistical analysis All differences greater than 20% are considered to be significant.
- Results
- Dendritic Cells Experiments
- Cell yield of ex vivo bone-marrow cell cultures. To determine the in vivo effect of LPS and NMPF treatment on the cell yield obtained from a nine-day culture of bone-marrow with rmGM-CSF, cells were isolated from the BM of treated mice and cultured, harvested and counted as described. As shown in FIGS. 1 and 2, the cell yield of the bone-marrow cultures of LPS (10 mg/kg) treated mice is significantly decreased compared to PBS treated mice. Mice treated with
NMPF 4,NMPF 7,NMPF 46 andNMPF 60 after LPS shock induction, had a significantly increased cell yield compared to LPS in the presence of rmGM-CSF. In addition, BM cultures fromNMPF 46 treated mice gave a significantly increased cell yield even compared to the PBS group. - Immunofluorescence staining of in vivo treated bone-marrow derived DC. Culture of BM cells in the presence of rmGM-CSF gave rise to an increased population of cells that are positive for CD11c and MHC-II. Cells positive for these cell membrane markers are bone-marrow derived dendritic cells (DC). DC are potent antigen presenting cells (APC) and modulate immune responses. In order to determine the maturation state of myeloid derived DC, cells were stained with CD11c and MHC-II.
- As shown in FIG. 3, the expression of the MHC-II molecule was significantly decreased on CD11c-positive cells from LPS treated mice as compared to the PBS group. This decrease in MHC-II expression was further potentiated by the in vivo treatment with
NMPF 4 andNMPF 46. However, treatment of mice withNMPF 7 andNMPF 60 significantly increased the expression of the MHC-II molecule even as compared to the PBS group. - Cell yields of in vitro bone-marrow cell cultures. To determine the effect of LPS and NMPF in vitro on the cell yield of a nine-day culture of bone-marrow cells, we isolated the BM cells from untreated BALB/c mice and cultured in the presence of rmGM-CSF. In addition to rmGM-CSF, cultures were supplemented with NMPF at either
day 0 orday 6 with or without the addition of LPS atday 6. - As shown in FIGS.4-7, there is a significant decrease in cell yield in LPS treated BM cells as compared to PBS. BM cells treated with
NMPF NMPF 4 at time point t=6 showed significant decrease in cell yield as compared to the PBS group and this effect is comparable with the effect of LPS (FIG. 4). In addition, BM cells treated withNMPF NMPF 7 the cell yield was significantly increased as compared to the PBS group. Immunofluorescence staining of in vitro treated bone-marrow derived DC. To determine the maturation state of DC, CD11c positive cells were stained for MHC-II antibody. FIGS. 7-11 show that there is an opposite effect of LPS on MHC-II expression as compared to in vivo experiments, namely, MHC-11 expression is significantly increased with LPS treatment in vitro as compared to PBS.NMPF 4 with LPS further potentiated the effect of LPS, whileNMPF 7 with or without LPS (t=6), significantly inhibited the expression of MHC-11 as compared to LPS and PBS, respectively. However, cells treated withNMPF 46 without LPS (t=0) showed significantly increased expression of MHC-II on CD11c positive cells. Furthermore, no significant differences were found in thegroup NMPF 60 with or without LPS on MHC-II expression as compared to LPS and PBS treated cells. - To determine the in vivo effect of LPS and NMPF treatment on the cell yield obtained from a nine-day culture of bone-marrow with rmGM-CSF, cells were isolated from the BM of treated mice and cultured, harvested and counted as described. The cell yield of ‘attached’ cells was significant increased with
NMPF NMPF NMPF NMPF 46 the cell yield was significant increased as compared to the PBS group (FIGS. 12-13). - To determine the effect of LPS and NMPF in vitro on the cell yield of a nine-day culture of bone-marrow cells of female NOD mice, we isolated the BM cells from untreated NOD mice and cultured in the presence of rmGM-CSF. In addition to rmGM-CSF, cultures were supplemented with NMPF. In these experiments the bone-marrow cell yield of ‘un-attached’ cells was significant increased with
NMPF NMPF NMPF - Coronary Artery Occlusion (CAO) Experiments
- CAO induction and treatment. NMPF have immunoregulatory effects in chronic inflammatory as well as acute inflammatory mice models. Since certain cytokines like TGF-beta1, TNF-alpha, IL-1 and ROS (reactive oxygen species) have been implicated in irreversible myocardial damage produced by prolonged episodes of coronary artery occlusion and reperfusion in vivo that leads to ischaemia and myocardial infarct, we tested the cardio-protective properties of peptides in ad libitum fed male Wistar rats (300 g). The experiments were performed in accordance with the Guiding principles in the Care and Use of Animals as approved by the Council of the American Physiological Society and under the regulations of the Animal Care Committee of the Erasmus University Rotterdam. Shortly, rats (n—3) were stabilised for 30 minutes followed by i.v. 1 ml of peptide treatment (0.5 mg/ml) in 10 minutes. Five minutes after completion of treatment, rats were subjected to a 60-min coronary artery occlusion (CAO). In the last 5 minutes of CAO, rats were again treated over 10 minutes i.v. with 1 ml of peptide (0.5 mg/ml) followed by 120 minutes of reperfusion (IP). Experimental and surgical procedures are described in detail in Cardiovascular Research 37(1998) 76-81. At the end of each experiment, the coronary artery was re-occluded and was perfused with 10 ml Trypan Blue (0.4%, Sigma Chemical Co.) to stain the normally perfused myocardium dark blue and delineate the nonstained area at risk (AR). The heart was then quickly excised and cut into slices of 1 mm from apex to base. From each slice, the right ventricle was removed and the left ventricle was divided into the AR and the remaining left ventricle, using micro-surgical scissors. The AR was then incubated for 10 min in 37° C. Nitro-Blue-Tetrazolium (Sigma Chemical Co.; 1 mg per 1 ml Sorensen buffer, pH 7.4), which stains vital tissue purple but leaves infarcted tissue unstained. After the infarcted area (IA) was isolated from the noninfarcted area, the different areas of the LV were dried and weighed separately. Infarct size was expressed as percentage of the AR. Control rats were treated with PBS.
- Results
- Coronary Artery Occlusion (CAO) Experiments
- Our CAO data showed that 15 rats in control group treated with only PBS had infarcted area of 70±2% (average±standard error) after 60-minutes of CAO followed by 2 hours of reperfusion. While rats treated with peptide VLPALP, LQGV, VLPALPQVVC, LQGVLPALPQ, LAGV, LQAV and MTRV showed infarcted area of 62±6%, 55±6%, 55±5%, 67±2%, 51±4%, 62±6% and 68±2%, respectively. Here, we see that certain peptides (such as VLPALP, LQGV, VLPALPQVVC, LAGV) have a protective effect on the area at risk for infarction. In addition, peptide LQAV showed smaller infarcted area but in some instances the area was haemorhagic infarcted. In addition NMPF-64 (LPGCPRGVNPVVS) had also protective effect (35%) in CAO experiment. It is important to note that mice treated with certain above mentioned peptides showed less viscousity of blood. Apart from immunological effect, these peptides may have also effect on blood coagulation system directly or indirectly since there is certain homology with blood coagulation factors (for additional results of NMPF peptides see table 5.) So, in both models the circulatory system plays an important role in the pathogenesis of the disease.
- Chicken Eggs Experiments
- In vivo treatment of fertilised chicken eggs with NMPF. Fertile chicken eggs (Drost Loosdrecht BV, the Netherlands) were incubated in a diagonal position in an incubator (Pas Reform BV, the Netherlands) at 37° C. and 32% relative humidity.
- Solutions of NMPF peptides (1 mg/ml) and VEGF were made in PBS. At least ten eggs were injected for every condition. The treatment was performed as follows: on
day 0 of incubation, a hole was drilled into the eggshell to open the air cell. A second hole was drilled 10 mm lower and right from the first hole for injection. The holes in the eggshell were disinfected with jodium. The NMPF peptides (100 □g/egg) and/or VEGF (100 ng/ml) were injected in volume of 100 μl. The holes in the eggshell were sealed with tape (Scotch Magic™ Tape, 3M) and the eggs were placed into the incubator. - Quantification of angiogenesis. On
day 7 of incubation, the eggs were viewed under an UV lamp to check if the embryos were developing in a normal way and the dead embryos were counted. Onday 8 of incubation, the embryos were removed from the eggs by opening the shell at the bottom of the eggs. The shell membrane was carefully dissected and removed. The embryos were placed in a 100-mm Petri dish. The embryo and the blood vessels were photographed (Nikon E990, Japan) in vivo with the use of a microscope (Zeiss Stemi SV6, Germany). One overview picture was taken and 4 detail pictures of the blood vessels were taken. Only eggs with vital embryos were evaluated. - Data analysis. Quantification of angiogenesis was accomplished by counting the number of blood vessels branches. Quantification of vasculogenesis was accomplished by measuring the blood vessel thickness. The number of blood vessel branches and the blood vessel thickness were counted in the pictures (4 pictures/egg) using
Corel Draw 7. Thereafter, the number of blood vessel branches and the thickness of the blood vessels were correlated to a raster of microscope (10 mm2) for comparison. The mean number of branches and the mean blood vessel thickness of each condition (n=10) were calculated and compared to the PBS control eggs using a Student's T-test. - Results
- Chicken Eggs Experiments
- In order to determine the effect of NMPF on angiogenesis and vasculogenesis we treated fertilized chicken eggs with NMPF or NMPF in combination with VEGF as described in materials and methods section. FIGS.20-30 show that
NMPF NMPF NMPF 6 itself did not show any effect on angiogensis, but it inhibited (p<0.05)NMPF 3 induced angiogenesis. - FIGS.31-32 show that
NMPF - NOD Experiment
- Mice. Female NOD mice at the age of 13-14 weeks were treated i.p. with PBS (n=6) or NMPF peptides (VLPALPQVVC, LQGV, GVLPALPQ, VLPALP, VLPALPQ, MTRV, LPGCPRGVNPVVS, CPRGVNPVVS, LPGC, MTRVLQGVLPALPQVVC, VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCAL) (5 mg/kg, n=6) three times a week for 2 weeks. Every four days urine was checked for the presence of glucose (Gluketur Test; Boehringer Mannheim, Mannheim, Germany). All mice used in these studies were maintained in a pathogen-free facility. They were given free access to food and water. The experiments were approved by the Animal Experiments Committee of the Erasmus University Rotterdam. Diabetes was assessed by measurement of the venous blood glucose level using an Abbott Medisense Precision glucometer. Mice were considered diabetic after two consecutive glucose measurements ≧11 mmol/l (200 mg/dl). Onset of diabetes was dated from the first consecutive reading.
- Glucose tolerance test (GTT) test was performed at 28 weeks of age in fasted mice (n=5) by injecting 1 g/kg D-glucose intraperitoneally (i.p.). At 0 (fasting), 5, 30 and 60 minutes blood samples were collected from the tail and tested for glucose content.
- NO Experiment
- Cell culture. The RAW 264.7 murine macrophage cell line, obtained from American Type Culture Collection (Manassas, Va., USA), were cultured at 37° C. in 5% CO2 using DMEM containing 10% fetal calf serum (FCS), 50 U/ml penicillin, 50 μg/ml streptomycin, 0.2 M Na-pyruvate, 2 mM glutamine and 50 μM 2-mercaptoethanol (Bio Whittaker, Europe). The medium was changed every 2 days.
- Nitrite measurements. Nitrite production was measured in the RAW 264.7 macrophage supernatants. The cells (7.5×105/ml) were cultured in 48-well plates in 500 □l of culture medium. The cells were stimulated with LPS (10 microg/ml) and/or NMPF (1 pg/ml, 1 ng/ml, 1 □g/ml) for 24 hours, then the culture media were collected. Nitrite was measured by adding 100 microl of Griess reagent (Sigma) to 100 microl samples of culture medium. The OD540 was measured using a microplate reader, and the nitrite concentration was calculated by comparison with the OD540 produced using standard solutions of sodium nitrite in the culture medium.
- Results
- NOD Experiment
- In order to determine whether NMPF has effect on the disease development in NOD mice, we tested NMPF on pre-diabetic female NOD mice at the age of 13-14 weeks. After only two weeks of treatment (injection of NMPF (5 mg/kg) every other day) glucosuria data of all NOD mice was analysed at the of 17 weeks. Profound anti-diabetic effect (mice negative for glucosuria) was observed in different NMPF groups as compared to PBS group, especially in NMPF groups treated with peptide VLPALPQVVC, VLPALP, MTRV, LPGCPRGVNPVVS and LPGC. In addition, impairment of the glucose tolerance test was positively correlated to insulitis, but negatively correlated to the number of functional beta cells, also this test showed that NOD mice successfully treated with NMPF were tolerant for glucose as compared to PBS group. Our results show that PBS treated NOD mice were all diabetic at the age of 23 weeks. Whereas, NOD mice treated with three times a week for two weeks with NMPF showed profound inhibition of diabetes development. The strongest anti-diabetic effects were seen with NMPF-1, 4, 5, 6, 7, 65, 66 and commercial hCG preparation (Pregnyl, Organon, Oss, The Netherlands, batch no. 235863). These mice had a low fasting blood glucose level and were tolerant for glucose (data partially shown). However, NMPF-71 showed no effect on the incidence of diabetes, while NMPF-64 and NMPF-11 had a moderate anti-diabetic effect.
- NO Experiment
- NO production is a central mediator of the vascular and inflammatory response. Our results show that macrophages (RAW 264.7) stimulated with LPS produce large amount of NO. However, these cells co-stimulated with most of the NMPF peptides (
NMPF peptide 1 to 14, 43 to 66 and 69) even in a very low dose (1 pg/ml) inhibited the production of NO. - Results
- ApoE Experiment
- The invention provides a method and a signalling molecule for the treatment of conditions that are associated with dysfunctional LDL receptors such as ApoE and other members of the apolipoprotein family. In particular, use of a signalling molecule comprising GVLPALPQ (NMPF-5) and/or VLPALP (NMPF-6) or a functional analogue or derivative thereof is preferred. Groups of ApoE deficient mice (n=6 per group) were fed a high cholesterol food and given PBS or NMPF every other day intraperitonealy. After 2.5 weeks body weight was determined as shown in the Table below.
Average Weight (g) SD (g) p-value ApoE −/− PBS 31.667 1.007 ApoE −/− NMPF-4 31.256 1.496 0.536 ApoE −/− NMPF-5 29.743 1.160 0.019 Background/PBS 26.760 1.582 10−6 ApoE −/− NMPF-6 29.614 1.064 0.004 - Analysis of Different Peptides in Data Bases
- Examples of different data bases in which peptides were analysed are:
- Proteomics tools: Similarity searches
- BLAST data base (ExPasy, NCBI)
- SMART (EMBL)
- PATTINPROT (PBIL)
- Post-translational modification prediction
- SignalP (CBS)
- Primary structure analysis
- HLA Peptide Binding Predictions (BIMAS)
- Prediction of MHC type I and II peptide binding
- (SYFPEITHI)
- Amino acid scale representation (Hydrophobicity, other conformational parameters, etc.) (PROTSCALE)
- Representations of a protein fragment as a helical wheel(HelixWheel/HelixDraw)
- Results
- A non-extensive l,ist of relevant oligopeptides useful for application in a method to identify signalling molecules according to the invention derivable from protein data bases
- pdb|1DE7|1DE7-A INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN
- LQGV, LQGVV, LQGVVP
- pdb|1DL6|1DL6-A SOLUTION STRUCTURE OF HUMAN TFIIB N-TERMINAL DOMAIN
- LDALP
- pdb|1QMH|1QMH-A CRYSTAL STRUCTURE OF
RNA 3′-TERMINAL PHOSPHATE CYCLASE, AN UBIQUITOUS ENZYME - LQTV, VLPAL, LVLQTVLPAL
- pdb|1LYP|1LYP CAP18 (RESIDUES 106-137)
- IQG, IQGL, LPKL, LLPKL
- pdb|1B9O|1B9O-A HUMAN ALPHA-LACTALBUMIN
- LPEL
- pdb|1GLU|1GLU-A GLUCOCORTICOID RECEPTOR (DNA-BINDING DOMAIN)
- PARP
- pdb|2KIN|2KIN-B KINESIN (MONOMERIC) FROM RATTUS NORVEGICUS
- MTR1
- pdb|1SMP|1SMP-I MOL_ID: 1; MOLECULE: SERRATIA METALLO PROTEINASE; CHAIN: A
- LQKL, LQKLL, PEAP, LQKLLPEAP
- pdb|1ES7|1ES7-B COMPLEX BETWEEN BMP-2 AND TWO BMP RECEPTOR IA ECTODOMAINS
- LPQ, PTLP, LQPTL
- pdb|1BHX|1BHX-F X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357
- LQV, LQVV
- pdb|1VCB|1VCB-A THE VHL-ELONGINC-ELONGINB STRUCTURE
- PELP
- pdb|1CQK|1CQK-A CRYSTAL STRUCTURE OF THE CH3 DOMAIN FROM THE MAK33 ANTIBODY
- PAAP, PAAPQ, PAAPQV
- pdb|1FCB|1FCB-A FLAVOCYTOCHROME
- LQG,
- pdb|1LDC|1LDC-A L-LACTATE DEHYDROGENASE: CYTOCHROME C OXIDOREDUCTASE (FLAVOCYTOCHROME B=2=) (E.C.1.1.2.3) MUTANT WITH TYR 143 REPLACED BY PHE (Y143F) COMPLEXED WITH PYRUVATE
- LQG
- pdb|1BFB|1BFB BASIC FIBROBLAST GROWTH FACTOR COMPLEXED WITH HEPARIN TETRAMER FRAGMENT
- LPAL, PALP, PALPE
- pdb|1MBF|1MBF MOUSE C-MYB DNA-BINDING
DOMAIN REPEAT 1 - LPN
- pdb|1R2A|1R2A-A THE MOLECULAR BASIS FOR PROTEIN KINASE A
- LQG, LTELL
- pdb|1CKA|1CKA-B C-CRK (N-TERMINAL SH3 DOMAIN) (C-CRKSH3-N) COMPLEXED WITH C3G PEPTIDE (PRO-PRO-PRO-ALA-LEU-PRO-PRO-LYS-LYS-ARG)
- PALP
- pdb|1RLQ|1RLQ-R C-SRC(SH3 DOMAIN) COMPLEXED WITH THE PROLINE-RICH LIGAND RLP2 (RALPPLPRY) (NMR, MINIMIZED AVERAGE STRUCTURE)
- LPPL, PPLP
- pdb|1TNT|1TNT MU TRANSPOSASE (DNA-BINDING DOMAIN) (NMR, 33 STRUCTURES)
- LPG, LPGL, LPK
- pdb|1GJS|1GJS-A SOLUTION STRUCTURE OF THE ALBUMIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G
- LAAL, LAALP
- pdb|1GBR|1GBR-B GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2 (GRB2, N-TERMINAL SH3 DOMAIN) COMPLEXED WITH SOS-A PEPTIDE (NMR, 29 STRUCTURES)
- LPKL, PKLP
- pdb|1A78|1A78-A COMPLEX OF TOAD OVARY GALECTIN WITH THIO-DIGALACTOSE
- VLPSIP
- pdb|1ISA|1ISA-A IRON(II) SUPEROXIDE DISMUTASE (E.C.1.15.1.1)
- LPAL, PALP
- pdb|1FZV|1FZV-A THE CRYSTAL STRUCTURE OF HUMAN PLACENTA GROWTH FACTOR-1 (PLGF-1), AN ANGIOGENIC PROTEIN AT 2.0A RESOLUTION
- PAVP, MLPAVP
- pdb|1JLI|1JLI HUMAN INTERLEUKIN 3 (IL-3) MUTANT WITH TRUNCATION AT BOTH N- AND C-TERMINI AND 14 RESIDUE CHANGES, NMR, MINIMIZED AVERAGE
- LPC, LPCL, PCLP
- pdb|1HSS|1HSS-A 0.19 ALPHA-AMYLASE INHIBITOR FROM WHEAT
- VPALP
- pdb|3CRX|3CRX-A CRE RECOMBINASE/DNA COMPLEX INTERMEDIATE I
- LPA, LPAL, PALP
- pdb|1PRX|1PRX-A HORF6 A NOVEL HUMAN PEROXIDASE ENZYME
- PTIP, VLPTIP
- pdb|1RCY|1RCY RUSTICYANIN (RC) FROM THIOBACILLUS FERROOXIDANS
- VLPGFP
- pdb|1A3Z|1A3Z REDUCED RUSTICYANIN AT 1.9 ANGSTROMS
- PGFP, VLPGFP
- pdb|1GER|1GER-A GLUTATHIONE REDUCTASE (E.C.1.6.4.2) COMPLEXED WITH FAD
- LPALP, PALP
- pdb|1PBW|1PBW-A STRUCTURE OF BCR-HOMOLOGY (BH) DOMAIN
- PALP
- pdb|1BBS|1BBS RENIN (E.C.3.4.23.15)
- MPALP
- AI188872 11.3 366 327 18 382 [Homo sapiens]
qd27c01.x1 Soares_placenta —8 to 9weeks—2NbHP8 to 9W -
- MXRVLQGVLPALPQVVC, MXRV, MXR,
- AI126906 19.8 418 343 1 418 [Homo sapiens]qb95f01.x1 Soares_fetal_heart_NbHH19W
-
- ITRVMQGVIPALPQVVC
- AI221581 29.1 456 341 23 510 [Homo sapiens]
qg20a03.x1 Soares_placenta —8 to 9weeks 2 NbHP8 to 9W Homo sapiens cDNA clone IMAGE:1760044 3′ similar to gb:J00117 CHORIOGONADOTROPIN BETA CHAIN PRECURSOR (HUMAN);, mRNA sequence.; minus strand; translated - MTRVLQVVLLALPQLV
- Mm.42246.3 Mm.42246 101.3 837 304 28 768 GENE=Pck1 PROTSIM=pir:T24168 phosphoenolpyruvate carboxykinase 1, cytosolic; translated
- KVIQGSLDSLPQAV, LDSL, LPQ
- Mm.22430.1 Mm.22430 209.4 1275 157 75 1535 GENE=Ask-pending PROTSIM=pir:T02633 activator of S phase kinase; translated
- VLQAILPSAPQ, LQA, LQAIL, PSAP, LPS
- Hs.63758.4 Hs.63758 93.8 3092 1210 51 2719 GENE=TFR2 PROTSIM=pir:
T30154 transferrin receptor 2; translated KVLQGRLPAVAQAV, LQG, LPA, LPAV - Mm.129320.2 Mm.129320 173.0 3220 571 55 2769 GENE=PROTSIM=pir:
T16409 Sequence 8 from Patent WO9950284; translated - LVQKVVPMLPRLLC, LVQ, LPRL, PMLP
- Mm.22430.1 Mm.22430 209.4 1275 157 75 1535 GENE=Ask-pending PROTSIM=pir:T02633 activator of S phase kinase; translated
- VLQAILPSAPQ, LQA, LQAIL, PSAP, PSAPQ
- P20155 IAC2_HUMAN Acrosin-trypsin inhibitor II precursor (HUSI-II) [SPINK2] [Homo sapiens]
- LPGCPRHFNPV, LPG, LPGC
- Rn.2337.1 Rn.2337 113.0 322 104 1 327 GENE=PROTSIM=PRF:1402234A Rat pancreatic secretory trypsin inhibitor type II (PSTI-II) mRNA, complete cds; minus strand; translated
- LVGCPRDYDPV, LVG, LVGC
- Hs.297775.1 Hs.297775 43.8 1167 753 31 1291 GENE=PROTSIM=sp:000268 ESTs, Weakly similar to T2D3_HUMAN TRANSCRIPTION INITIATION FACTOR TFIID 135 KDA SUBUNIT [H.sapiens]; minus strand; translated
- PGCPRG, PGCP
- Mm.1359.1 Mm.1359 PROTSTM=pir.A39743 urokinase plasmiogen activator receptor
- LPGCP, PGCP, LPG, LPGC
- sptremb1|O56177|O56177 ENVELOPE GLYCOPROTEIN
- VLPAAP, PAAP
- sptrembl|Q9W234|Q9W234 CG 13509 PROTEIN.//:trembl|AE003458|
AE003458 —7 gene: “CG13509”; Drosophila melanogaster genomic scaffold - LAGTIPATP, LAG, PATP
- swiss|P81272|NS2B HUMAN NITRIC-OXIDE SYNTHASE IIB (EC 1.14.13.39) (NOS, TYPE II B) (NOSIIB) (FRAGMENTS)
- GVLPAVP, LPA, VLPAVP, PAVP
- sptrembl|O30137|O30137 HYPOTHETICAL 17.2 KDA
- GVLPALP, PALP, LPAL
- sptrembl|Q91YZ3|Q91YZ3 DNA POLYMERASE
- GLLPCLP, LPC, LPCL, PCLP
- sptrembl|Q9PVW5|Q9PVW5 NUCLEAR PROTEIN NP220
- PGAP, LPQRPRGPNP, LPQ, PRGP, PNP
- Hs.303116.2 PROTSIM=pir; T33097 stromal cell-derived factor 2-like1; translated
- GCPR
- pdb|1DU3|1DU3-A CRYSTAL STRUCTURE OF TRAIL-SDR5
- GCPRGM
- pdb|1D0G|1D0G-R CRYSTAL STRUCTURE OF DEATH RECEPTOR 5 (DR5) BOUND TO APO2L/TRAIL
- GCPRGM
- pdb|1BIO|1BIO HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR
- LQHV
- pdb|4NOS|4NOS-A HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE WITH INHIBITOR
- FPGC, PGCP
- pdb|1FL7|1FL7-B HUMAN FOLLICLE STIMULATING HORMONE
- PARP, VPGC
- pdb|1HR6|1HR6-A YEAST MITOCHONDRIAL PROCESSING PEPTIDASE
- CPRG, LKGC
- pdb|1BFA|1BFA RECOMBINANT BIFUNCTIONAL HAGEMAN FACTOR/AMYLASE INHIBITOR FROM
- PPGP, LPGCPREV, LPGC, PGCP, CPRE
- swissnew|P01229|LSHB HUMAN Lutropin beta chain precursor
- MMRVLQAVLPPLPQVVC, MMR, MMRV, LQA, LQAV, VLPPLP, PPLP, QVVC, VVC, VLPPLPQ, AVLPPLP, AVLPPLPQ
- swissnew|P07434|CGHB PAPAN Choriogonadotropin beta chain precursor
- MMRVLQAVLPPVPQVVC, MMR, MMRV, LQA, LQAG, VLPPVP, VLPPVPQ, QVVC, VVC, AVLPPVP, AVLPPVPQ
- swissnew|Q28376|TSHB HORSE Thyrotropin beta chain precursor
- MTRD, LPK, QDVC, DVC, IPGC, PGCP
- swissnew|P95180|NUOB MYCTU NADH dehydrogenase I chain B
- LPGC, PGCP
- sptrembl|Q9Z284|Q9Z284 NEUTROPHIL ELASTASE
- PALP, PALPS
- sptrembl|Q9UCG8|Q9UCG8 URINARY GONADOTROPHIN PEPTIDE (FRAGMENT).
- LPGGPR, LPG, LPGG, GGPR
- XP—028754 growth hormone releasing hormone [Homo sapiens]
- LQRG, LQRGV, LGQL
- SignalP predictions: (for example)
SignalP (CBS) SignalP pre- (for example) dictions: MTRVLQGVLPALP QVVC HLA Peptide Binding Predictions (BIMAS) (For example) Half time of dissociation HLA molecule VLQGVLPAL (84) type I (A_ GVLPALPQV (51) 0201): VLPALPQVV (48) RLPGCPRGV (14) TMTRVLQGV (115) scores MHC II (H2- Ak CPTMTRVLQGVLPAL 14 15-mers) PGCPRGVNPVVSYAV 14 HLA-DRB1*0101 PRGVNPVVSYAVALS 29 15-mers TRVLQGVLPALPQVV 28 LQGVLPALPQVVCNY 22 HLA-DRB1*0301 CPTMTRVLQGVLPAL 26 (DR17) 15- mers MTRVLQGVLPALPQV 21 SIRLPGCPRGVNPVV 17 -
TABLE 1 Results of shock experiments in mice % SURVIVAL IN TEST SUBSTANCE TIME (HRS) 0 16 40 72 PBS 100 100 67 17 PG23 100 100 100 100 PG25 100 83 83 83 PEPTIDE NMPF SEQUENCE 1 VLPALPQVVC 100 100 50 17 2 LQGVLPALPQ 100 67 0 0 3 LQG 100 83 20 17 4 LQGV 100 100 100 100 5 GVLPALPQ 100 100 80 17 6 VLPALP 100 100 100 100 7 VLPALPQ 100 83 0 0 8 GVLPALP 100 100 83 67 9 VVC 100 100 50 50 11 MTRV 100 100 67 50 12 MTR 100 100 67 50 13 LQGVLPALPQVVC 100 100 100 100 14 (CYCLIC) LQGVLPALPQVVC 10083 83 83 64 LPGCPRGVNPVVS 100 100 100 100 66 LPGC 100 100 100 100 -
TABLE 2 Additional results of shock experiments NMPF SEQUENCE ID: ANTI-SHOCK EFFECT LQGV +++ AQGV +++ LQGA +++ VLPALP +++ ALPALP ++ VAPALP ++ ALPALPQ ++ VLPAAPQ ++ VLPALAQ +++ SHOCK ACCELERATING EFFECT LAGV +++ LQAV +++ VLAALP +++ VLPAAP +++ VLPALA +++ VLPALPQ +++ VLAALPQ +++ VLPALPA +++ -
TABLE 3 Further additional results of shock experiments NMPF PEPTIDES % SURVIVAL IN TIME (IRS) Tx Tx 0 14 24 48 PBS 100 100 100 0 NMPF-3 100 100 100 0 NMPF-5 100 100 100 100 NMPF-7 100 100 100 67 NMPF-8 100 100 100 100 NMPF-9 100 100 100 100 NMPF-11 100 100 100 100 NMPF-12 100 100 100 100 NMPF-43 100 100 100 100 NMPF-45 100 100 100 100 NMPF-46 100 100 100 100 NMPF-50 100 100 100 100 NMPF-53 100 100 100 100 NMPF-58 100 100 100 100 NMPF-60 100 100 100 100 -
TABLE 4 Further additional results NMPF PEPTIDES SICKNESS SCORES Tx Tx 0 14 24 48 PBS 0,0,0,0,0,0 5,5,5,5,4,4 5,5,5,5,5,5 †††††† NMPF-3 0,0,0,0,0,0 3,3,3,3,3,4 4,4,4,4,4,4 †††††† NMPF-5 0,0,0,0,0,0 5,5,5,5,5,5 5,5,5,5,5,5 2,2,2,2,2,2 NMPF-7 0,0,0,0,0,0 1,1,4,4,4,4 5,5,5,5,5,5 2,2,2,2,†† NMPF-8 0,0,0,0,0,0 3,3,5,5,5,5 5,5,5,5,5,5 2,2,4,4,4,5 NMPF-9 0,0,0,0,0,0 3,3,4,4,5,5 2,2,2,2,2,2 1,1,2,2,2,2 NMPF-11 0,0,0,0,0,0 1,1,3,3,4,4, 2,2,2,2,4,4 1,1,1,1,1,1 NMPF-12 0,0,0,0,0,0 1,1,1,1,3,3 1,1,1,1,1,1 1,1,1,1,1,1 NMPF-43 0,0,0,0,0,0 1,1,4,4,4,4 1,1,1,1,3,3 2,2,2,2,2,2 NMPF-45 0,0,0,0,0,0 5,5,5,5,4,4 3,3,4,4,5,5 2,2,4,4,5,5 NFPF-46 0,0,0,0,0,0 1,1,2,2,3,3 1,1,2,2,2,2 1,1,1,1,1,1 NMPF-50 0,0,0,0,0,0 1,1,1,1,3,3 2,2,2,2,3,3 1,1,1,1,1,1 NMPF-53 0,0,0,0,0,0 5,5,5,5,5,5 5,5,5,5,5,5 1,1,2,2,2,2 NMPF-58 0,0,0,0,0,0 5,5,5,5,3,3 5,5,5,5,3,3 1,1,1,1,1,1 NMPF-60 0,0,0,0,0,0 1,1,4,4,2,2 2,2,2,2,4,4 1,1,1,1,1,1 -
TABLE 5 Summary of results of the various peptides in the various experiments. ID SEQUENCE SEPSIS ANGIOGENSIS CAO DC NOD NMPF-1 VLPALPQVVC −+ + + NMPF-2 LQGVLPALPQ −+ + NMPF-3 LQG −+ + + + NMPF-4 LQGV + + + + NMPF-5 GVLPALPQ −+ + NMPF-6 VLPALP + + + + NMPF-7 VLPALPQ + + + NMPF-8 GVLPALP −+ + NMPF-9 VVC + + + NMPF-11 MTRV + + + + NMPF-12 MTR −+ + + NMPF-13 LQGVLPALPQVVC + + NMPF-14 cyclic-LQGVLPALPQVVC + NMPF-43 AQG + + + NMPF-44 LAG + NMPF-45 LQA + + NMPF-46 AQGV + + + NMPF-47 LAGV −+ + + NMPF-48 LQAV NMPF-49 LQGA + NMPF-50 ALPALP + + NMPF-51 VAPALP + + NMPF-52 VLAALP NMPF-53 VLPAAP + + NMPF-54 VLPALA NMPF-55 ALPALPQ + NMPF-56 VAPALPQ + NMPF-57 VLAALPQ NMPF-58 VLPAAPQ + + NMPF-59 VLPALAQ + + NMPF-60 VLPALPA + + NMPF-61 VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCAL −+ + NMPF-62 VVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSGQ NMPF-63 LPGCPRGVNPVVS + NMPF-64 LPGCPRGVNPVVS + NMPF-65 CPRGVNPVVS NMPF-66 LPGC + + + NMPF-67 CPRGVNP NMPF-68 PGCP −+ NMPF-69 RPRCRPINATLAVEKEGCPVCITVNTTICAGYCPT NMPF-70 MTRVLQGVLPALPQ −+ NMPF-71 MTRVLPGVLPALPQVVC −+ NMPF-74 CALCRRSTTDCGGPKDHPLTC NMPF-75 SKAPPPSLPSPSRLPGPC NMPF-76 TCGGPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ -
TABLE 6 MODULATION OF NO AND/OR TNF-α ID SEQUENCE TNF-A NO TNF-A and NO NMPF-1 VLPALPQVVC ++ ++++ ++++ NMPF-2 LQGVLPALPQ −+ ++++ ++++ NMPF-3 LQG + ++++ ++++ NMPF-4 LQGV ++++ ++++ +++++++ NMPF-5 GVLPALPQ ++++ ++++ +++++++ NMPF-6 VLPALP ++++ ++++ +++++++ NMPF-7 VLPALPQ ++++ ++++ +++++++ NMPF-8 GVLPALP ++++ ++++ +++++++ NMPF-9 VVC ++++ ++++ +++++++ NMPF-10 QVVC ++++ +++ ++++ NMPF-11 MTRV ++++ ++++ ++++ NMPF-12 MTR ++++ ++++ ++++ NMPF-13 LQGVLPALPQVVC ++ ++++ ++++ NMPF-14 cyclic-LQGVLPALPQVVC ++ ++++ ++++ NMPF-43 SQG ++++ ++++ +++++++ NMPF-44 LAG −+ ++++ ++++ NMPF-45 LQA ++++ ++++ +++++++ NMPF-46 AQGV ++++ ++++ +++++++ NMPF-47 LAGV ++ ++++ ++++ NMPF-48 LQAV ++ ++++ ++++ NMPF-49 LQGA ++ ++++ ++++ NMPF-50 ALPALP ++++ ++++ +++++++ NMPF-51 VAPALP + +++ ++++ NMPF-52 VLAALP ++ ++++ ++++ NMPF-53 VLPAAP ++++ ++++ +++++++ NMPF-54 VLPALA + ++++ ++++ NMPF-55 APALPQ + ++++ ++++ NMPF-56 VAPALPQ −+ ++++ ++++ NMPF-57 VLAALPQ + ++++ ++++ NMPF-58 VLPAAPQ ++++ ++++ +++++++ NMPF-59 VLPALAQ ++ ++++ ++++ NMPF-60 VLPALPA ++++ ++++ +++++++ VVCNYRDVRIFESIRLPGCPRGVNPVVSY NMPF-61 AVALSCQCAL −+ ++++ ++++ VVCNYRDVRFESIRLPGCPRGVNPVVSY NMPF-62 AVALSCQ −+ +++ ++++ NMPF-63 SIRLPGCPRGVNPVVS −+ ++ ++ NMPF-64 LPGCPRGVNPVVS ++ ++++ ++++ NMPF-65 CPRGVNPVVS ++ +++ +++ NMPF-66 LPGC +++ ++ +++ NMPF-67 CPRGVNP −+ + + NMPF-68 LGCP + + +++ RCRPINATLAVEK NMPF-69 EGCPVCITVNTTICAGYCPT −+ ++ ++ NMPF-70 MTRVLQGVLPALPQ −+ + + NMPF-71 MTRVLPGVLPALPQVVC −+ −+ −+ NMPF-74 CALCRRSTTDCGGPKDHPLTC −+ ++ + NMPF-75 SKAPPPSLPSPSRLPGPS + ++ ++ TCDDPRFQDSSSSKAPPPSLPSPSRLPGPS NMPF-76 DTPILPQ + + + NMPF-78 CRRSTTDCGGPKDHPLTC + + + - Monkey Experiment
- Efficacy of NMPF, here a mixture 1:1:1 of LQGV, AQGV and VLPALP, administered in a gram-negative induced rhesus monkey sepsis model for prevention of septic shock. Overwhelming inflammatory and immune responses are essential features of septic shock and play a central part in the pathogenesis of tissue damage, multiple organ failure, and death induced by sepsis. Cytokines, especially tumour necrosis factor (TNF)-□ interleukin (IL)-1□, and macrophage migration inhibitory factor (MIF) have been shown to be critical mediators of septic shock. Yet, traditional anti-TNF and anti-IL-1 therapies have not demonstrated much benefit for patients with severe sepsis. We have designed peptides that block completely LPS induced septic shock in mice, even when treatment with these peptides is started up to 24 hours after LPS injection. These peptides are also able to inhibit the production of MIF. This finding provides the possibility of therapeutic use of these peptides for the treatment of patients suffering from septic shock. Since primates are evolutionary more closer to humans, we tested these peptides for their safety and effectiveness in a primate system.
- Experimental Design
EXPERIMENTAL TREATMENT (independent variable, e.g. placebo treated GROUP) control group) BIOTECHNIQUES NUMBER animal I i.v. infusion of a lethal Live E.coli infusion N = 1 dose of live Blood sampling Escherichia.coli (10E10 No CFU/kg) recovery + antibiotics (section) + placebo treated animal II i.v. infusion of a lethal Live E.coli infusion N = 1 dose of live Blood sampling Escherichia.coli (10E10 No CFU/kg) recovery + antibiotics (section) + oligopeptide (5 mg/kg of each of 3 peptides) - Only naive monkeys were used in this preclinical study to exclude any interaction with previous treatments. The animals were sedated with ketamine hydrochloride. Animals were intubated orally and are allowed to breathe freely. The animals were kept anesthesized with O2/N2O/isoflurane. The animals received atropin as pre-medication for O2/N2O/isoflurane anesthesia. A level of surgical anesthesia was maintained during the 2 h infusion of E.coli and for 6 h following E.coli challenge after which the endothracheal tubes were removed and the animals were euthanized. Before bacteria were induced, a 1 hour pre-infusion monitoring of heart-rate and blood pressure was performed.
- Two rhesus monkeys were infused with a 1010CFU per kg of the Gram negative bacterium E.coli to induce a fatal septic shock. One monkey received placebo-treatment and was sacrificed within 7 hours after infusion of the bacteria without recovery from the anesthesia. The second monkey received treatment with test compound and was sacrificed at the same time point.
- In a limited dose-titration experiment performed with the same bacterium strain in 1991 the used dose proved to induce fatal shock within 8 hours. In recent experiments a 3-fold lower dose was used inducing clear clinical and pathomorphological signs of septic shock without fatal outcome.
- The monkeys were kept anaesthetized throughout the observation period and sacrificed 7 hours after the start of the bacterium infusion for pathological examination. The animals underwent a gross necropsy in which the abdominal and throrac cavities were opened and internal organs examined in situ.
- Full Description of the Experiment With Three Rhesus Monkeys
- The study was conducted in rhesus monkeys (Maccaca mulatta). Only experimentally naive monkeys were used in study to exclude any interaction with previous treatments. Prior to the experiment the state of health of the animals was assessed physically by a veterinarian. All animals had been declared to be in good health and were free of pathogenic ecto- and endoparasites and common bacteriological infections: Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Shigella, Aeromonas hydrophilia, pathogenic Campylobacter species and Salmonella.
- Reagents. TheEscherichia coli strain was purchased from ATCC (E-coli; 086a: K61 serotype, ATCC 33985). In a control experiment the strain proved equally susceptible to bactericidal factors in human and rhesus monkey serum.
- Prior to the experiment a fresh culture was set-up; theE.coli strain was cultured for one day, harvested and washed thoroughly to remove free endotoxine. Prior to infusion into the animal the number and viability of the bacteria was assessed. Serial dilutions of the E.coli stock were plated on BHI agar and cultured overnight at 37oC. The colonies on each plate were counted and the number of colony forming units per ml were calculated. The body weight measurement of the day of the experiment was used to calculate the E.coli dose and E.coli stock was suspended in isotonic saline (N.P.B.I., Emmer-Compascuum, The Netherlands) at the concentration needed for infusion (total dose volume for infusion approximately 10 ml/kg. The E.coli suspension was kept on ice until infusion.
- Antibiotic was used to synchronise the shock induction in the monkeys. Baytril (Baytril 2.5%, Bayer, Germany) was used instead of gentamycin, as the strain proved only marginally susceptible to the latter antibiotic.
- Individual animals were identified by a number or letter combination tattooed on the chest.
- Experimental Design.
EXPERIMENTAL GROUP TREATMENT (number/ (independent variable, letter or other e.g. placebo treated identification control group) NUMBER SEX Animal I i.v. infusion of a lethal Live E. N = 1 F dose of live coli Escherichia.coli (10E10 infusion CFU/kg) Blood + antibiotic sampling placebo treated No recovery Animal II i.v. infusion of a lethal Live E. N = 1 F dose of live coli Escherichia.coli (10E10 infusion CFU/kg) Blood antibiotic sampling NMPF-4, 6, 46; each No 5 mg/kg recovery (section) Animal III i.v. infusion of a lethal Live E. N = 1 F dose of live coli Escherichia.coli (10E10 infusion CFU/kg) Blood antibioti sampling + NMPF-4, 6, 46; each Recovery 5 mg/kg and survival - Anesthesia. All animals were fasted overnight prior to the experiment. On the morning of the experiment the animals were sedated with ketamine hydrochloride (Tesink, The Netherlands) and transported to the surgery. The animal was placed on its side on a temperature controlled heating pad to support body temperature. Rectal temperature was monitored using a Vet-OX 5700. The animals were intubated orally and were allowed to breathe freely. The animals were kept anesthesized using O2/N2O/isoflurane inhalation anaesthesia during the E.coli infusion and the 7 hour observation period following E.coli challenge after which the endothracheal tubes were removed and the animals were euthanized or allowed to recover from anesthesia. The femoral or the cephalic vein was cannulated and used for infusing isotonic saline, live E.coli and antibiotic administration. Insensible fluid loss was compensated for by infusing isotonic saline containing 2.5% glucose (Fresenius, 's Hertogenbosch, The Netherlands) at a rate of 3.3 ml/kg/hr.
- Preparative actions. During anesthesia the animals were instrumented for measurement of blood pressure (with an automatic cuff), heart rate and body temperature. Isotonic saline was infused at 3.3 ml/kg/hr to compensate for fluid loss. Femoral vessels were cannulated for infusion ofE.coli and antibiotics. Temperature controlled heating pads were used to support body temperature. The monkeys were continuously monitored during E.coli challenge and for the 6 hr period following E.coli administration. After 7
hrs 2 animals (the control animal and one treated with NMPF) were sacrificed to compare the direct effect of the compound at the level of histology. The 3rd animal, treated with NMPF, was allowed to recover from anaesthesia and was intensively observed during the first 12 hours after recovery followed by frequent daily observation. The decision to allow 3rd animal to recover was made after consulting with the veterinarian. - Induction of septic shock. Before the infusion ofE.coli, a 1 hr pre-infusion monitoring of heart-rate and blood pressure was performed. All three animals received an i.v. injection of E.coli 086 (k61 serotype; ATCC 33985) at a lethal dose of 10×109 CFU/kg bodyweight. In a dose titration study with this batch performed in 1991, this bacterial dose induced lethal shock within 8 hrs after the start of the infusion. The infusion period was 2 hrs.
- Antibiotics. Baytril was administered intravenously immediately after completion of the 2 h.E.coli infusion (i.v.; dose 9 mg/kg).
- Treatment with NMPF. 30 minutes post-onset ofE.coli infusion the animals were administered a single intravenous bolus injection a mixer of NMPF oligopeptide. The oligopeptide mixer contained the following NMPF peptides: LQGV (5 mg/kg), AQGV (5 mg/kg) and VLPALP (5 mg/kg). These NMPF peptides were dissolved in 0.9% sodium chloride for injection (N.P.B.I., Emmer Compascuum, The Netherlands).
- Results
- Preliminary Monkey Results
- An anti-shock effect of the test compound on sepsis in the monkey treated with the oligopeptide mixture, namely the inhibition of the effect of the sepsis in this early 7-hour trajectory of this primate model was observed. Immunomodulatory effects with these peptides have been observed in vitrolex vivo such as in T-cell assays the inhibition of pathological Th1 immune responses, suppression of inflammatory cytokines (MIF), increase in production of anti-inflammatory cytokines (IL-10, TGF-beta) and immunomodulatory effects on antigen presenting cells (APC) like dendritic cells and macrophages.
- The following organs were weighed and a bacterial count were performed:
- kidneys
- liver
- lungs
- lymph nodes
- gross lesions
- Tissues of all organs were preserved in neutral aqueous phosphate buffered 4% solution of formaldehyde. Lymphoid organs were be cryopreserved. All tissues will be processed for histopathological examination.
- Further Results Obtained in the Three-Monkey Experiment
- Monkey 429(control). Female monkey (5.66 kg) received an i.v. injection ofE.coli 086 (10E10 CFU/kg). In a dose titration study with this batch performed in 1991, this bacterial dose induced lethal shock within 8 hrs after the start of the infusion. The infusion period was 2 hrs. Baytril was administered intravenously immediately after completion of the 2 h. E.coli infusion (i.v.; dose 9 mg/kg). After the E.coli injection the monkey was observed by the authorized veterinarian without knowing which of the monkey received NMPF treatment. The clinical observations were as follows: vomiting, undetectable pulse, heart arythmia, abnormalities in ECG: signs of ventricle dilatation/heart decompensation (prolonged QRS complex, extra systoles), decreased blood clotting and forced respiration. In addition, there was big fluctuation in heart rate (30-150 beats per minute), collapse of both systolic and diastolic blood pressure (35/20 mmHg) and decrease in blood oxygen concentration (80-70%). Seven hours after the start of the E.coli infusion, monkey began to vomit blood and faeces, and have convulsions. After final examination, the veterinarian did not gave permission to let this monkey awake. At this time point control monkey was euthanised. Hereafter, post mortem examination was conducted and internal organs were examined in situ. Number of internal bleedings were found by the pathologist.
- Monkey 459(NMPF). Female monkey (5.44 kg) received an i.v. injection ofE.coli 086 (10E10 CFU/kg). In a dose titration study with this batch performed in 1991, this bacterial dose induced lethal shock within 8 hrs after the start of the infusion. The infusion period was 2 hrs. 30 minutes after the initiation of E.coli infusion, NMPF was i.v. injected in a single bolus injection. Baytril was administered intravenously immediately after completion of the 2 h. E.coli infusion (i.v.; dose 9 mg/kg). After the E.coli injection this monkey was also observed by the authorized veterinarian without knowing which of the monkey received NMPF treatment. The clinical observations were as follows: normal pulse, heart sounds normal, normal ECG, higher heart-rate but otherwise stable (180 beats per minute), no hypotension (75/30 mmHg), normal blood oxygen concentration (95-85%), lungs sound normal, normal turgor. Seven hours after the start of the E.coli infusion, the clinical condition of the monkey was stable. After final examination, the veterinarian did give permission to let this monkey awake due to her stable condition. In order to compare the hematological and immunological parameters between the control and NMPF treated monkey, at this time point NMPF treated monkey 459 was euthanised. Hereafter, post mortem examination was conducted and internal organs were examined in situ. No macroscopic internal bleedings were found by the pathologist.
- Monkey 427(NMPF). Female monkey (4.84 kg) received an i.v. injection ofE.coli 086 (10E10 CFU/kg). In a dose titration study with this batch performed in 1991, this bacterial dose induced lethal shock within 8 hrs after the start of the infusion. The infusion period was 2 hrs. 30 minutes after the initiation of E.coli infusion, NMPF was i.v. injected. Baytril was administered intravenously immediately after completion of the 2 h. E.coli infusion (i.v.; dose 9 mg/kg). After the E.coli injection this monkey was also observed by the authorised veterinarian doctor without knowing which of the monkey received NMPF treatment. The clinical observations were as follows: normal pulse, heart sounds normal, normal ECG, moderately higher heart-rate but otherwise stable (160 beats per minute), no hypotension (70/30 mmHg), normal blood oxygen concentration (95-90%), lungs sound normal, normal turgor. Seven hours after the start of the E.coli infusion, the clinical condition of the monkey was stable. After final examination, the veterinarian did give permission to let this monkey wake up due to her stable condition. Monkey woke up quickly, she was alert and there was a slow disappearance of oedema.
- Genomic Experiment
- PM1 T-cell line was obtained from American Type Culture Collection (Manassas, Va.) and was cultured at 37° C. in 5% CO2. These cells were maintained and cultured in
RPMI 1640, 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics penicillin and streptomycin. For genomic experiments cells (2×106/ml) were incubated with phytohemagglutinin (PHA, 10 □g/ml) and IL-2 (200 IU/ml) or PHA, IL-2 and peptide LQGV (10 mg/ml) in a volume of 2 ml in 6-wells plates. After 4 h ofcultures 10×106 cells were washed and prepared for genechip probe arrays experiment. The genechip expression analysis was performed according to the manufacturer's instructions (Expression Analysis, Technical Manual, Affymetrix Genechip). The following major steps outline Genechip Expression Analysis: 1) Target preparation 2) Target hybridization 3) Experiment and fluidics station setup 4) Probe Array washing and staining 5) Probe array scan and 6) Data analysis. - Results
- Genomic Experiment
- The gene chip expression analysis revealed that due to LQGV treatment of PM1 (T-cell line) cells for 4 hours in the presence of PHA/IL-2 down-regulated at least 120 genes more than 2 fold as compared to control PM1 cells (stimulated with PHA/IL-2) only. Moreover, at least 6 genes were up-regulated more than 2 fold in peptide treated cells as compared to control cells.
- Down regulated genes due to treatment with LQGV in genomics experiment
Fold Change/Descriptions 21.2 M11507 Human transferrin receptor mRNA, complete cds (_5, _M, _3 represent transcript regions 5 prime, Middle, and 3 prime respectively)10.1 Human (c-myb) gene, complete primary cds, and five complete alternatively spliced cds (U22376 /FEATURE = cds# 5 /DEFTNITION = HSU22376)9.7 Cluster Incl. X68836:H.sapiens mRNA for S-adenosylmethionine synthetase (cds = (65,1252) /gb = X68836 /gi = 36326 /ug = Hs.77502 /len = 1283) 9.3 M97935 Homo sapiens transcription factor ISGF-3 mRNA, complete cds (_5, _MA, _MB, _3 represent transcript regions 5 prime,MiddleA, MiddleB, and 3 prime respectively) 8.7 Human mRNA for phosphatidylinositol transfer protein (PJ-TPbeta), complete cds (D30037 /FEATURE = /DEF1NTTION = HUMPITPB) 7.5 Cluster Incl. U28964:Homo sapiens 14-3-3 protein mRNA, complete cds (cds = (126,863) /gb = U28964 /gi = 899458 /ug = Hs.75103 /len = 1030) 6.7 Human CDK tyrosine 15-kinase WEE1Hu (Wee1Hu) mRNA, complete cds (U10564 /FEATURE = /DEFINITION = HSU10564) 6.7 Homo sapiens E2F-related transcription factor (DP-1) mRNA, complete cds (L23959 /FEATURE = /DEFINITION = HUMDP1A) 6.5 Cluster Incl. W29030:55c4 Homo sapiens cDNA (gb = W29030 /gi = 1308987 /ug = Hs.4963 /len = 758) 6.1 Cluster Incl. U08997:Human glutamate dehydrogenase gene, complete cds (cds = (0,1676) /gb = U08997 /gi = 478987 /ug = Hs.239377 /len = 1677) 5.7 M97935 Homo sapiens transcription factor ISGF-3 mRNA, complete cds (_5, _MA, _MB, _3 represent transcript regions 5 prime,MiddleA, MiddleB, and 3 prime respectively) 5.6 Cluster Incl. Y00638:Human mRNA for leukocyte common antigen (T200) (cds = (86,4000) /gb = Y00638 /gi = 34280 /ug = Hs.170121 /len = 4315) 5.3 Ras-Like Protein Tc21 5.3 H.sapiens mRNA for Fas/Apo-1 (clone pCRTM11-Fasdelta(4,7))(X83492 / FEATURE = exons #1-2 /DEFINITION = HSFAS47) 4.8 Cluster Incl. AJ002428:Homo sapiens VDAC1 pseudogene (cds = (0,853) / gb = AJ002428 /gi = 3183956 /ug = Hs.201553 /len = 854) 4.7 Ras-Related Protein Rap1b 4.6 Cluster Incl. AL080119:Homo sapiens mRNA; cDNA DKFZp564M2423 (from clone DKFZp564M2423) (cds = (85,1248) /gb = AL080119 /gi = 5262550 / ug = Hs.165998 /len = 2183) 4.5 Cluster Incl. AF047448:Homo sapiens TLS-associated protein TASR mRNA, complete cds (cds = (29,580) /gb = AF047448 /gi = 2961148 /ug = Hs.239041 / len = 620) 4.5 Cluster Incl. D14710:Human mRNA for ATP synthase alpha subunit, complete cds (cds = (63,1724) /gb = 14710 /gi = 559324 /ug = Hs.155101 /len = 1857) 4.5 Cluster Incl. X59618:H.sapiens RR2 mRNA for small subunit ribonucleotide reductase (cds = (194,1363) /gb = X59618 /gi = 36154 /ug = Hs.75319 / len = 2475) 4.5 Human mRNA for annexin II, 5 UTR (sequence from the 5 cap to the start codon) (D28364/FEATURE = /DEFINITION = HUMAI23) 4.5 Cluster Incl. AA477898:zu34f08.rl Homo sapiens cDNA, 5 end / clone = IMAGE-739911 /clone_end = 5 (gb = AA477898 /gi = 2206532 /ug = Hs.239414 / len = 449) 4.4 Cluster Incl. L19161:Human translation initiation factor eIF-2 gamma subunit mRNA, complete cds (cds = (0,1418) /gb = L19161 /gi = 306899 /ug = Hs.211539 / len = 1440gb = AA477898 / gi = 2206532 /ug = Hs.239414 /len = 449) 4.4 Human serine/threonine-protein kinase PRP4h (PRP4h) mRNA, complete cds (U48736 /FEATURE = /DEFINITION = HSU48736) 4.4 Cluster Incl. L43821:Homo sapiens enhancer of filamentation (HEF1) mRNA, complete cds (cds = (163,2667) /gb = L43821 /gi = 1294780 / ug = Hs.80261 /len = 3817) 4.4 Ras-Like Protein Tc21 4.4 Human (c-myb) gene, complete primary cds, and five complete alternatively spliced cds (U22376 /FEATURE = cds # 3 /DEFINITION = HSU22376)4.3 Cluster Incl. U18271 :Human thymopoietin (TMPO) gene (cds = (313,2397) /gb = U18271 /gi = 2182141 /ug = Hs.170225 /len = 2796) 4.2 Fk506-Binding Protein, Alt. Splice 24.2 Human proliferating cell nuclear antigen (PCNA) gene, promoter region (J05614 /FEATURE = mRNA /DEFINITION = HUMPCNAPRM) 4.1 Human insulin-stimulated protein kinase 1 (ISPK-1) mRNA, complete cds (U08316 /FEATURE = /DEFINITION = HSU08316) 4.1 Cluster Incl. W28732:50h7 Homo sapiens cDNA (gb = W28732 /gi = 1308680 /ug = Hs.177496 /len = 818) 4.1 Cluster Incl. Y00638:Human mRNA for leukocyte common antigen (T200) (cds = (86,4000) /gb = Y00638 /gi = 34280 /ug = Hs.170121 /len = 4315) 4 Homo sapiens putative purinergic receptor P2Y10 gene, complete cds (AF000545 /FEATURE = cds /DEFINITION = HSAF000545) 3.8 Cluster Incl. U08997:Human glutamate dehydrogenase gene, complete cds (cds = (0,1676) /gb = U08997 /gi = 478987 /ug = Hs.239377 /len = 1677) 3.6 Human mRNA for raf oncogene (X03484 /FEATURE = cds /DEFINITION = HSRAFR) 3.6 Cluster Incl. M32886:Human sorcin CP-22 mRNA, complete cds (cds = (12,608) /gb = M32886 /gi = 338481 /ug = Hs.117816 /len = 952) 3.6 Homo sapiens GTP-binding protein (RAB1) mRNA, complete cds (M28209 /FEATURE = /DEFINITION = HUMRAB1A) 3.5 Human FKBP-rapamycin associated protein (FRAP) mRNA, complete cds (L34075 /FEATURE = /DEFINITION = HUMFRAPX) 3.5 Human DNA topoisomerase II (top2) mRNA, complete cds (J04088 /FEATURE = /DEFINITION = HUMTOPII) 3.4 Human translation initiation factor eIF-2 gamma subunit mRNA, complete cds (L19161 /FEATURE = /DEFINITION = HUMIEF2G) 3.4 Human mRNA for pre-mRNA splicing factor SRp20, 5 UTR (sequence from the 5 cap to the start codon) (D28423 /FEATUIRE = /DEFINITION = HUMLPSF82) 3.4 Cluster Incl. AA442560:zv75g07.r1 Homo sapiens cDNA, 5 end / clone = IMAGE-759516 /clone_end = 5 (gb = AA4425 60 /gi = 2154438 /ug = Hs.135198 /len = 566) 3.4 Cluster Incl. X98248:H.sapiens mRNA for sortilin /cds = (21,2522) (gb = X98248 /gi = 1834494 /ug = Hs.104247 /len = 3723) 3.3 Cluster Incl. AB020670:Homo sapiens mRNA for KIAA0863 protein, complete cds (cds = (185,3580) /gb = AB020670 /gi = 4240214 /ug = Hs.131915 /len = 4313) 3.3 Cluster Incl. W28869:53h2 Homo sapiens cDNA (gb = W28869 / gi = 1308880 /ug = Hs.74637 /len = 975) 3.3 Cluster Incl. Z12830:H.sapiens mRNA for SSR alpha subunit /cds = (29,889) (gb = Z12830 /gi = 551637 /ug = Hs.76152 /len = 974). 3.3 Cluster Incl. AL021546:Human DNA sequence from BAC 15E1 on chromosome 12.Contains Cytochrome C Oxidase Polypeptide VIa-liver precursor gene, 60S ribosomal protein L31 pseudogene, pre-mRNA splicing factor SRp30c gene, two putative genes, ESTs, STSs and putative CpG islands (cds = (0,230) /gb = AL021546 /gi = 2826890 / ug = Hs.234768 /len = 547) 3.2 Cluster Incl. U78082:Human RNA polymerase transcriptional regulation mediator (h-MED6) mRNA, complete cds (cds = (50,523) /gb = U78082 /gi = 2618737 /ug = Hs.167738 /len = 885) 3.2 H.sapiens RbAp48 mRNA encoding retinoblastoma binding protein (X74262 /FEATURE = cds /DEFINITION = HSRBAP48) 3.1 Cluster Incl. M64174:Human protein-tyrosine kinase (JAK1) mRNA, complete cds (cds = (75,3503) /gb = M64174 /gi = 190734 /ug = Hs.50651 /len = 3541) 3.1 Cluster Incl. A1862521:wj15a06.x1 Homo sapiens cDNA, 3 end / clone = IMAGE-2402866 /clone_end = 3 (gb = A1862521 /gi = 5526628 /ug = Hs.146861 /len = 606) 3.1 Cluster Incl. W27517:31h6 Homo sapiens cDNA (gW = W27517 /gi = 1307321 /ug = Hs.13662 /len = 732) 3 Human rab GDI mRNA, complete cds (D13988 /FEATURE = /DEFINITION = HUMRABGDI) 3 Cluster Incl. AL080119:Homo sapiens mRNA; cDNA DKFZp564M2423 (from clone DKFZp564M2423) (cds = (85,1248) /gb = AL080119 /gi = 5262550 /ug = Hs.165998 /len = 2183) 3 Human cAMP-dependent protein kinase type I-alpha subunit (PRKAR1A) mRNA, complete cds (M33336 /FEATURE = /DEFINITION = HUMCAMPPK) 3 Cluster Incl. L75847:Human zinc finger protein 45 (ZNF45) mRLNA, complete cds (cds = (103,2151) /gb = L75847 /gi = 1480436 /ug = Hs.41728 / len = 2409) 3 Cluster Incl. M21154:Human S-adenosylmethionine decarboxylase mRNA, complete cds (cds = (248,1252) /gb = M21154 /gi = 178517 /ug = Hs.75744 /len = 1805) 3 Cluster Incl. AA675900:g02504r Homo sapiens cDNA, 5 end / clone = g02504 /clone_end = 5 (gb = AA675900 /gi = 2775247 /ug = Hs.119325 /len = 647) 3 Cluster Incl. M97936:Human transcription factor ISGF-3 mRNA sequence (cds = UNKNOWN /gb = M97936 /gi = 475254 /ug = Hs.21486 /len = 2607) 2 M33336 /DEFINITION = HUMCAMPPK Human cAMP-dependent protein kinase type I-alpha subunit (PRKAR1A) mRNA, complete cds 2 U16720 /FEATURE = mRNA /DEFINITION = HSU16720 Human interleukin 10 (IL10) gene, complete cds 2 M33336 HUMCAMPPK Human cAMP-dependent protein kinase type I-alpha subunit (PRKAR1A) mRNA 2 U50079 /FEATURE = /DEFINITION = HSU50079 Human histone deacetylase HD1 mRNA, complete cds 2 U16720 /FEATURE = mRNA /DEFINITION = HSU16720 Human interleukin 10 (IL10) gene, complete cds 2 X87212 /FEATURE = cds /DEFINITION = HSCATHCGE H.sapiens mRNA for cathepsin C 2 Cluster Incl. AI740522:wg16b07.x1 Homo sapiens cDNA, 3 end /clone = IMAGE- 2365237 /clone_end = 3 /gb = A1740522 2 M21154 /FEATURE = mRNA /DEFINITION = HUMAMD Human S adenosylmethionine decarboxylase mRNA, complete cds 2 X00737 /FEATURE = cds /DEFINITION = HSPNP Human mRNA for purine nucleoside phosphorylase (PNP; EC 2.4.2.1) 2.1 Cluster Incl. AF034956:Homo sapiens RAD51D mRNA, complete cds / cds = (124,993) /gb = AF034956 /gi = 2920581 2.1 Ras Inhibitor Inf 2.1 Cluster Incl. M27749:Human immunoglobulin-related 14.1 protein mRNA, complete cds /cds = (118,759) /gb = M27749 2.1 Ras-Like Protein Tc4 2.1 X92106 /FEATURE = cds /DEFINITION = HSBLEO H.sapiens mRNA for bleomycin hydrolase 2.1 D88674 /FEATURE = /DEFINITION = D88674 Homo sapiens mRNA for antizyme inhibitor, complete cds 2.1 Cluster Incl. H15872:ym22b12.r1 Homo sapiens cDNA, 5 end /clone = IMAGE- 48838 /clone_end = 5 /gb = H15872 2.1 Cluster Incl. L07541:Human replication factor C, 38-kDa subunit mRNA, complete cds /cds = (9,1079) /gb = L07541 2.1 V01512 /FEATURE = mRNA # 1 /DEFINITION = HSCFOS Human cellularoncogene c-fos (complete sequence) 2.1 Cluster Incl. L23959:Homo sapiens E2F-related transcription factor (DP-1) mRNA, complete cds /cds = (37,1269) 2.1 Stimulatory Gdp/Gtp Exchange Protein For C-Ki-Ras P21 And Sing P21 2.1 Cluster Incl. L13943:Human glycerol kinase (GK) mRNA exons 1-4, complete cds / cds = (66,1640) /gb = L13943 /gi = 348166 2.1 Cluster Incl. X78925:H.sapiens HZF2 mRNA for zinc finger protein /cds = (0,2198) / gb = X78925 /gi = 498722 /ug = Hs.2480 2.1 X74794 /FEATURE = cds /DEFINITION = HSP1CDC21 H.sapiens P1-Cdc21 mRNA 2.1 U78733 /FEATURE = mRNA # 1 /DEFINITION = HSSMAD2S8 Homo sapiens madprotein homolog Smad2 gene, exon 112.2 Cluster Incl. L07540:Human replication factor C, 36-kDa subunit mRNA, complete cds /cds = (9,1031) /gb = L07540 2.2 Cluster Incl. AF040958:Homo sapiens lysosomal neuraminidase precursor, mRNA, complete cds /cds = (129,1376) 2.2 D00596 /FEATURE = cds /DEFINITION = HUMTS1 Homo sapiens gene for thymidylate synthase, exons 2.2 Cluster Incl. A1659108:tu08c09.x1 Homo sapiens cDNA, 3 end /clone = IMAGE- 2250448 /clone_end = 3 /gb = A1659108 2.2 Cluster Incl. AF042083:Homo sapiens BH3 interacting domain death agonist (BID) mRNA, complete cds /cds = (140,727) 2.2 Cluster Incl. W28907:53e12 Homo sapiens cDNA /gb = W28907 /gi = 1308855 / ug = Hs.111429 /len = 989 2.3 Cluster Incl. AF073362:Homo sapiens endo/exonuclease Mre11 (MRE11A) mRNA, complete cds /cds = (0,2126) 2.3 Escherichia coli /REF = J04423 /DEF = E coli bioD gene dethiobiotin synthetase / LEN = 676 (−5 and −3 represent transcript 2.3 Cluster Incl. D59253:Human mRNA for NCBP interacting protein 1, complete cds /cds = (36,506) /gb = D59253 2.3 M21154 /FEATURE = mRNA/DEFINITION = HUMAMDHuman5- adenosylmethionine decarboxylase mRNA, complete cds 2.3 Proto-Oncogene C-Myc, Alt. Splice 3, Orf 1142.3 Cluster Incl. W26787:15d8 Homo sapiens cDNA /gb = W26787 /gi = 1306078 / ug = Hs.195188 /len = 768 2.4 L12002 /FEATURE = /DEFINITION = HUMITGA4A Human integrin alpha 4subunit mRNA, complete cds 2.4 Cluster Incl. M55536:Human glucose transporter pseudogene /cds = UNKNOWN / gb = M55536 /gi = 183299 /ug = Hs.121583 2.4X98743/FEATURE = cds / DEFINITION = HSRNAHELC H.sapiens mRNA for RNA helicase (Myc-regulated dead box protein) 2.4 S75881 /FEATURE = /DEFINITION = S75881 A-myb = DNA-binding transactivator {3 region}[human, CCRF-CEM T leukemia line, mRNA Partial, 831 nt] 2.4 Cluster Incl. AF050110:Homo sapiens TGFb inducible early protein and early growth response protein alpha genes, complete cds /cds = (123,1565) /gb = AF050110 /gi = 3523144 /ug = Hs.82173 / len = 2899 2.5 Cluster Incl. M86667:H.sapiens NAP (nucleosome assembly protein) mRNA, complete cds /cds = (75,1250) /gb = M86667 / gi = 189066 /ug = Hs.179662 /len = 1560 2.5 U17743 /FEATURE = /DEFINITION = HSU17743 Human JNK activating kinase (JNKK1) mRNA, complete cds 2.5 Cluster Incl. U90549:Human non-histone chromosomal protein (NHC) mRNA, complete cds /cds = (691,963) /gb = U90549 / gi = 2062699 /ug = Hs.63272 /len = 1981 2.5 Cluster Incl. U31382:Human G protein gamma-4 subunit mRNA, complete cds / cds = (98,325) /gb = U31382 /gi = 995916 / ug = Hs.32976 /len = 670 2.5 Cluster Incl. S81916:phosphoglycerate kinase {alternatively spliced} [human, phosphoglycerate kinase deficient patient with episodes of musci, mRNA Partial Mutant, 307 nt] /cds = (0,143) /gb = S81916/ gi = 1470308 /ug = Hs.169313 /len = 307 2.5 Cluster Incl. M64595:Human small G protein (Gx) mRNA, 3 end /cds = (0,542) / gb = M64595 /gi = 183708 /ug = Hs.173466 / len = 757 2.5 Serine Hydroxymethyltransferase, Cytosolic, Alt. Splice 32.5 U88629 /FEATURE = cds /DEFINITION = HSU88629 Human RNA polymerase II elongation factor ELL2, complete cds 2.5 Cluster Incl. U72518:Human destrin-2 pseudogene mRNA, complete cds / cds = (268,798) /gb = U72518 /gi = 1673523 / ug = Hs.199299 /len = 1057 2.5 Cluster Incl. L14595:Human alanine/serine/cysteine/threonine transporter (ASCT 1) mRNA, complete cds 2.5 Cluster Incl. AB014584:Homo sapiens mRNA for KIAA0684 protein, partial cds / cds = (0,2711) /gb = AB014584 / gi = 3327181 /ug = Hs.24594 /len = 4124 2.5 Cluster Incl. AI924594:wn57a11.x1 Homo sapiens cDNA, 3 end /clone = IMAGE- 2449532 /clone_end = 3 /gb = A1924594 / gi = 5660558 /ug = Hs.122540 /len = 685 2.5 U68111 /FEATURE = mRNA /DEFINITION = HSPPP1R2E6 Human protein phosphatase inhibitor 2 (PPP1R2) gene, exon 62.5 Cluster Incl. AL009179:dJ97D16.4 (Histone H2B) /cds = (25,405) /gb = AL009179 / gi = 3217024 /ug = Hs.137594 /len = 488 2.6 Cluster Incl. AF091077:Homo sapiens clone 558 unknown mRNA, complete sequence /cds = (1,300) /gb = AF091077 / gi = 3859991 /ug = Hs.40368 /len = 947 2.7 Cluster Incl. M28211:Homo sapiens GTP-binding protein (RAB4) mRINA, complete cds /cds = (70,711) /gb = M28211 / gi = 550067 /ug = Hs.234038 /len = 735 2.6 X69549 /FEATURE = cds /DEFINITION = HSRHO2 H.sapiens mRNA for rho GDP- dissociation Inhibitor 22.6 Cluster Incl. Z85986:Human DNA sequence from clone 108K11 on chromosome 6p21 Contains SRP20 (SR protein family member), Ndr protein kinase gene similar to yeast suppressor protein SRP4O, EST and GSS /cds = (0,932) /gb = Z85986 gi = 4034056 /ug = Hs.152400 /len = 933 2.6 Zinc Finger Protein, Kruppel-Like 2.7 D10656 /FEATURE = /DEFINITION = HUMCRK Human mRNA for CRK-II, complete cds 2.7 M28211 /FEATURE = /DEFINITION = HUMRAB4A Homo sapiens GTP-binding protein (RAB4) mRNA, complete cds 2.7 Cluster Incl. AB019435 :Homo sapiens mRNA for putative phospholipase, complete cds /cds = (72,3074) /gb = AB019435 / gi = 4760646 /ug = Hs.125670 /len = 3088 2.8 U39318 /FEATUIRE = /DEFINITION = HSU39318 Human E2 ubiquitin conjugating enzyme UbcH5C (UBCH5C) mRNA, complete cds 2.9 Cluster Incl. X78711:H.sapiens mRNA for glycerol kinase testis specific 1 / cds = (26,1687) /gb = X78711 /gi = 515028 / ug = Hs.1466 /len = 1838 2.8 Cluster Incl. W27594:34h4 Homo sapiens cDNA /gb = W27594 /gi = 1307542 / ug = Hs.8258 /len = 702 2.8 X05360 /FEATUiRE = cds /DEFINITION = HSCDC2 Human CDC2 gene involved in cell cycle control 2.8 V00568 /FEATURE = cds /DEFINITION = HSMYC1 Human mRNA encoding the c-myc oncogene 2.8 Cluster Incl. L24804:Human (p23) mRNA, complete cds /cds = (232,714) / gb = L24804 /gi = 438651 /ug = Hs.75839 /len = 782 2.1 0Cluster Incl. Y09443:H.sapiens mRNA for alkyl-dihydroxyacetonephosphate synthase precursor /cds = (15,1991) / gb = Y09443 /gi = 1922284 /ug = Hs.22580 /len = 2074 2.8 Cluster Incl. Z82200:Human DNA sequence from clone 333E23 on chromosome Xq21.1 Contains putative purinergic receptor P2Y10 /cds = (0,1019) /gb = Z82200 /gi = 2370075 /ug = Hs.166137 / len = 1020 2.9 L05624 /FEATURE = /DEFINITION = HUMMKK Homo sapiens MAP kinase kinase mRNA, complete cds 2.9 Cluster Incl. D88357:Homo sapiens mRNA for CDC2 delta T, complete cds / cds = (27,749) /gb = D88357 /gi = 3126638 / ug = Hs.184572 /len = 780 Up regulated genes due to LQGV treatment 4.9 Cluster Incl. AF043324:Homo sapiens N- myristoyltransferase 1 mRNA, completecds(cds = (10,1500)/gb = AF043324 /gi = 3005062 /ug = Hs.111039 /len = 4378) 3.3 Cluster Incl. L08096:Human CD27 ligand mRNA, complete cds /cds = (150,731) (gb = L08096 /gi = 307127 /ug = Hs.99899 /len = 926) Cluster Incl. AF043325 :Homo sapiens N- myristoyltransferase 2 MRNA,complete cds /cds = (46,1542) /gb = AF043325 / gi = 3005064 /ug = Hs.122647 /len = 2838 2.1 Cluster Incl. AL031681:dJ862K6.2.2 (splicing factor, arginine/serine-rich 6 (SRP55-2)(isoform 2)) /cds = (106,513) 2.1 Cluster Incl. X87838:H.sapiens mRNA for beta-catenin /cds = (214,2559) / gb = X87838 /gi = 1154853 /ug = Hs.171271 2.2 Cluster Incl. AW024285:wt69d06.x1 Homo sapiens cDNA, 3 end /clone = IMAGE- 2512715 /clone_end = 3 /gb = AW024285 2.2 Cluster Incl. D38524:Human mRNA for 5-nucleotidase /cds = (83,1768) / gb = D38524 /gi = 633070 /ug = Hs.138593 2.2 Cluster Incl. L38935:Homo sapiens GT212 mRNA /cds = UNKNOWN /gb = L38935 / gi = 1008845 /ug = Hs.83086 /len = 1165 2.5 Cluster Incl. L12711:Homo sapiens transketolase (tk) mRNA, complete cds / cds = (98,1969) /gb = L12711 /gi = 388890 2.6 Cluster Incl. AF026029:Homo sapiens poly(A) binding protein II (PABP2) gene, complete cds /cds = (1282,2202) 2.8 Cluster Incl. X70683:H.sapiens mRNA for SOX-4 protein /cds = (350,1774) / gb = X70683 /gi = 36552 /ug = Hs.83484 - Further Examples of Use
- Examples of different receptor-intracellular signalling pathways involved in different disease pathogenesis where signalling molecules according to the invention find their use are:
- LPS stimulation of antigen presenting cells (like DC, macrophages, monocytes) through different Toll-like receptors activates different signalling pathways including, MAPK pathways, ERK, JNK and p38 pathways. These pathways directly or indirectly phosphorylate and activate various transcription factors, including Elk-1, c-Jun, c-Fos, ATF-1, ATF-2, SRF, and CREB. In addition, LPS activates the IKK pathway of MyD88, IRAK, and TRAF6. TAK1-TAB2 and MEKK1-ECSIT complexes phosphorylate IKKb, which in turn phosphorylates IkBs. Subsequent degradation of IkBs permits nuclear translocation of NFkB/Rel complexes, such as p50/p65. Moreover, the P13K-Akt pathway phosphorylates and activates p65 via an unknown kinase. Some of these pathways could also be regulated by other receptor signalling molecules such as hormones/growth factor receptor tyrosine kinases (PKC/Ras/IRS pathway) and cytokine receptors (JAK/STAT pathway). In the genomic experiment with the T-cell line several of these genes appeared to be downregulated or upregulated by the peptide used (LQGV). It is now clear that other peptides in T cells and the same and other peptides in other cell types similarly down-regulate or up-regulate several of these transcription factors and signalling molecules. In DC and fertilized eggs experiments NMPF had the ability to modulate growth factor (GM-CSF, VEGF) and LPS signalling. Some diseases associated with dysregulation of NF-kB and related transcription factors are: Atherosclerosis, asthma, arthritis, anthrax, cachexia, cancer, diabetes, euthyroid sick syndrome, AIDS, inflammatory bowel disease, stroke, (sepsis) septic shock, inflammation, neuropathological diseases, autoimmunity, thrombosis, cardiovascular disease, psychological disease, post surgical depression, wound healing, burn-wounds healing and neurodegenerative disorders.
- PKC plays an essential role in T cell activation via stimulation of for example AP-1 and NF-kB that selectively translocate to the T cell synapse via Vav/Rac pathway. PKC is involved in a variety of immunological and non-immunological diseases as is clear from standard text books of internal medicine (examples are metabolic diseases, cancer, angiogenesis, immune mediated disorders, diabetes etc.)
- LPS and ceramide induce differential multimeric receptor complexes, including CD14, CD11b, Fc-gRIII, CD36, TAPA, DAF and TLR4. This signal transduction pathway explains the altered function of monocytes in hypercholesterolemia and lipid disorders.
- Oxidized low-density lipoproteins contribute to stages of the atherogenic process and certain concentrations of oxidized low-density lipoproteins induce apoptosis in macrophages through signal transduction pathways. These pathways are involved in various vascular diseases such as atherosclerosis, thrombosis etc.
- Bacterial DNA is recognized by cells of the innate immune system. This recognition requires endosomal maturation and leads to activation of NF-kB and the MAPK pathway. Recently it has been shown that signaling requires the Toll like receptor 9 (TLR9) and the signalling adaptor protein MyD88. Recognition of dsRNA during viral infection seems to be dependent on intracellular recognition by the dsRNA dependent protein kinase PKR. TLRs play an essential role in the immune system and they are important in bridging and balancing innate immunity and adaptive immunity. Modulation of these receptors or their down-stream signalling pathways are important for the treatment of various immunological conditions such as infections, cancer, immune-mediated diseases, autoimmunity, certain metabolic diseases with immunological component, vascular diseases, inflammatory diseases etc.
- Effect of growth factor PDGF-AA on NF-kB and proinflammatory cytokine expression in rheumatoid synoviocytes; PDGF-AA augmented NF-kB activity and mRNA expression of IL-1b, IL-8 and MIP-1a. Therefore, PDGF-AA may play an important role in progression of inflammation as well as proliferation of synoviocytes in RA.
- Dendritic cell (DC) activation is a critical event for the induction of immune responses. DC activation induced by LPS can be separated into two distinct processes: first, maturation, leading to upregulation of MHC and costimulatory molecules, and second, rescue from immediate apoptosis after withdrawal of growth factors (survival). LPS induces NF-kB transcription factor. Inhibition of NF-kB activation blocked maturation of DCs in terms of upregulation of MHC and costimulatory molecules. In addition, LPS activates the extracellular signal-regulated kinases (ERK), and specific inhibition of MEK1, the kinase which activates ERK, abrogate the ability of LPS to prevent apoptosis but do not inhibit DC maturation or NF-kB nuclear translocation. This shows that ERK and NF-kB regulate different aspects of LPS induced DC activation. Our DC data and NF-kB data also show the various effects of NMPF peptide on DC maturation and proliferation in the presence or absence of LPS. NMPF peptides modulate these pathways and are novel tools for the regulation of DC function and immunoregulation. This opens new ways for the treatment of immune diseases, particularly those in which the immune system is in disbalance (DC1-DC2, Th1-Th2, regulatory cell etc.)
- DC mediate NK cell activation which can result in tumour growth inhibition. DC cells and other antigen presenting cells (like macrophages, B-cells) play an essential role in the immune system and they are also important in bridging and balancing innate immunity and adaptive immunity. Modulation of these cells or their down-stream signalling pathways are important for the treatment of various immunological conditions such as infections, cancer, immune-mediated diseases, autoimmunity, certain metabolic diseases with immunological component, vascular diseases, inflammatory diseases etc. There is also evidence in the literature that mast cells play important roles in exerting the innate immunity by releasing inflammatory cytokines and recruitment of neutrophils after recognition of infectious agents through TLRs on mast cells.
- In murine macrophages infected withMycobacterium tuberculosis through JAK pathway activate STAT1 and activation of STAT1 may be the main transcription factor involved in IFN-g-induced MHC class II inhibition.
- Recognition of mannose-binding lectin (MBL) through TLRs influences multiple immune mechanisms in response to infection and involved in innate immunity. Balance between innate and adoptive immunity is crucial for balanced immune system and dysregulation in immune system lead to different spectrum of diseases such as, inflammatory diseases, autoimmunity, infectious diseases, pregnancy associated diseases (like miscarriage and pre-eclampsia), diabetes, atherosclerosis and other metabolic diseases.
- Nuclear factor-kappaB (NFkappaB) is critical for the transcription of multiple genes involved in myocardial ischemia-reperfusion injury. Clinical and experimental studies have shown that myocardial ischemia-reperfusion injury results in activation of the TLRs and the complement system through both the classical and the alternative pathway in myocardial infarction, atherosclerosis, intestinal ischaemia, hemorrhagic shock pulmonary injury, and cerebral infarction etc.
- Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors which function as regulators of lipid and lipoprotein metabolism, glucose homeostasis, influence cellular proliferation, differentiation and apoptosis and modulation of inflammatory responses. PPAR alpha is highly expressed in liver, muscle, kidney and heart, where it stimulates the beta-oxidative degradation of fatty acids. PPAR gamma is predominantly expressed in intestine and adipose tissue, where it triggers adipocyte differentiation and promotes lipid storage. Recently, the expression of PPAR alpha and PPAR gamma was also reported in cells of the vascular wall, such as monocyte/macrophages, endothelial and smooth muscle cells. The hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPAR alpha and PPAR gamma, respectively. Furthermore, fatty acid-derivatives and eicosanoids are natural PPAR ligands: PPAR alpha is activated by leukotriene B4, whereas prostaglandin J2 is a PPAR gamma ligand, as well as of some components of oxidized LDL, such as 9- and 13-HODE. These observations suggested a potential role for PPARs not only in metabolic but also in inflammation control and, by consequence, in related diseases such as atherosclerosis. More recently, PPAR activators were shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNF alpha and metalloproteases) by negatively interfering with the NF-kappa B, STAT and AP-1 signalling pathways in cells of the vascular wall. Furthermore, PPARs may also control lipid metabolism in the cells of the atherosclerotic plaque. PPARs are also involved in a variety of immunological and non-immunological diseases as is clear from standard text books of internal medicine (examples are metabolic diseases, cancer, angiogenesis, immune mediated disorders, diabetes etc.)
- As mentioned above the nuclear receptor PPARg is important in adipogenesis, lipid storage and involved in atherosclerosis. While expressed in adipose tissue this receptor is also expressed in macrophages and in the colon. In addition, PPARg is implicated in a number of processes such as cancer and inflammation. Moreover, microbes, via its cognate receptors, typified by the TLRs, possess the capacity to regulate PPARg dependent metabolic functions and as such illustrates the intricate interplay between the microbial flora and metabolic control in the alimentary tract.
- Cyclo-oxygenase 2 (COX2), an inducible isoform of prostaglandin H synthase, which mediates prostaglandin synthesis during inflammation, and which is selectively overexpressed in colon tumours, is thought to play an important role in colon carcinogenesis. Induction of COX2 by inflammatory cytokines or hypoxia-induced oxidative stress can be mediated by nuclear factor kappa B (NF-kappaB). So, inhibition of NF-kB modulate COX pathway and this inhibition of NF-kB can be therapeutically useful in diseases in which COXs are involved, such as inflammation, pain, cancer (especially colorectal cancer), inflammatory bowel disease and others.
- Neuronal subsets in normal brains constitutively express functionally competent C5a receptors. The functional role of C5a receptors revealed that C5a triggered rapid activation of protein kinase C and activation and nuclear translocation of the NF-kappa B transcription factor. In addition, C5a was found to be mitogenic for undifferentiated human neuroblastoma cells, a novel action for the C5aR. In contrast, C5a protects terminally differentiated human neuroblastoma cells from toxicity mediated by the amyloid A beta peptide. This shows that normal hippocampal neurons as well as undifferentiated and differentiated human neuroblastoma cells express functional C5a receptors. These results show the role of neuronal C5aR receptors in normal neuronal development, neuronal homeostasis, and neuroinflammatory conditions such as Alzheimer's disease.
- Activation of the complement system plays also an important role in the pathogenesis of atherosclerosis. The proinflammatory cytokine interleukin (IL)-6 is potentially involved in the progression of the disease. Here the complement system induces IL-6 release from human vascular smooth-muscle cells (VSMC) by a Gi-dependent pathway involving the generation of oxidative stress and the activation of the redox sensitive transcription factors NF-kB and AP-1. Modulation of complement system is important for broad ranges of disorders such as blood disorders, infections, some metabolic diseases (diabetes), vascular diseases, transplant rejection and related disorders, autoimmune diseases, and other immunological diseases.
- Different transcription factors like NF-kB and intracellular signaling molecules such as different kinases are also involved in multiple drug resistance. So, it is reasonable to believe that NMPF peptides will be effective against multiple drug resistance. Moreover, our genomic data shows that a number of genes and signalling molecules involved in tumorogenesis and metastasis are modulated. In addition since oligopeptides have also effect on angiogenesis, thus these peptides will also be used for the treatment of cancer and related diseases whereby angiogenesis requires modulation.
- Proliferative diabetic retinopathy (PDR) is one of the major causes of acquired blindness. The hallmark of PDR is neovascularisation (NV), abnormal angiogenesis that may ultimately cause severe vitreous cavity bleeding and/or retinal detachment. Since NMPF peptides have angiogenesis stimulatory as well as inhibitory effects and have the ability to modulate intracellular signaling involved in growth factors (like insulin), pharmacologic therapy with certain NMPF peptides can improve metabolic control (like glucose) or blunt the biochemical consequences of hyperglycaemia (through mechanisms such as in which aldose reductase, protein kinase C (PKC), PPARs are involved). For this metabolic control or diabetes (type 2) NMPF (LQGV, VLPALP, VLPALPQ, GVLPALPQ, AQG, LAG, LQA, AQGV, VAPALP, VAPALPQ, VLPALPA, LPGC, MTR, MTRV, LQG, CRGVNPVVS are recommended. The angiogenesis in PDR could be also treated with above mentioned oligopeptides.
Claims (24)
1. A method for obtaining information about the capacity or tendency of an oligopeptide, or a modification or derivative thereof, to regulate expression of a gene comprising the steps of:
a) contacting said oligopeptide, or a modification or derivative thereof, with at leaste one cell;
b) determining the presence of at least one gene product in or derived from said cell.
2. The method according to claim 1 wherein said oligopeptide comprises an amino acid sequence corresponding to a fragment of a naturally occurring polypeptide.
3. The method according to claim 2 wherein said naturally occurring polypeptide comprises human chorionic gonadotropic hormone (hCG).
4. The method according to any one of claims 1 to 3 wherein said cell comprises an eukaryotic cell.
5. The method according to any one of claims 1 to 4 further comprising
c) determining the presence of said gene product in or derived from a cell which has not been contacted with said oligopeptide, or a modification or derivative thereof, and determining the ratio of gene product found in step b to gene product found in step c.
6. A method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing said cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor and then synthesising the molecule with the desired activity.
7. The method according to claim 6 further comprising determining whether said signalling molecule is membrane-permeable.
8. The method according to claim 6 or 7 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.
9. A method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing said cell with a peptide or derivative or analogue thereof and determining relative up-regulation and/or down-regulation of at least one gene expressed in said cell and then synthesising the molecule with the desired activity.
10. The method according to claim 6 , 7, 8 or 9 further comprising determining relative up-regulation and/or down-regulation of at least one gene expressed in said cell.
11. The method according to claim 6 to 10 further comprising determining relative up-regulation and/or down-regulation of a multitude of genes expressed in said cell.
12. A method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing a peptide or derivative or analogue thereof and determining binding of said peptide or derivative or analogue thereof to a factor related to gene control and then synthesising the molecule with the desired activity.
13 The method according to claim 12 further comprising providing a multitude of peptides or derivatives or analogues thereof and determining binding of at least one of said peptides or derivatives or analogues thereof to a factor related to gene control.
14. The method according to claim 12 or 13 wherein said factor related to gene control comprises a transcription factor.
15. The method according to claim 14 wherein said transcription factor comprises a NF-kappaB-Rel protein.
16. The method according any one of claims 12 to 15 further comprising providing a cell with said peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor in said cell.
17. The method according to any one of claims 12 to 16 further comprising providing a cell with said peptide or derivative or analogue thereof and determining relative up-regulation and/or down-regulation of at least one gene expressed in said cell.
18. A signalling molecule useful in modulating expression of a gene in a cell and identifiable or obtainable by employing a method according to any one of claims 1 to 17 .
19. A signalling molecule according to claim 18 selected from the group of peptides LQG, AQG, LQGV, AQGV, LQGA, VLPALP, ALPALP, VAPALP, ALPALPQ, VLPAAPQ, VLPALAQ, LAGV, VLAALP, VLAALP, VLPALA, VLPALPQ, VLAALPQ, VLPALPA, GVLPALP, LQGVLPALPQVVC, LPGCPRGVNPVVS, LPGC, MTRV, MTR, VVC, and functional analogues or derivatives thereof.
20. A signalling molecule capable of modulating expression of a gene in a cell comprising a peptide of at most 30 amino acids or a functional analogue or derivative thereof.
21. A signalling molecule according to claim 20 wherein said peptide is an oligopeptide of from about 3 to at about 15 amino acids long.
22. A modulator of NF-kappaB/Rel protein activation comprising a signalling molecule according to anyone of claims 18 to 21 .
23. Use of a signalling molecule according to anyone of claim 18 to 21 for the production of a pharmaceutical composition for the modulation of gene expression.
24. Use according to claim 23 for the modulation of gene expression by inhibiting NF-kappaB/Rel protein activation.
Priority Applications (45)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01203748A EP1300418A1 (en) | 2001-10-04 | 2001-10-04 | Gene regulation by oligopeptides |
US10/028,075 US20030113733A1 (en) | 2001-10-04 | 2001-12-21 | Gene regulator |
PCT/NL2002/000639 WO2003029292A2 (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
CA002462796A CA2462796A1 (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
KR10-2004-7005020A KR20040074975A (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
NZ532173A NZ532173A (en) | 2001-10-04 | 2002-10-04 | Signalling molecules for modulating gene expression particularly transcription factors derived from hCG |
AU2002328028A AU2002328028B2 (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
EP08171382A EP2060585A3 (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
EP08171373A EP2036924B1 (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
JP2003532537A JP2005519867A (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptide |
CNA028242947A CN1599753A (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
CN200910163475A CN101721676A (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
AT02763111T ATE517915T1 (en) | 2001-10-04 | 2002-10-04 | METHOD FOR IDENTIFYING GENE-REGULATING PEPTIDES |
EP02763111A EP1432733B1 (en) | 2001-10-04 | 2002-10-04 | Method for identifying gene regulatory peptides |
AT08171373T ATE535542T1 (en) | 2001-10-04 | 2002-10-04 | GENE REGULATING PEPTIDES |
IL16120102A IL161201A0 (en) | 2001-10-04 | 2002-10-04 | Gene regulatory peptides |
US10/409,630 US7560433B2 (en) | 2001-12-21 | 2003-04-08 | Treatment of multiple sclerosis (MS) |
US10/409,671 US20030220261A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of iatrogenic disease |
US10/409,654 US20030220259A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of neurological disorders |
US10/409,694 US20030224995A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of burns |
US10/409,657 US20040013661A1 (en) | 2001-12-21 | 2003-04-08 | Stratification |
US10/409,659 US20030220260A1 (en) | 2001-12-21 | 2003-04-08 | Peptide compositions |
US10/409,032 US20030220257A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of trauma |
US10/409,642 US20030220258A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of ischemic events |
US10/409,027 US7501391B2 (en) | 2001-12-21 | 2003-04-08 | Treatment of transplant survival |
US10/753,510 US7358330B2 (en) | 2001-03-29 | 2004-01-07 | Immunoregulatory compositions |
IL161201A IL161201A (en) | 2001-10-04 | 2004-03-31 | Signalling molecules derived from hcg for modulating gene expression |
US10/817,756 US20050214943A1 (en) | 2001-10-04 | 2004-04-02 | Gene regulatory peptides |
US10/821,240 US20050037430A1 (en) | 2000-03-29 | 2004-04-08 | Methods and uses for protein breakdown products |
HK04106110.8A HK1063327A1 (en) | 2001-10-04 | 2004-08-16 | Method for identifying gene regulatory peptides |
US11/346,761 US7524820B1 (en) | 2001-10-04 | 2006-02-03 | Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology |
US11/593,329 US8216998B2 (en) | 2001-12-21 | 2006-11-06 | Treatment of ischemic events |
US11/859,265 US20080076719A1 (en) | 2001-03-29 | 2007-09-21 | Immunoregulatory compositions |
US11/986,043 US20080242837A1 (en) | 2001-12-21 | 2007-10-30 | Peptide compositions |
US11/981,491 US20080194489A1 (en) | 2001-12-21 | 2007-10-30 | Treatment of iatrogenic disease |
US11/981,505 US7786084B2 (en) | 2001-12-21 | 2007-10-30 | Treatment of burns |
US11/982,292 US20080318871A1 (en) | 2001-12-21 | 2007-10-31 | Treatment of neurological disorders |
US11/982,293 US20080242618A1 (en) | 2001-12-21 | 2007-10-31 | Stratification |
US12/001,035 US20080176243A1 (en) | 2001-10-04 | 2007-12-06 | Gene regulator |
US12/069,401 US20080306009A1 (en) | 2001-03-29 | 2008-02-08 | Immunoregulatory compositions |
US12/074,020 US20090042807A1 (en) | 1998-05-20 | 2008-02-29 | Oligopeptide treatment of ischemia reperfusion injury |
AU2008261169A AU2008261169A1 (en) | 2001-10-04 | 2008-12-22 | Novel peptides |
US12/386,135 US20110105415A1 (en) | 2001-10-04 | 2009-04-14 | Gene regulator |
US12/802,967 US20100297258A1 (en) | 2001-12-21 | 2010-06-16 | Treatment of burns |
US13/065,317 USRE43309E1 (en) | 2000-03-29 | 2011-03-17 | Immunoregulatory compositions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01203748.7 | 2001-10-04 | ||
EP01203748A EP1300418A1 (en) | 2001-10-04 | 2001-10-04 | Gene regulation by oligopeptides |
US10/028,075 US20030113733A1 (en) | 2001-10-04 | 2001-12-21 | Gene regulator |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/262,522 Continuation US7365155B2 (en) | 1998-05-20 | 2002-09-30 | Immunoregulator |
US11/346,761 Continuation-In-Part US7524820B1 (en) | 2001-10-04 | 2006-02-03 | Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology |
Related Child Applications (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2002/000639 Continuation-In-Part WO2003029292A2 (en) | 2000-03-29 | 2002-10-04 | Gene regulatory peptides |
US10/409,642 Continuation-In-Part US20030220258A1 (en) | 1998-05-20 | 2003-04-08 | Treatment of ischemic events |
US10/409,032 Continuation-In-Part US20030220257A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of trauma |
US10/409,654 Continuation-In-Part US20030220259A1 (en) | 2001-10-04 | 2003-04-08 | Treatment of neurological disorders |
US10/409,694 Continuation-In-Part US20030224995A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of burns |
US10/409,671 Continuation-In-Part US20030220261A1 (en) | 2001-12-21 | 2003-04-08 | Treatment of iatrogenic disease |
US10/409,027 Continuation-In-Part US7501391B2 (en) | 2001-12-21 | 2003-04-08 | Treatment of transplant survival |
US10/409,657 Continuation-In-Part US20040013661A1 (en) | 2001-12-21 | 2003-04-08 | Stratification |
US10/409,630 Continuation-In-Part US7560433B2 (en) | 2001-12-21 | 2003-04-08 | Treatment of multiple sclerosis (MS) |
US10/409,659 Continuation-In-Part US20030220260A1 (en) | 2001-12-21 | 2003-04-08 | Peptide compositions |
US10/753,510 Continuation-In-Part US7358330B2 (en) | 2000-03-29 | 2004-01-07 | Immunoregulatory compositions |
US12/001,035 Continuation US20080176243A1 (en) | 2001-10-04 | 2007-12-06 | Gene regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030113733A1 true US20030113733A1 (en) | 2003-06-19 |
Family
ID=26077008
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/028,075 Abandoned US20030113733A1 (en) | 1998-05-20 | 2001-12-21 | Gene regulator |
US10/817,756 Abandoned US20050214943A1 (en) | 2001-10-04 | 2004-04-02 | Gene regulatory peptides |
US11/346,761 Expired - Fee Related US7524820B1 (en) | 2001-10-04 | 2006-02-03 | Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology |
US12/001,035 Abandoned US20080176243A1 (en) | 2001-10-04 | 2007-12-06 | Gene regulator |
US12/386,135 Abandoned US20110105415A1 (en) | 2001-10-04 | 2009-04-14 | Gene regulator |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/817,756 Abandoned US20050214943A1 (en) | 2001-10-04 | 2004-04-02 | Gene regulatory peptides |
US11/346,761 Expired - Fee Related US7524820B1 (en) | 2001-10-04 | 2006-02-03 | Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology |
US12/001,035 Abandoned US20080176243A1 (en) | 2001-10-04 | 2007-12-06 | Gene regulator |
US12/386,135 Abandoned US20110105415A1 (en) | 2001-10-04 | 2009-04-14 | Gene regulator |
Country Status (12)
Country | Link |
---|---|
US (5) | US20030113733A1 (en) |
EP (4) | EP1300418A1 (en) |
JP (1) | JP2005519867A (en) |
KR (1) | KR20040074975A (en) |
CN (2) | CN101721676A (en) |
AT (2) | ATE535542T1 (en) |
AU (2) | AU2002328028B2 (en) |
CA (1) | CA2462796A1 (en) |
HK (1) | HK1063327A1 (en) |
IL (2) | IL161201A0 (en) |
NZ (1) | NZ532173A (en) |
WO (1) | WO2003029292A2 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119720A1 (en) * | 2001-03-29 | 2003-06-26 | Khan Nisar Ahmed | Oligopeptide treatment of anthrax |
US20030161797A1 (en) * | 2002-02-22 | 2003-08-28 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
US20030166556A1 (en) * | 2000-03-29 | 2003-09-04 | Khan Nisar Ahmed | Immunoregulator |
US20030215434A1 (en) * | 2001-12-21 | 2003-11-20 | Khan Nisar Ahmed | Treatment of multiple sclerosis (MS) |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US20040138096A1 (en) * | 1998-05-20 | 2004-07-15 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
US20050119184A1 (en) * | 1998-05-20 | 2005-06-02 | Khan Nisar A. | Immunoregulator |
US20050214943A1 (en) * | 2001-10-04 | 2005-09-29 | Khan Nisar A | Gene regulatory peptides |
US20050227273A1 (en) * | 2002-10-04 | 2005-10-13 | Incyte Corporation | Protein modification and maintenance molecules |
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
WO2005116051A2 (en) * | 2004-05-25 | 2005-12-08 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind to mhc-molecules |
US20060111292A1 (en) * | 2003-04-08 | 2006-05-25 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising HCG fragments |
WO2007004869A2 (en) | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
US20070197447A1 (en) * | 1998-05-20 | 2007-08-23 | Khan Nisar A | Oligopeptide acetate and formulations thereof |
US20070219138A1 (en) * | 2000-03-29 | 2007-09-20 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US20080027007A1 (en) * | 2006-03-07 | 2008-01-31 | Robbert Benner | Control of radiation injury |
US20080076714A1 (en) * | 2003-04-08 | 2008-03-27 | Biotempt B.V. | Administration of gene-regulatory peptides |
US20080076719A1 (en) * | 2001-03-29 | 2008-03-27 | Khan Nisar A | Immunoregulatory compositions |
US20080171094A1 (en) * | 2001-12-21 | 2008-07-17 | Robbert Benner | Treatment of burns |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US20080267936A1 (en) * | 2007-02-12 | 2008-10-30 | Biotempt B.V. | Treatment of trauma-hemorrhage with short oligopeptides |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
US20100029571A1 (en) * | 2008-05-14 | 2010-02-04 | Immatics Biotechnologies Gmbh | Novel and powerful mhc-class ii peptides derived from survivin |
US20100247525A1 (en) * | 2006-05-08 | 2010-09-30 | University Of Virginia Patent Foundation | Compositions and methods for treating anthrax lethality |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
WO2021154900A1 (en) * | 2020-01-31 | 2021-08-05 | Bio-Rad Laboratories, Inc. | Stable reference materials for automated hematology testing platforms |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
EP1466611A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Use of HCG derived peptides in the treatment of iatrogenic diseases |
CA2520655A1 (en) * | 2003-04-08 | 2004-11-04 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising hcg fragments |
EP1466613A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Compositions for mucosal and oral administration comprising hCG fragments |
EP1466612A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Treatment of inflammation and sepsis with hCG derived peptides |
US20060014136A1 (en) * | 2004-07-14 | 2006-01-19 | Inimex Pharmaceuticals, Inc. | Method of screening for protection from microbial infection |
WO2006025352A1 (en) * | 2004-08-30 | 2006-03-09 | Toray Industries, Inc. | Fractionation apparatus |
KR100877824B1 (en) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2EPF ubiquitin carrier protein-von Hippel-Lindau interaction and uses of thereof |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
ES2397441T5 (en) | 2006-02-13 | 2022-09-14 | Daiichi Sankyo Co Ltd | Polynucleotide and polypeptide sequences involved in the bone remodeling process |
WO2009014440A1 (en) * | 2007-07-23 | 2009-01-29 | Biotempt B.V. | Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides |
US20090312249A1 (en) * | 2007-12-06 | 2009-12-17 | Korea Advanced Institute Of Science And Technology | TLR4 decoy receptor protein |
EP2109054A1 (en) | 2008-04-09 | 2009-10-14 | Biotempt B.V. | Methods for identifying biologically active peptides and predicting their function |
BR112013033674A2 (en) | 2011-06-29 | 2018-07-17 | Penn State Res Found | compositions, methods and kits for treating leukemia |
EP2875051B1 (en) | 2012-07-19 | 2019-02-20 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibodies |
WO2018081250A1 (en) * | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neuronal and oligodendrocyte survival modulation |
CN106801101B (en) * | 2017-02-23 | 2020-12-04 | 吉林大学 | Application of MED6 gene as acute myocardial infarction risk prediction marker |
CN111925411B (en) * | 2017-06-29 | 2022-04-08 | 安徽省农业科学院农产品加工研究所 | Cys-Ser-containing high-zinc-chelating-activity zinc chelating peptide and application thereof |
CN110740558B (en) * | 2019-10-18 | 2021-05-07 | 南昌大学 | Method for measuring plasma electron non-extensive parameter |
CN114901259B (en) * | 2019-12-30 | 2024-03-12 | 伊利亚斯生物制品公司 | Compositions comprising exosomes bearing NF-kB inhibitors and methods of use thereof |
AU2021354766A1 (en) | 2020-09-30 | 2023-05-11 | Biotempt B.V. | Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability |
AU2022359382A1 (en) * | 2021-10-05 | 2024-05-02 | Biotempt B.V. | Angiogenic control, preferably combined with glycaemic control. |
CN113992687B (en) * | 2021-12-28 | 2022-04-08 | 浙江宇视科技有限公司 | Intelligent service cluster scheduling method and device, electronic equipment and storage medium |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330466A (en) * | 1980-06-10 | 1982-05-18 | Amano Pharmaceutical Co., Ltd. | Process for the production of cholecystokinin-pancreozymin C-terminal peptide amide sulfate esters |
US4855285A (en) * | 1985-12-04 | 1989-08-08 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
US4977244A (en) * | 1985-06-27 | 1990-12-11 | The United States Of America As Represented By The Department Of Health And Human Services | Uromodulin and a process of purifying it |
US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5677275A (en) * | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
US5851997A (en) * | 1994-10-04 | 1998-12-22 | Harris; Pamela Jo | Use of human chorionic gonadotropin as an immune-potentiating antiviral agent |
US5854004A (en) * | 1991-11-25 | 1998-12-29 | Boehringer Ingleheim Gmbh | Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path |
US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
US5981486A (en) * | 1995-04-13 | 1999-11-09 | Chugai Seiyaku Kabushiki Kaisha | Peptide suppressing IκBα phosphorylation |
US5994126A (en) * | 1992-04-01 | 1999-11-30 | The Rockefeller University | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
US6022696A (en) * | 1998-04-02 | 2000-02-08 | Washington State University Research Foundation | Methods of identifying agonists or antagonists of angiotensin IV |
US6150500A (en) * | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
US6319504B1 (en) * | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
US6361992B1 (en) * | 1996-05-08 | 2002-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Thyroid stimulating hormone superagonists |
US20020041871A1 (en) * | 2000-06-01 | 2002-04-11 | Brudnak Mark A. | Genomeceutical and/or enzymatic composition and method for treating autism |
US20020064501A1 (en) * | 1998-05-20 | 2002-05-30 | Khan Nisar Ahmed | Immunoregulator |
US6489296B1 (en) * | 1997-10-20 | 2002-12-03 | Eli Lilly And Company | Method of reducing mortality in severe sepsis |
US20030003545A1 (en) * | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
US6518021B1 (en) * | 1997-04-07 | 2003-02-11 | Bioimage A/S | Method for extracting quantitative information relating to an influence on a cellular response |
US6583109B1 (en) * | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
US6727227B1 (en) * | 1999-05-11 | 2004-04-27 | Obschestvo S Ogranichennoi Otvetstven-Nostiju “Klinika Instituta {overscore (B)}ioregulyatsii Gerontologii” | Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
US20040208885A1 (en) * | 2001-03-29 | 2004-10-21 | Khan Nisar Ahmed | Immunoregulatoratory compositions |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2360794C2 (en) * | 1973-12-06 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Process for the production of peptides |
US4108846A (en) * | 1977-02-01 | 1978-08-22 | Hoffmann-La Roche Inc. | Solid phase synthesis with base N alpha-protecting group cleavage |
US4351762A (en) * | 1981-03-10 | 1982-09-28 | Bioresearch, Inc. | Rapid, quantitative peptide synthesis using mixed anhydrides |
US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
US4571336A (en) * | 1983-08-25 | 1986-02-18 | Endorphin, Inc. | Immune stimulation |
IE59895B1 (en) | 1986-05-12 | 1994-04-20 | Wellcome Found | Medicaments containing tissue plasminogen activator |
US4753965A (en) * | 1987-04-09 | 1988-06-28 | Merrell Dow Pharmaceuticals, Inc. | Method of treating multiple sclerosis with chalcone derivatives |
US5002961A (en) * | 1987-10-19 | 1991-03-26 | Merrell Dow Pharmaceuticals | Method for reducing injury with imidazol-2-thionecarboxamides |
US4966848A (en) * | 1988-02-08 | 1990-10-30 | The General Hospital Corporation | Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase |
ATE136551T1 (en) * | 1988-05-10 | 1996-04-15 | Alpha 1 Biomedicals Inc | SOLID PHASE PROCESS FOR OBTAINING THYMOSINE-ALPHA-1 |
US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US6309822B1 (en) * | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
US5102393A (en) * | 1989-07-17 | 1992-04-07 | Survival Technology, Inc. | Autoinjector converted from intramuscular to subcutaneous mode of injection |
US5223421A (en) * | 1989-10-25 | 1993-06-29 | The General Hospital Corporation | Identification of methionine Nα-acetyltransferase |
US6051596A (en) * | 1990-08-10 | 2000-04-18 | Anormed, Inc. | Immunosuppressive compositions |
US5200507A (en) * | 1991-04-12 | 1993-04-06 | Mallinckrodt Specialty Chemicals Company | Method of separating a peptide from a resin |
US5223397A (en) * | 1991-06-05 | 1993-06-29 | Sangstat Medical Corporation | Soluble hla cross-match |
DE69219590T2 (en) * | 1992-05-30 | 1997-11-27 | Marko Duvnjak | BPC peptides, their production and use |
US5436270A (en) * | 1993-04-07 | 1995-07-25 | National Science Council | Method for protecting against endotoxin-induced shock |
FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
US5837478A (en) * | 1993-12-23 | 1998-11-17 | Icos Corporation | Method of identifying modulators of binding between and VCAM-1 |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
US5807746A (en) * | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
US5700781A (en) * | 1994-10-04 | 1997-12-23 | Harris; Pamela Jo | Method for treating Kaposi's sarcoma and HIV infections |
US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
US5942494A (en) * | 1995-10-06 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70) |
US6159940A (en) * | 1996-02-28 | 2000-12-12 | Immunotech Developments Inc. | Method for modulating hemopoiesis |
US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US6207145B1 (en) * | 1997-05-09 | 2001-03-27 | Pharma Pacific Pty Ltd. | Therapeutic applications of high dose interferon |
AU3587797A (en) * | 1996-06-24 | 1998-01-14 | University Of Maryland Biotechnology Institute | Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin |
CA2180786C (en) * | 1996-07-02 | 2008-05-27 | David Lightfoot | Plants containing the gdha gene and methods of use thereof |
GB9617021D0 (en) * | 1996-08-13 | 1996-09-25 | Salpep Biotechnology Inc | Novel peptides for treatment of inflammation and shock |
GB9624927D0 (en) * | 1996-11-29 | 1997-01-15 | Oxford Glycosciences Uk Ltd | Gels and their use |
CN1159061C (en) * | 1997-02-15 | 2004-07-28 | 千年药物公司 | Treatment of infarcts through inhibition of NF-KAPPAB |
US6416959B1 (en) * | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
DE19735587B4 (en) * | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | A peptide having a radioprotective effect, a cosmetic or pharmaceutical composition containing the same, a nucleic acid encoding the same, a preparation process for this peptide and the use as a radioprotective agent |
EP1036174B1 (en) * | 1997-12-12 | 2006-08-30 | The University Of Western Ontario | Novel peptide, apoep1.b, compositions and uses thereof |
US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
US6069129A (en) * | 1998-03-13 | 2000-05-30 | Mrs, Llc | Elastin derived composition and method of using same |
AU3147699A (en) | 1998-03-27 | 1999-10-18 | Andre Rosenthal | Nucleic acid molecules which code proteins influencing bone development |
DE29808821U1 (en) | 1998-05-17 | 1999-09-23 | GIP Medizin Technik GmbH, 83224 Grassau | Bandage with a flat bandage part for holding a cannula, probe or catheter holder |
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
EP1138692A1 (en) * | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
DE69911401T2 (en) * | 1998-05-20 | 2004-06-24 | Erasmus Universiteit Rotterdam | IMMUNOREGULATOR |
US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
US20090042807A1 (en) * | 1998-05-20 | 2009-02-12 | Nisar Ahmed Khan | Oligopeptide treatment of ischemia reperfusion injury |
RU2139085C1 (en) * | 1998-06-23 | 1999-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Agent stimulating reparative processes and method of its use |
CA2342960C (en) * | 1998-09-17 | 2010-03-09 | Hopital Sainte-Justine | G protein-coupled receptor antagonists |
WO2000032217A1 (en) * | 1998-12-03 | 2000-06-08 | Histatek, Llc | Small peptides and methods for treatment of asthma and inflammation |
US6507788B1 (en) * | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6379970B1 (en) * | 1999-04-30 | 2002-04-30 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Analysis of differential protein expression |
US7994278B1 (en) * | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
WO2001029069A1 (en) * | 1999-10-15 | 2001-04-26 | Histatek, Llc | N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent |
RU2155063C1 (en) | 1999-10-20 | 2000-08-27 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Tetrapeptide stimulating functional activity of neurons, pharmacological agent based on thereof and method of its use |
DE19953339A1 (en) | 1999-11-05 | 2001-05-17 | Goldham Pharma Gmbh | Secret fragments |
EP2368898B1 (en) * | 1999-11-18 | 2014-10-01 | Ischemix, Inc | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
WO2001068113A1 (en) | 2000-03-10 | 2001-09-20 | Monsanto Technology Llc | Anti-hypertensive peptides |
EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US7576174B2 (en) * | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US6586403B1 (en) * | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US6539102B1 (en) * | 2000-09-01 | 2003-03-25 | Large Scale Proteomics | Reference database |
EP1217540A1 (en) * | 2000-11-29 | 2002-06-26 | Lafayette Software Inc. | Methods of organizing data and processing queries in a database system, and database system and software product for implementing such method |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
US6894028B2 (en) * | 2001-04-06 | 2005-05-17 | Zengen, Inc. | Use of KPV tripeptide for dermatological disorders |
US20040198652A1 (en) | 2001-04-24 | 2004-10-07 | Carter J. Paul | Methods and compositions for preventing and treating septic shock and endotoxemia |
CA2448668A1 (en) * | 2001-05-24 | 2002-11-28 | Trillium Therapeutics Inc. | Modulation of cd200 receptors |
US20040072246A1 (en) * | 2001-09-11 | 2004-04-15 | Roland Martin | System and method for identifying t cell and other epitopes and the like |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20080194489A1 (en) * | 2001-12-21 | 2008-08-14 | Khan Nisar A | Treatment of iatrogenic disease |
US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US20080242618A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Stratification |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US7135286B2 (en) * | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
US20060173162A1 (en) * | 2002-08-15 | 2006-08-03 | Rene Djurup | Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) |
US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
IL157772A (en) * | 2003-09-04 | 2016-06-30 | Bmr Solutions Ltd | Compositions comprising an oligopeptide derived from tortoise spleen for use in stimulating mammalian hemopoiesis |
US7638485B2 (en) * | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
WO2007004869A2 (en) * | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
-
2001
- 2001-10-04 EP EP01203748A patent/EP1300418A1/en not_active Withdrawn
- 2001-12-21 US US10/028,075 patent/US20030113733A1/en not_active Abandoned
-
2002
- 2002-10-04 IL IL16120102A patent/IL161201A0/en unknown
- 2002-10-04 WO PCT/NL2002/000639 patent/WO2003029292A2/en active Application Filing
- 2002-10-04 CA CA002462796A patent/CA2462796A1/en not_active Abandoned
- 2002-10-04 AT AT08171373T patent/ATE535542T1/en active
- 2002-10-04 EP EP08171373A patent/EP2036924B1/en not_active Expired - Lifetime
- 2002-10-04 CN CN200910163475A patent/CN101721676A/en active Pending
- 2002-10-04 NZ NZ532173A patent/NZ532173A/en not_active IP Right Cessation
- 2002-10-04 EP EP02763111A patent/EP1432733B1/en not_active Expired - Lifetime
- 2002-10-04 JP JP2003532537A patent/JP2005519867A/en active Pending
- 2002-10-04 AT AT02763111T patent/ATE517915T1/en not_active IP Right Cessation
- 2002-10-04 KR KR10-2004-7005020A patent/KR20040074975A/en not_active Application Discontinuation
- 2002-10-04 AU AU2002328028A patent/AU2002328028B2/en not_active Ceased
- 2002-10-04 CN CNA028242947A patent/CN1599753A/en active Pending
- 2002-10-04 EP EP08171382A patent/EP2060585A3/en not_active Withdrawn
-
2004
- 2004-03-31 IL IL161201A patent/IL161201A/en not_active IP Right Cessation
- 2004-04-02 US US10/817,756 patent/US20050214943A1/en not_active Abandoned
- 2004-08-16 HK HK04106110.8A patent/HK1063327A1/en not_active IP Right Cessation
-
2006
- 2006-02-03 US US11/346,761 patent/US7524820B1/en not_active Expired - Fee Related
-
2007
- 2007-12-06 US US12/001,035 patent/US20080176243A1/en not_active Abandoned
-
2008
- 2008-12-22 AU AU2008261169A patent/AU2008261169A1/en not_active Abandoned
-
2009
- 2009-04-14 US US12/386,135 patent/US20110105415A1/en not_active Abandoned
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330466A (en) * | 1980-06-10 | 1982-05-18 | Amano Pharmaceutical Co., Ltd. | Process for the production of cholecystokinin-pancreozymin C-terminal peptide amide sulfate esters |
US4977244A (en) * | 1985-06-27 | 1990-12-11 | The United States Of America As Represented By The Department Of Health And Human Services | Uromodulin and a process of purifying it |
US4855285A (en) * | 1985-12-04 | 1989-08-08 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
US5854004A (en) * | 1991-11-25 | 1998-12-29 | Boehringer Ingleheim Gmbh | Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path |
US5994126A (en) * | 1992-04-01 | 1999-11-30 | The Rockefeller University | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
US5677275A (en) * | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
US5877148A (en) * | 1994-08-05 | 1999-03-02 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
US5851997A (en) * | 1994-10-04 | 1998-12-22 | Harris; Pamela Jo | Use of human chorionic gonadotropin as an immune-potentiating antiviral agent |
US5981486A (en) * | 1995-04-13 | 1999-11-09 | Chugai Seiyaku Kabushiki Kaisha | Peptide suppressing IκBα phosphorylation |
US6361992B1 (en) * | 1996-05-08 | 2002-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Thyroid stimulating hormone superagonists |
US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
US20030049273A1 (en) * | 1996-06-24 | 2003-03-13 | Gallo Robert C. | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
US6319504B1 (en) * | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
US6150500A (en) * | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
US6518021B1 (en) * | 1997-04-07 | 2003-02-11 | Bioimage A/S | Method for extracting quantitative information relating to an influence on a cellular response |
US6620416B1 (en) * | 1997-06-24 | 2003-09-16 | University Of Maryland Biotechnology Institute | Method for treating HIV |
US6583109B1 (en) * | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
US6596688B1 (en) * | 1997-06-24 | 2003-07-22 | University Of Maryland Biotechnology Institute | Method for promoting hematopoiesis |
US6489296B1 (en) * | 1997-10-20 | 2002-12-03 | Eli Lilly And Company | Method of reducing mortality in severe sepsis |
US6022696A (en) * | 1998-04-02 | 2000-02-08 | Washington State University Research Foundation | Methods of identifying agonists or antagonists of angiotensin IV |
US20020064501A1 (en) * | 1998-05-20 | 2002-05-30 | Khan Nisar Ahmed | Immunoregulator |
US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20030003545A1 (en) * | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
US6727227B1 (en) * | 1999-05-11 | 2004-04-27 | Obschestvo S Ogranichennoi Otvetstven-Nostiju “Klinika Instituta {overscore (B)}ioregulyatsii Gerontologii” | Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
US20020041871A1 (en) * | 2000-06-01 | 2002-04-11 | Brudnak Mark A. | Genomeceutical and/or enzymatic composition and method for treating autism |
US20040208885A1 (en) * | 2001-03-29 | 2004-10-21 | Khan Nisar Ahmed | Immunoregulatoratory compositions |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070197447A1 (en) * | 1998-05-20 | 2007-08-23 | Khan Nisar A | Oligopeptide acetate and formulations thereof |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20050119184A1 (en) * | 1998-05-20 | 2005-06-02 | Khan Nisar A. | Immunoregulator |
US7820617B2 (en) | 1998-05-20 | 2010-10-26 | Biotempt B.V. | Methods of selecting immunoregulator peptides obtained from gonadotropins |
US7402322B2 (en) | 1998-05-20 | 2008-07-22 | Biotempt B.V. | Methods of treatment for septic shock with urine extract |
US20040138096A1 (en) * | 1998-05-20 | 2004-07-15 | Erasmus Universiteit Rotterdam | Immunoregulator |
US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US20070219138A1 (en) * | 2000-03-29 | 2007-09-20 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
USRE43140E1 (en) | 2000-03-29 | 2012-01-24 | Biotempt B.V. | Immunoregulator |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
US7365155B2 (en) | 2000-03-29 | 2008-04-29 | Biotempt B.V. | Immunoregulator |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
US20030166556A1 (en) * | 2000-03-29 | 2003-09-04 | Khan Nisar Ahmed | Immunoregulator |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
USRE43309E1 (en) | 2000-03-29 | 2012-04-10 | Biotempt B.V. | Immunoregulatory compositions |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
US20030119720A1 (en) * | 2001-03-29 | 2003-06-26 | Khan Nisar Ahmed | Oligopeptide treatment of anthrax |
US20080076719A1 (en) * | 2001-03-29 | 2008-03-27 | Khan Nisar A | Immunoregulatory compositions |
US7524820B1 (en) | 2001-10-04 | 2009-04-28 | Biotempt B.V. | Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology |
US20110105415A1 (en) * | 2001-10-04 | 2011-05-05 | Biotempt B.V. | Gene regulator |
US20050214943A1 (en) * | 2001-10-04 | 2005-09-29 | Khan Nisar A | Gene regulatory peptides |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US20030215434A1 (en) * | 2001-12-21 | 2003-11-20 | Khan Nisar Ahmed | Treatment of multiple sclerosis (MS) |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US20080171094A1 (en) * | 2001-12-21 | 2008-07-17 | Robbert Benner | Treatment of burns |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US8216998B2 (en) | 2001-12-21 | 2012-07-10 | Biotempt B.V. | Treatment of ischemic events |
US7030129B2 (en) * | 2002-02-22 | 2006-04-18 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
US20030161797A1 (en) * | 2002-02-22 | 2003-08-28 | 3M Innovative Properties Company | Method of reducing and treating UVB-induced immunosuppression |
US20050227273A1 (en) * | 2002-10-04 | 2005-10-13 | Incyte Corporation | Protein modification and maintenance molecules |
US20080076714A1 (en) * | 2003-04-08 | 2008-03-27 | Biotempt B.V. | Administration of gene-regulatory peptides |
US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
US20060111292A1 (en) * | 2003-04-08 | 2006-05-25 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising HCG fragments |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
US20060142205A1 (en) * | 2004-04-08 | 2006-06-29 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
AU2005247598B2 (en) * | 2004-05-25 | 2011-06-02 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind to MHC-molecules |
US20100029573A1 (en) * | 2004-05-25 | 2010-02-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind to mhc-molecules |
WO2005116051A2 (en) * | 2004-05-25 | 2005-12-08 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind to mhc-molecules |
US8242239B2 (en) | 2004-05-25 | 2012-08-14 | Immatics Biotechnologies Gmbh | MHC molecule-binding tumor-associated peptides |
WO2005116051A3 (en) * | 2004-05-25 | 2006-03-02 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind to mhc-molecules |
US8008431B2 (en) | 2004-05-25 | 2011-08-30 | Immatics Biotechnologies Gmbh | Tumor-associated peptides that bind to MHC-molecules |
US7662776B2 (en) | 2005-07-05 | 2010-02-16 | Biotempt B.V. | Treatment of tumors using short peptides from human chorionic gonadotropin (HCG) |
WO2007004869A2 (en) | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
US20070021347A1 (en) * | 2005-07-05 | 2007-01-25 | Biotempt B.V. | Treatment for tumors |
US20090281033A1 (en) * | 2006-03-07 | 2009-11-12 | Biotempt B.V. | Control of radiation injury |
US20080027007A1 (en) * | 2006-03-07 | 2008-01-31 | Robbert Benner | Control of radiation injury |
US20110009344A1 (en) * | 2006-03-07 | 2011-01-13 | Biotempt B.V. | Control of radiation injury |
US8288341B2 (en) | 2006-03-07 | 2012-10-16 | Biotempt B.V. | Control of radiation injury |
US20090291901A1 (en) * | 2006-03-07 | 2009-11-26 | Biotempt B.V. | Control of radiation injury |
US7795226B2 (en) | 2006-03-07 | 2010-09-14 | Biotempt B.V. | Control of radiation injury |
US20100247525A1 (en) * | 2006-05-08 | 2010-09-30 | University Of Virginia Patent Foundation | Compositions and methods for treating anthrax lethality |
US20080267936A1 (en) * | 2007-02-12 | 2008-10-30 | Biotempt B.V. | Treatment of trauma-hemorrhage with short oligopeptides |
US8647629B2 (en) | 2008-05-14 | 2014-02-11 | Immatics Biotechnologies Gmbh | Powerful MHC-class II peptides derived from survivin |
US20100029571A1 (en) * | 2008-05-14 | 2010-02-04 | Immatics Biotechnologies Gmbh | Novel and powerful mhc-class ii peptides derived from survivin |
US9498512B2 (en) | 2008-05-14 | 2016-11-22 | Immatics Biotechnologies Gmbh | Powerful MHC-class II peptides derived from survivin |
US10434136B2 (en) | 2008-05-14 | 2019-10-08 | Immatics Biotechnologies Gmbh | Powerful MHC-class II peptides derived from survivin |
US11957729B2 (en) | 2008-05-14 | 2024-04-16 | Immatics Biotechnologies Gmbh | Powerful MHC-class II peptides derived from survivin |
WO2021154900A1 (en) * | 2020-01-31 | 2021-08-05 | Bio-Rad Laboratories, Inc. | Stable reference materials for automated hematology testing platforms |
Also Published As
Publication number | Publication date |
---|---|
IL161201A0 (en) | 2004-08-31 |
EP1432733B1 (en) | 2011-07-27 |
US20050214943A1 (en) | 2005-09-29 |
CN1599753A (en) | 2005-03-23 |
EP2036924A2 (en) | 2009-03-18 |
US7524820B1 (en) | 2009-04-28 |
EP1300418A1 (en) | 2003-04-09 |
HK1063327A1 (en) | 2004-12-24 |
AU2008261169A1 (en) | 2009-01-22 |
JP2005519867A (en) | 2005-07-07 |
CA2462796A1 (en) | 2003-04-10 |
AU2002328028B2 (en) | 2008-09-25 |
WO2003029292A2 (en) | 2003-04-10 |
EP2036924B1 (en) | 2011-11-30 |
IL161201A (en) | 2010-06-16 |
ATE517915T1 (en) | 2011-08-15 |
WO2003029292A3 (en) | 2003-12-11 |
ATE535542T1 (en) | 2011-12-15 |
US20110105415A1 (en) | 2011-05-05 |
EP2060585A2 (en) | 2009-05-20 |
EP1432733A2 (en) | 2004-06-30 |
NZ532173A (en) | 2006-07-28 |
US20080176243A1 (en) | 2008-07-24 |
KR20040074975A (en) | 2004-08-26 |
EP2036924A3 (en) | 2010-02-24 |
EP2060585A3 (en) | 2010-01-06 |
CN101721676A (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7175679B2 (en) | Oligopeptide treatment of NF-κB mediated inflammation | |
US20030113733A1 (en) | Gene regulator | |
AU2002328028A1 (en) | Gene regulatory peptides | |
US20090042807A1 (en) | Oligopeptide treatment of ischemia reperfusion injury | |
US20050037430A1 (en) | Methods and uses for protein breakdown products | |
Ondetti et al. | Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis | |
US20080076714A1 (en) | Administration of gene-regulatory peptides | |
Suetsuna | Isolation and characterization of angiotensin I-converting enzyme inhibitor dipeptides derived from Allium sativum L (garlic) | |
US7517529B2 (en) | Treatment of type I diabetes | |
US8492329B2 (en) | Bioactive peptides and methods of using same | |
US20090227505A1 (en) | Methods and uses for protein breakdown products | |
CN107412723A (en) | Method for reducing CD36 expression | |
WO1995003067A1 (en) | Pharmaceutical with immunomodulating activity | |
WO2006018431A2 (en) | Peptides for the treatment of herpes virus infections | |
US20080175837A1 (en) | Dpp4 inhibitor and pharmaceutical use thereof | |
AU2005205750B2 (en) | Immunoregulator | |
US7625870B2 (en) | Peptide substance restoring respiratory organs function | |
EP1466613A1 (en) | Compositions for mucosal and oral administration comprising hCG fragments | |
RU2223113C1 (en) | Peptide eliciting regulating biological activity of protein synthesis in hepatocytes | |
TW202228755A (en) | Hair growth agent and drinks and food containing the same for stimulating hair growth and preventing hair loss | |
JPH0859697A (en) | Peptide, prolylendopeptidase inhibitor containing the same, functional food and feed for animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ERASMUS UNIVERSITEIT ROTTERDAM, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KHAN, NISAR AHMED;BENNER, ROBERT;REEL/FRAME:013163/0893 Effective date: 20020724 |
|
AS | Assignment |
Owner name: BIOTEMPT B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ERASMUS UNIVERSITEIT ROTTERDAM;REEL/FRAME:017215/0455 Effective date: 20050831 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |